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Abstract 
 
Stress urinary incontinence (SUI) and pelvic organ prolapse (POP) are two related conditions 
that significantly impair the quality of life. One in ten women will require primary surgery for 
SUI and POP. Surgical treatment of both conditions often necessitates the use of a surgical 
mesh material which is now known to be associated with serious complications in up to 40% 
of women in long term follow- up. Recently, the use of vaginal mesh products in 
urogyneacological procedures have been suspended in NHS hospitals in England. There 
appears to be an unmet and urgent need for better biomaterials to support the pelvic floor 
which are able to better integrate into tissues at the sites of implantation. The aim of this 
thesis was to develop a synthetic, degradable material for use in the female pelvic floor that 
can promote angiogenesis and that can integrate well into tissues.  
As a first step, an in vivo assay has been developed and optimized to allow effective screening 
of constructed biomaterials. Biomaterials were processed with electrospinning of polylactic 
acid (PLA) which is a commonly used, degradable polymer for soft tissue applications. 
Electrospun PLA scaffolds were functionalized by incorporation of Vitamin C and Estradiol 
and were tested for their effects on stimulating new blood vessel formation and extracellular 
matrix production. As a final step, mesenchymal stem cells (MSCs) were also tested for their 
ability to promote angiogenesis. The final biomaterials were always tested for suitability of 
their biomechanical properties for applications in the pelvic floor.  
Both Vitamin C and Estradiol could effectively be incorporated into the electrospun PLA 
scaffolds with desirable ultrastructural and mechanical properties. Vitamin C was released 
from the scaffolds over several weeks whereas Estradiol was released over months. Both 
drugs increased the angiogenic potential of scaffolds and extracellular matrix production. 
Estradiol releasing electrospun PLA scaffolds resulted in the most dramatic increase in new 
blood vessel formation. Also MSCs had a mild stimulatory effect on angiogenesis. Future 
work is underway to test the Estradiol releasing scaffolds in relevant animal models.  
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1.1 Stress Urinary Incontinence (SUI) and Pelvic Organ Prolapse (POP) in Women 
1.1.1. Definitions 
 
Stress urinary incontinence (SUI) is defined as a symptom as  “the complaint of involuntary 
loss of urine on effort or physical exertion (e.g. sporting activities), or on sneezing or 
coughing” [1]. Synonymously SUI also refers to an objective indication of a disease or a 
health problem when it is used as a sign defined as ‘observation of involuntary leakage from 
the urethra synchronous with effort or physical exertion or on sneezing or coughing’.    
The POP is “the descent of one or more of the anterior vaginal wall, posterior vaginal wall, 
the uterus (cervix) or the apex of the vagina (vaginal vault or cuff scar after hysterectomy). 
The presence of any such sign should be correlated with relevant POP symptoms. Most 
commonly this correlation would occur at the level of the hymen or beyond” [1]. 
1.1.2. Prevalance 
 
The prevalence of SUI in the population is studied in several large scale epidemiological 
studies. In a population based prevalence study involving women from four European 
countries and Canada, the overall prevalence of SUI was reported to be 6.4% (95% 
Confidence interval 5.9- 6.9). The prevalence increased with age from 0.1% in women aged 
<39 years old to 8% in women aged >60 years old [2]. In another large cross- sectional study 
conducted in USA, Sweden and UK 31.8% of the women had SUI symptoms ‘at least 
sometimes’ and 14.8% had SUI ‘at least often’ [3]. One of the largest population based 
evaluation of lower urinary tract symptoms to date was conducted in China, reporting a 18.9% 
prevalance of SUI in women >20 years old [4]. Worldwide a total of nearly 153 million 
women were predicted to have SUI by 2018, representing a 20% increase from 2008 to 2018 
[5]. The variability in the prevalence rates of SUI can be due to the definition of SUI used, the 
population studied and the methodologies used in the studies (e.g. design and conduct of 
questionnaires).    
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Similarly the prevalence of POP increases with increasing age. In the UK, prolapse symptoms 
were reported by 8.4% of women in the community [6]. In the large, prospective (n=161 861)  
Women’ s Health Initiative study conducted in 40 centres in the USA 41.1% of women with a 
uterus and 38% of women without a uterus had some form of POP on physical examination, 
respectively. The vast majority of these were cystoceles followed by uterine prolapse and 
rectocele [7].    
 
1.1.3. Impact 
 
SUI has a significant impact on the indivual patients suffering from the condition, family 
members and the health care systems. UI also poses a great economic burden for health care 
systems. In USA over 13 billion USD were spent in 1995 on treatment of SUI [8]. These costs 
include costs of diagnosis and treatment, however many patients find themselves in a position 
to pay for extra amounts for routine care of incontinence (primary care visits and towels/ 
pads) because healthcare providers often impose limits on the maximum number pads etc. In 
the UK the cost of SUI to the NHS is estimated to be £117M per year [9].   
Urinary incontinence has significant impact on physical, psychological and social well- being 
of women. Regardless of the methodology used to measure patients with urinary incontinence  
consistently have lower quality of life scores when compared to continent women [10].  The 
type of UI effects the health related quality of life differently. Patients with urgency UI and 
mixed UI have significantly worse health related quality of life scores compared to patients 
with SUI [11]. Additionally  depression, anxiety and stress levels are known to increase with 
increased severity of UI [12].  
Despite its negative impact on the quality of life of women, less then 25% of women seek 
help for their UI [13].  In a population based cross- sectional study performed in Staffordshire, 
UK, only 17% of women sought professional help for their incontinence. UI is often quoted as 
a stigmatized condition however the relationship between help seeking behaviour and stigma 
associated with UI is not well studied.  
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POP can also effect a women’ s quality of life, psychosocial and sexual well being. Validated 
disease specific questionnaires have been developed and used mainly to assess the effects of 
various treatments on the QoL of women with POP. A few studies have demonstrated an 
impairment of quality of life in women living with POP [14]. Although the relationship 
between POP and health related quality of life is not well studied, POP has been shown to 
have profound effects on the body image of women. Women with POP reported  feelings of 
being ‘less feminine’, ‘self-conscious’ and ‘isolated’ [15]. As the perceived  body image gets 
worse both the disease specific and the generalized quality of life decreases [16].   
 
1.1.4. Risk factors 
 
Childbirth (obstetric) injury is believed to be the principle factor causing pelvic floor 
disorders in female. Although epidemiological evidence shows a clear relationship between 
childbirth and pelvic floor disorders [7] the exact mechanisms of such an injury leading to 
POP is not yet known. The mechanisms investigated constitute direct injury to the nerves, 
muscles and connective tissues. The severity of the injury may vary between compression, 
stretching or tearing. The ability of the tissue remodelling after the injury and co- existing 
morbidities all decide the final outcome.  
The levator ani muscle complex, particularly the pubococygeal muscle, is known to be injured 
during vaginal delivery in 20% of women [17] being more common in forceps assisted 
vaginal delivery [18]. Also levator defects were present in 55% of women seeking treatment 
for POP as opposed to 16% of controls. Therefore, although the long term effects of a levator 
injury during childbirth on development of POP is not completely elucidated in long term 
follow up studies, it is likely to be one of the contributing factors.   
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Injury to the nerves innervating the pelvic floor muscles, particularly the pudental nerve that 
arises from the S2- S4 nerve roots during childbirth has also been suggested as a mechanism 
resulting in injury to pelvic floor muscles. Neurophysiologic studies demonstrated 
significantly prolonged pudental nerve terminal motor latency and reduced anal pressure on 
voluntary contraction 2-3 days after vaginal delivery. Repeat measurements in the same 
patients 2 months after vaginal delivery showed shorter pudental nerve motor latency times 
suggesting a denervation injury of the pudental nerve after vaginal delivery with a subsequent 
reinnervation [19]. Also electromyographic studies demonstrated that in women with SUI and 
POP denervation of pubococcygeus muscle was significantly more compared to normal 
women [20].   The risk of pudental nerve denervation was found to be higher in difficult 
vaginal deliveries such as forceps deliveries, high birth weight and prolonged second stage of 
labour.  
During and after pregnancy there is extensive connective tissue remodelling in the pelvic 
floor. The synthesis and degradation of main components of the extracellular matrix, mainly 
collagen and elastin, are changed and the connective tissue is remodelled. Defects in these 
biochemical processes are proposed as a mechanism for development of POP and SUI. The 
changes in connective tissues of women with SUI and POP are reviewed elsewhere and 
include: increased collagen turnover, decreased elastin synthesis and differential expression of 
candidate genes involved in structural proteins [21].  
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1.2. The pelvic floor support 
 
1.2.1. Anatomical basis of pelvic floor support 
 
Pelvic organs in women are kept in place by ligaments and other connective tissue 
components at three levels in the pelvis (Figure 1.1). Level I is formed by the cardinal and 
uterosacral ligaments providing apical support. The cardinal ligaments attach uterus and upper 
vagina to the pelvic side walls whereas uterosacral ligaments attach it to the sacral bone. Both 
ligaments are composed of thick and strong collagenous fibres extending vertically and 
posteriorly towards the sacrum indicating a function that does not necessarily involve 
flexibility but strength mostly in the vertical direction. Level II support comprises of fascia 
and connective tissues attaching the lateral walls of the vagina to the arcus tendinous fascia 
pelvis which supports the mid- vagina laterally. Biomechanically level II support structures 
are less fibrous than level I. Level III urogenital diaphragm and perineal body supporting 
lower part of the vagina and urethra [22].   
The pelvic floor is the hammock- like structure made up of skeletal and smooth muscles 
surrounded by connective tissues and attached to pelvic bones. Its’ main function is to 
counteract the forces generated by gravity and intra- abdominal pressure. 
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Figure 1.1. The three levels forming the female pelvic floor support (Reproduced with permission 
from DeLancey, John OL. "Anatomie aspects of vaginal eversion after hysterectomy." American Journal of 
Obstetrics & Gynecology 166.6 (1992): 1717-1728.) 
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1.2.2. Biomechanical basis of pelvic floor support 
 
Biomechanics is an interdisciplinary area that applies the principles of engineering and the 
methods of mechanics to biological systems. Mechanics is concerned with the description of 
motion and how forces create motion [23]. Biomechanics help us understand how the forces 
acting on structural elements of our bodies create motion that leads to normal development 
and functioning or to damage tissues in cases where there is an overload. When studying 
bioengineering of the pelvic floor, the biological constitution in relation to the mechanical 
forces acting on it needs to be considered and materials used in pelvic floor reconstruction 
needs to have defined characteristics of material deformation and load bearing as well as how 
it contributes to tissue remodelling once it is implanted in to the body. It is important that 
clinicians/ surgeons have a basic understanding of biomechanical principles so that they can 
define the biomechanics of the tissue to be replaced and select the best material to meet the 
specific needs.   
The available knowledge on the biomechanical properties of the female pelvic floor mainly 
comes from mechanical testing of samples from the pelvic floor from human and animal 
samples. The availability of human samples for mechanical testing is limited due to 
challenges and ethical concerns related to obtaining large tissue samples. Therefore, in 
humans biopsy samples or cadaveric tissues are used to define the biomechanical features of 
the pelvic floor muscles and fascia [24]. Another method was to study whole pelvic floor 
samples of animals that contain all the muscles and the connective tissues of the pelvic floor 
(e.g. ‘vaginal supportive tissue complex’). Such samples obtained from rats demonstrated that 
the ultimate failure in the testing protocol was due to a failure of paravaginal attachments 
[25]. Samples that only contain the connective tissues (e.g. fascia) have also been tested [26]. 
Disruption in the fascial structures is thought to be the main mechanism by which pelvic 
organ prolapse occurs [25].    
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Another factor limiting our ability to have robust definitions of mechanical properties of 
pelvic floor structures is the lack of standardized mechanical testing protocols for biological 
tissue samples. To obtain reproducible results when mechanically testing biological samples 
their unique organization, composition and in vivo functions need to be adapted to the 
mechanical testing protocols. Currently mechanical testing of samples from animal or human 
pelvic floor can mainly be tested by uniaxial and biaxial tensile testing. In uniaxial testing, the 
tissue to be tested is placed between two clamps (clamp-to-clamp testing) and a load is 
applied to the sample in one direction while observing the sample for elongation/ strain. 
Uniaxial testing is most commonly performed in these studies and it gives more reproducible 
results.  
Biaxial testing has the advantage of allowing a more reflective measurement of the in vivo 
loading conditions by applying force from several different directions, not one single 
direction. However biaxial testing is more complex giving highly variable results [27]. In 
addition to this, the preconditioning of the biological samples to be tested, the temperature 
and the level of hydration of the tissues can also potentially affect the test results. With these 
limitations, the mechanical characteristics of healthy vaginal tissue in women have been 
measured to be as follows: the ultimate tensile strength 0.79±0.05 MPa, maximum elongation 
1.68±0.11 mm and elastic modulus 6.65±1.48 MPa [28].   
From a biomechanical point of view, the pelvic floor is a complex structure composed of 
active and passive soft tissue components attached to the pelvic bones (Figure 1.2). Passive 
components of the pelvic floor cannot by themselves generate any force however they can 
resist force when applied to them. These are all together called the pelvic floor connective 
tissues including the fascia. The active components of the pelvic floor are able to 
independently generate force which are mainly the muscular structures such as the levator ani 
muscles and the sphincteric muscles [29]. Muscular structures are mainly striated muscles and 
smooth muscles. Striated muscles of the pelvic floor (levator ani complex, coccygeus muscle, 
external urethral sphincters and external anal sphincters) have a major contribution to the 
biomechanical properties and they play a role in voluntary control of urinary and anal 
continence. The smooth muscles (the smooth muscles in the vaginal wall and internal urethral 
and anal sphincters) are essential in maintenance of continence.   
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Figure 1.2. The main normal support structures forming the female pelvic floor. The sections go from 
surface to deep down in the pelvic cavity as you go from section 1 to 4. The uterus, bladder and rectum 
are removed when necessary for demonstration purposes.      
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The connective tissues of the pelvic floor are an interconnected network of supportive tissues 
including the ligaments, endopelvic fascia and the perineal membrane. They are composed of 
different combinations of extracellular matrix proteins, mainly collagen, elastin and smooth 
muscle, together with blood vessels and nerves. Collagen generally exists in the fibrillar form 
which appears as bundles in cross sectional images. The collagen fibre alignment of the fascia 
is known to directly influence the mechanical properties, with the more aligned the fibres 
towards a particular direction the stiffer the fascia is in that direction (the lower the elasticity/ 
the less distensible) [30]. Another ECM protein is elastin which is an important element in 
those tissues and organs which exhibit resistance and recoil properties. Elastin gives elasticity 
to the structures meaning the structure is stretched when the force is applied and recoil occurs 
when the force is removed.  Abnormalities in the homeostasis of the ECM tissues of the 
pelvic floor and their inability to maintain pelvic floor support have been implied in the 
pathogenesis of pelvic floor diseases [31], [32].  
When defining the biomechanical properties of the pelvic floor it is important to make the 
measurements on specific groups of patients, such as postmenopausal women or women with 
birth trauma. Estimations of the in vivo situation in healthy and diseased subjects has been 
made using computer based modelling methods [29]. Computational models of the pelvic 
floor have the potential to reliably define the normal biomechanical behaviour in the female 
pelvic floor and can predict the mechanisms leading to damage to pelvic floor structures (e.g. 
birth trauma) and pelvic floor disorders. Anatomical, mechanical and biochemical data 
pertinent to pelvic floor muscles and soft tissues are combined mathematically to create 
computational models. Anatomical models demonstrating detailed 3D anatomy of the pelvic 
floor can now be reliably produced thanks to magnetic resonance imaging [33]. The 
remaining considerable challenge seems to be how to integrate the functionality of the 
muscles and other soft tissues into these models. The hope they offer is that once an accurate 
biomechanical model is created, population based data can be applied to these models before 
they are used clinically to predict individual patient/ disease outcomes.  
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1.3. The mechanisms underlying the development of SUI and POP 
 
Both SUI and POP are thought to result from anatomical and/ or functional defects in the 
pelvic floor support structures. The anatomical and functional basis of SUI has been more 
fully investigated than POP.  
1.3.1. SUI 
 
The mechanisms  of female continence are not completely elucidated. It is probably 
multifactorial and complex involving a coordinated functioning of the central and peripheral 
nervous systems, bladder, urethra and the pelvic floor. Urinary incontinence is a problem of 
the storage phase of the voiding cycle and mechanically it occurs when the pressure in the 
bladder, intravesical pressure, overcomes the urethral resistance. During normal bladder 
filling the intravesical pressure remains low despite increasing volumes of urine collected 
inside the bladder. This is due to the viscoelastic properties of the bladder wall (the smooth 
muscle and the connective tissues) called bladder compliance. At the same time spinal reflex 
pathways neurologically inhibit bladder smooth muscle contraction. As a result urine is stored 
inside the bladder at low pressures. Abnormalities in bladder wall, smooth muscle or 
innervation can lead to detrusor overactivity incontinence.  In case of stress UI intravesical 
pressure exceeds that of the outflow pressure when a patient coughs, laughs or strains 
increasing the intravesical pressure. This is thought to be due to a decrease in normal urethral 
resistance.     
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SUI started being systematically evaluated after 1961 when Green devised a classification 
system for SUI based on the radiographic appearance of the bladder neck and urethra. He 
identified two types of SUI: type 1 with a loss of posterior urethro- vesical angle and type 2 
with a rotational descent of the urethra. With the use of urodynamic studies, which at the time 
were reserved to diagnose neurogenic incontinence,  McGuire added a type 3 SUI where a 
low urethral closure pressure and open bladder neck led to SUI. Type 3 SUI is also named as 
intrinsic sphincter deficiency.   With the addition of urodynamic stuies, SUI started to being 
seen as a functional event rather than purely an anatomical defect. The treatment decisions 
also started to be made based on this classification. Types 1 and 2 would be good candidates 
for a retropubic urethropexy procedures which restore the retropubic position of the urethra 
whereas type 3 SUI would best be treated with an autologous fascia sling surgery as many 
patients would have undergone an unsuccessful retropubic urethropexy procedure.   
Urethral support and urethral hypermobility 
The female urethra has an important role in continence. The urethral mucosa and submucoca, 
urethral smooth muscle and periurethral striated muscles all contribute to the generation of 
urethral resistance.    
Historically, SUI was first thought to result from a structural defect in the urethral support 
structures. The female urethra rests on the anterior vaginal wall which constitutes the majority 
of its structural support. Initial theories on the pathophysiology of female SUI emphasized 
that a loss of the retropubic position of the bladder neck and the urethra would lead to SUI. 
Enhorning’ s theory of ‘pressure transmission’ stated that the maintanence of the retropubic 
position of the urethra during states of increased intraabdominal pressure  would lead to 
transmission of the abdominal pressure on to the urethra facilitating urethral compression 
when straining. This theory was confirmed  by the success of operations aiming to restore a 
retropubic position of the urethra (retropubic urethrapexy operations).  
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Intrinsic Sphincter deficiency 
The intrinsic urethral sphincter is formed by the circularly oriented outer fibers of the urethral 
smooth muscle and the detrusor muscle in the bladder base. The intrinsic sphinter mechanism 
contributes to the formation of urethral resistance at rest. Clinically ISD defines a clinical 
condition where the female urethra cannot maintain a watertight seal even at rest. This could 
be a result of laxity in the ISD mechanism or the urethral wall itself can be rigid, fixed or 
scarred. The causes of ISD can be multifactorial involving neurologic, muscular and 
connective tissue dysfunction.   ISD can also be demonstrated urodynamically with lower 
urethral closure pressures (<20 cmH2O) and lower vesical leak point pressures (<60 cmH2O).     
 Although the dichotomy of urethral hypermobility and ISD is still used and constitutes a 
useful framework when starting to evaluate SUI, recently more modern theories have 
provided unified concepts in understanding the pathophysiology of SUI.  Two important 
theories form the basis of the modern understanding of SUI. The ‘integral theory’ suggested 
that urethral closure occurs by the synergistic action of three components of the pelvic floor. 
In the presence of sufficient tension in the pubourethral ligament (PUL), increases in 
intraabdominal pressure lead to contraction of the pubococcygeus muscles (PCM) anteriorly 
and the levator muscles (LM) posteriorly closing the bladder outlet [34].  Overall it is the 
laxity in the anterior vaginal wall that causes SUI. Modern synthetic mid- urethral sling 
surgeries use this principle stating that the placement of the surgical mesh in the position of 
PUL form a backboard against which the urethra can be compressed [35]. This theory takes 
into account structural elements of the urethral support structures as they are dynamically 
acting to maintain continence. 
Similarly the ‘hammock hypothesis’ (Figure 1.3) proposed that the bladder neck and urethra 
normally rest on a hammock of musculofascial structures that enables compression of the 
urethra in cases of increased intraabdominal pressures maintaining the continence [36]. The 
main problem proposed by this model is the structural weakness of the hammock rather than 
the hypermobility of the urethra.   
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All these theories on the pathophysiology of SUI can be seen to have developed together with 
surgical techniques trying to understand how each technique worked. As a result, the surgical 
treatments evolved from urethral compression to restoration of the urethra back to its 
retropubic position and to creating a hammock-like structure where the urethra can be 
compressed when intraabdominal pressure increases.  Additionally, over the years the focus 
has shifted from the bladder neck to the mid- urethra.       
 
Figure 1.3. Illustration explaining the hammock hypothesis (DeLancey, John O.L. Structural 
support of the urethra as it relates to stress urinary incontinence: The hammock hypothesis. 
American Journal of Obstetrics & Gynecology , Volume 170 , Issue 6 , 1713 - 1723) 
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1.3.2. POP 
 
In contrast to SUI, POP has mainly been studied as a structural disease. It is likely that there is 
a functional component because there appears to be major differences in patient defined and 
physician defined treatment outcomes in POP. Current surgical treatments for POP are based 
on identification and repair of anatomical defects that broadly occur at three levels in the 
pelvis. Level I cardinal- uterosacral ligaments providing apical support, level II arcus 
tendinous fascia pelvis supporting middle part of vagina laterally and level III urogenital 
diaphragm and perineal body supporting lower part of the vagina [22]. This anatomical 
description provides the basis of pelvic floor support structures that guides the reconstructive 
surgeon. After the level of the defect is identified it can be repaired by either an abdominal or 
a vaginal approach.  
1.4. Treatment of SUI and POP 
1.4.1. Non- surgical treatment of SUI 
 
Traditionally non- surgical therapies are tried as a first line treatment for management of SUI 
as they usually are associated with least harm to the patient. The main conservative treatment 
option  for women with SUI is pelvic floor muscle training (PFMT). Pelvic floor muscle 
training was first introduced by a gyneacologist, Arnold Kegel, in 1940s. He proposed that 
women with SUI showed evidence of weakness in the muscles  surrounding the bladder neck 
and vagina [37]. PFMT improves SUI by strengthening the pelvic floor and improving 
urethral stabiliy. PFMT is not only used in the treatment of SUI but also to prevent SUI in 
childbearing women or in men before undergoing radical prostatectomy.  
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There is roboust clinical evidence to support the use of PFMT in women with SUI as a first 
line treatment to improve urinary incontinence and quality of life in women with SUI [38]. 
However there is high variability in the administration of PFMT to women. Supervised 
treatment regimes in the form of physiotherapy and schedules with different intensities have 
been used with greater benefit compared to purely self- motivated exercises done by the 
patient. The main limitation of PFMT is the difficulty in maintaining the initial short term 
benefits in the longer term follow up. It has been reported in a 15 year follow up study that 
long- term adherence to treatment with PFMT  was poor and half of patients eventually went 
for a surgical treatment [39]. 
1.4.2. Surgical treatment of SUI 
 
The estimated life- time risk of surgery for either SUI or POP in women was found to be 20% 
by the age of 80 [40]. Surgical treatment for SUI also reduces the money spent on the use of 
protective pads and towels from £3.84 to £1.36 per month [41].  
The surgical treatment of SUI started developing in the early 20th century on three main lines. 
Firstly, SUI was thought to be a result of the loss of the normal retropubic position of the 
urethra. Hence surgical techniques aimed at repositioning the urethra back to its high 
retropubic position. Marshall- Marchetti- Krantz  and Burch colposuspension operations 
where the urethra is secured and fixed in the retropubic area are based on this principle [42]. 
The invention and widespread clinical and surgical use of camera systems to look inside the 
viscus organs allowed cystoscopic assessment of bladder and urethra. This led to recognition 
of the internal urethral sphincter mechanism in the development of SUI. Vaginal plication 
operations such as the Kelly plication procedure, were described to strengthen the urethral 
sphincter [43]. Thirdly, the widespread use of urodynamic studies resulted in the definition of 
intrinsic sphincter deficiency which paved the way for the ‘pubovaginal sling’ operations.  
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The modern autologous fascia sling (AFS) surgeries as described by McGuire [44] and the 
integral theory for female SUI formed the basis for the modern synthetic mesh sling surgeries. 
The placement of the surgical mesh in the position of PUL in a tension free manner would 
induce fibrosis and form a collagenous ‘neoligament’ to replace the PUL forming a backboard 
where the urethra can be compressed [35]. Additionally, the integral theory stated that the 
placement of the fascia sling to the bladder neck was responsible for occurrence of storage 
symptoms after AFS surgeries. Therefore, Ulmsten when defining the synthetic sling 
surgeries suggested an alternative site for placement of the sling, the mid- urethra. The laxity 
of PUL was demonstrated by urodynamic (urethral pressure profile) studies identifying the 
mid- urethra as the most critical location to place the mesh. Importantly, the mid- urethra 
concept was validated by pre and post- operative urethral pressure measurements 
demonstrating improvement in urethral closure pressures after the mid- urethral sling 
surgeries.   
 
1.4.3. Surgical treatment of POP 
 
Historically the treatment of POP relied on pessaries until the 19th century. Advancements in 
the surgical sciences with widespread use of anaesthesia, new suture materials and antibiotics 
led to POP started to being treated surgically. Vaginal hysterectomy was first performed to 
treat uterine prolapse in 1861 by Samual Choppin.  Also obliterative procedures that are still 
being used today for selected cases, such as Le Fort’ s operation (colpocleisis)  was also 
described in second half of the 19th century [45].   
Modern surgical treatments of POP can be grouped as anterior compartment repairs, apical 
repairs and posterior compartment repairs all of which are based on identification and repair 
of anatomical defects. These repairs can be native tissue repairs or augmented repairs where 
biological or synthetic soft tissue support prostheses are used to reinforce the repairs.  
Additionally, the repairs can be performed via a vaginal route (transvaginally) or an 
abdominal route (transabdominally).  
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Anterior compartment repairs involve prolapse of bladder and/ or urethra. The two most 
commonly performed operations for anterior compartment repair are anterior colporrhaphy 
(mostly performed transvaginally) for midline defects and paravaginal repair procedures 
(mostly performed transabdominally) for lateral defects. In both procedures the defective 
pelvic fascia is repaired and sutured to stronger adjacent fascia. Nevertheless, the recurrence 
rates in anterior compartment repair are high which necessitate augmentation of the repair 
site. The first prosthetic  material used to augment an anterior colporrhaphy procedure was 
performed in the mid-20th century to prevent recurrence of prolapse [46].    
Apical compartment repairs when performed transabdominally involve 
sacrocolpo(hystero)pexy operations. Transvaginal approach to fix the vaginal vault to stronger 
ligaments in the pelvic floor are also used involving uterosacral ligament suspension, 
sacrospinous ligament suspension and illiococcygeus fixation.  The posterior vaginal wall 
prolapse involves rectoceles which is mainly treated by posterior colporrhaphy procedures. 
Posterior colporrhaphy is when the rectovaginal fascia is plicated in the midline.   
 
1.5. Biomaterials used in surgical treatment of SUI and POP 
1.5.1.Biological materials 
 
The first biological graft used in 1907 to treat SUI was the autologous gracilis muscle [42]. 
This was followed by use of the pyrimidalis muscle which is a triangular shaped muscle 
attaching to the pubic symphyses ineriorly and the superior margins attach to the linea alba. 
The use of pyrimidalis muscle allowed harvesting the muscle flap through the same incision 
avoiding another incision on the inner thigh (to harvest the gracilis muscle). Muscle flaps 
were taken down and tied together around the bladder neck forming the basis of the first sling 
surgeries. Later on not the muscle but rectus fascia alone started to be used as a sling material. 
The advantage of using fascia alone was that the fascia being an avascular and thin structure 
could  be used as a graft rather than a flap making it easier to transpose from one part of the 
body to another. Another source of autologous fascia was the fascia lata (fascia of the thigh 
muscles).   
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Despite improvements and refinements made to the surgical technique, autologous fascia 
sling procedures  were still associated with significant donor site morbidity. An alternative to 
autologous fascia grafts was obtaining fascia from allogeneic (cadaveric fascia lata, cadaveric 
de- cellularized dermis) or xenogeneic sources (porcine sources of de-cellularized 
extracellular matrix such as dermis and small intestinal submucosa).  Allogeneic and 
xenogeneic sources of ECM can be transplanted after de-cellularization without a significant 
immune response to them. This is due to the conservation of ECM components (such as 
fibrillar collagen and collagen IV) during evolution from the early metazoan ancestor (early 
multicellular organisms)  to human [47].  
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The surgical outcomes of using allogeneic or xenogeneic ECM products in soft tissue 
reconstruction have been reported to be variable due to differences in the source materials and 
processing methods for decellularization and sterilization. For treatment of SUI, biological 
sling materials have been compared with synthetic slings in 12 clinical trials, the meta- 
analysis of which demonstrated equal efficacy in the short term with shorter operative times, 
less perioperative complications  and some evidence of less voiding dysfunction with the use 
of synthetic materials [48]. Additionally on comparison of different biological slings (porcine 
dermis, lyophilised dura mater, fascia lata, vaginal wall, autologous dermis and rectus fascia) 
autologous rectus fascia was found to be associated with better participant reported 
improvement rates within the first year over other biological materials.    
In the case of pelvic organ prolapse repair, a meta- analysis comparing biological grafts with 
native tissue repairs showed no evidence of a benefit with regards to awareness of prolapse 1-
3 years after surgery and prevention in recurrence of the prolapse in women treated with 
biological grafts [49]. Therefore prolapse repair with biological grafts is not any better than 
repair using native tissue repairs.  The use of synthetic materials was proposed  to reduce 
recurrence rates of vaginal POP repair procedures however this is now questioned. In a recent 
randomized controlled trial in the UK, the PROSPECT study, women were randomly 
allocated to vaginal prolapse repair with mesh versus biological graft. In one year follow up 
neither mesh nor the biological graft improved clinical outcomes for patients compared to 
native tissue repairs [50].  Also to be considered is the important potential risk of transmission 
of viral (e.g. Human immunodeficiency virus) and prion diseases and more commonly 
Hepatitis B and C with allografts. All can be reduced by the use of strict tissue banking 
protocols. 
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1.5.2. Synthetic materials 
 
The flow of events show that a prosthetic material would first be used in hernia repair and 
then be transferred to the pelvic floor. The first metallic prosthesis used to treat SUI was a 
‘tantalum’ plate implanted transvaginally, on top of Kelly plication sutures, to induce a 
fibrotic reaction [51].  The main idea here was to form a fixed plane at the posterior part of 
the proximal urethra. No significant adverse events were reported in 8 months follow up.  
Tantalum mesh was then inserted transvaginally to treat cystocele [46]. The logic behind was 
explained by the authors as follows: ‘although there are numerous recognized procedures for 
the correction of cystoceles, there is still a significant rate of recurrence; therefore, a trial use 
of tantalum mesh was considered justifiable’. In four of 10 patients exposure of the tantalum 
mesh was reported.  
Following the advancements in materials science and its application in hernia surgery, the 
first synthetic sling material, a ‘gauze hammock’ made of polyethylene  ((Mersilene®) mesh), 
was used to treat SUI in 1968 [52]. Moir placed the Mersilene mesh hammock to the bladder 
neck and proximal urethra in a tensionless manner and secured the edges of the mesh to the 
rectus fascia. He reported more than 80% success rate in 71 patients at up to 5 years follow 
up. Although no long term follow up data was ever presented tissue damage with dense 
scarring was reported. A few years later, polyethylene was further improved and PPL 
(Marlex®) mesh [53], considered inert and resistant to infection, was used to treat SUI in a  
modified gauze hammock operation where mesh is placed to the bladder neck and attached to 
the Cooper’s ligament. With most patients followed up for 5 years they reported 5% erosion 
rate [54].  
The plastic mesh sling surgeries started to be widely performed only after Ulmsten and Petros 
described the Integral theory of SUI and performed the first intravaginal mesh- sling surgery 
in 1995. Transvaginal POP meshes gained widespread use after the success of MUS surgeries.  
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1.5. Clinical outcomes of mesh repairs for SUI and POP 
 
Currently tension free vaginal tape procedures for SUI have long term subjective cure rates of 
up to 93% [55]. Nevertheless mesh related complications still occur in at least 4% of patients 
[56].  Professional societies and regulatory agencies are stating that the benefits of these 
operations outweigh the risks and that many women would be left without effective 
treatments if the use of mesh was to be banned. 
POP repairs are now being performed in 2 main groups: transabdominal and transvaginal POP 
repair procedures, with most being performed via a vaginal route (transvaginally) [60]. The 
main sites of surgical implantation are demonstrated in Figure 1.4. The safety of mesh 
augmented transvaginal POP repair procedures is widely questioned with a mesh erosion rate 
of 8% in 1-3 year follow- up and can go up to 42% in longer term follow up [57]. There 
appears to be a consensus on lack of safety with transvaginal mesh implantation for POP. In 
contrast abdominal sacrocolpopexy procedures are performed with long term success rates of 
97- 100% [58] and are considered the gold standard surgical treatment for advanced POP 
[59]. Mesh erosion still occurs in these operations in up to 6% in 2 years [60] and 10% of 
cases in 7 years follow up [61] however like synthetic mid- urethral slings the risks of mesh 
augmented abdominal POP repair procedures are considered to outweigh their risks.   
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Figure 1.4. Graphical demonstration of most common sites of surgical mesh implantation in the pelvic 
floor. (a) Transabdominal placement of PPL mesh to treat POP (sacrocolpopexy operations). (b) 
Transvaginal implantation of PPL mesh at the level of mid- urethra to treat SUI. (c) Transvaginal 
placement of PPL mesh for POP repair, 45° lateral view and 45° anterosuperior view. Many variations 
of these operations exist. Here fixation/ anchoring of the mesh to sacrospinous ligament and ATFP is 
demonstrated.  
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1.6. Polypropylene mesh as a material 
The PPL vaginal meshes in current clinical use were never designed or tested specifically for 
use in the treatment of SUI and POP. Instead they were developed for use as a soft tissue 
prosthetic material in the context of abdominal hernia repair. Based on the available clinical 
data on its biocompatibility, the PPL mesh was cleared for use in the female pelvic floor after 
demonstration of the similarity of their textile properties to the existing abdominal hernia 
products via a 510(k) loophole. Therefore, it will be useful to review the context in which the 
PPL mesh developed.   
Three main classes of materials have been used for biomedical applications: metals, ceramics 
and plastics. Plastics (plasticos: capable of being moulded in Greek) are synthetic, high 
molecular weight materials that became available for surgical applications after 1940s. 
Plastics provide unique material advantages over metals and ceramics that make them 
desirable for many biomedical applications.  They have a more advanced performance-to-
weight ratio compared to metals and they can easily be micro fabricated into small and 
complex structures.  Additionally, plastics are versatile materials that can be made into an 
ivory hard object with desired rigidity and strength, a flexible rubbery mass or a porous 
spongy structure. Each of these could be degradable and non- degradable.  
1.6.1.Synthesis and degradation of polypropylene 
PPL ([C3H6]n) is a thermoplastic (that can be processed and re-processed when heated), 
polymer synthesized from propylene monomers by addition polymerization. The resultant 
material is a series of long and flexible linear chains that can be oriented and crystallized. 
After the raw material of PPL is synthesized, it is melted and processed by a technique called 
‘extrusion’ to form the usable end product. Extrusion is the process of injecting a stream of 
molten polymer through a die of constant section. The extrusion process forms continuous 
filaments which are then twisted, knitted and interlocked to form the specific pattern. After 
knitting, the mesh is cleaned of the residuals and stabilized. The finished mesh is than cut into 
shape and sterilized by autoclaving/high pressure steam. The extrusion process is graphically 
demonstrated in Figure 1.5 together with a more modern polymer production method called 
electrospinning. This comparison can give the reader a better understanding of how different 
polymer processing technologies can lead to a significant difference in the final product and 
tissue response to it. A complete comparison is provided in Table 1.    
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Figure 1.5. Demonstration of the industrial process used to produce the monofilament polypropylene  
(extrusion) as compared to the process of electrospinning. The polymer extrusion process to produce 
the monofilament PPL mesh. the end product of the extrusion process gross view and electron 
microscopic view  can be seen in the upper raw. The electrospinning producing micro-nano sized 
fibrous mats are seen in the lower raw.  (yellow and white scale bars represent 200 and 10 µm, 
respectively) 
 
 
Table 2.1.  Comparison of two methods of manufacturing polymers: the extrusion 
process to produce the surgical mesh and the electrospinning process  
 Extruded mesh Electrospun mesh 
Raw material Polymer beads Polymer beads 
Additives Yes No 
Liquifying process Heating Dissolving 
Manufacturing principle Extrusion Electrical field 
Post process Knitting None 
Sterilization Autoclave GMP produced 
Pore size >70 µm 1-10 µm 
Fibre size 300-500 µm 1-10 µm 
Tissue integration Poor Excellent 
Level of technology Industrialized process Tissue engineering process 
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During polymer synthesis a variety of additives are used up to 30% of their  total weight, 
although they are generally much less in medical grade raw materials [62]. Additives are 
essential ingredients that are used to adjust the polymer properties so that they can become 
suitable for industrial processing. Additives can also be used for property enhancement and to 
neutralize the effects of other additives. For example the PPL needs to be  thermally stabilized 
by additives to survive melt processing [63].  Thus the quality of finished PPL surgical mesh 
depends on the quality of the raw materials and additives. 
The manufacturers rely on suppliers of raw materials and components to obtain polymer 
resins. The device manufacturers need to implement supplier qualification procedures that 
include audits, incoming raw material and component specifications and quality metrics. This 
is only required for devices classified as ‘high- risk’ by the FDA. Thus the raw materials 
supplied to manufacturers for PPL mesh production were not strictly controlled by the FDA 
until January 2016, when these vaginal mesh implants were re- classified from class II to III.   
This means the purity, product quality and consistency, molecular weight and additives in the 
PPL mesh can be variable [64]. 
The polypropylene material was traditionally considered as being ‘inert’. Although PPL 
completely degrades over many years, its’ inertness is now questioned after repeated 
demonstrations of surface degradation on the PPL fibres [65], [66].  Synthetic polymers 
degrade by bulk hydrolysis (bulk erosion) and/ or surface erosion after implantation [67]. 
Bulk erosion leads to rapid break down of the material and a decrease in mechanical 
properties whereas surface erosion affects the performance of the material in the long term 
without changing its bulk [68].  PPL does not undergo bulk degradation as it is hydrophobic 
meaning it is not susceptible to hydrolysis.   
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However, PPL can undergo surface degradation after implantation. The biochemical 
environment of the human body represents an aggressive medium with a set temperature (37° 
C), pH (7.4 in blood) and salt concentration [69]. This environment can cause PPL 
degradation by oxidation [70]. Furthermore, this can be considerably facilitated by the 
presence of static or cyclic mechanical forces. A focal site of surface cracking, abrasion or 
wear can induce generation of macroradicals originating from chain rupture leading to 
increased brittleness and deterioration in strength. Data has demonstrated that PPL mesh 
extracted from pelvic floor of women shows surface fissures and cracking due to oxidative 
degradation [71]. Tissue sections of mesh explants also showed signs of PPL degradation 
[65]. Thus PPL mesh is resistant to hydrolytic degradation however it undergoes significant 
chemical and mechanical changes in human body and cannot be considered inert.   
1.6.2. Mechanical properties of polypropylene mesh 
 
In addition to biochemical properties, plastics have unique mechanical properties that are very 
much time dependent, often non- linear and that affect their performance in the long term. 
When a controlled force (stress) is applied to a plastic it causes a change in its size (strain) 
which is initially proportionate to the force applied (linear elasticity) (Figure 1.6). This 
proportionality is lost at some point and the stress- strain curve becomes non- linear. In the 
linear region the material turns back to its exact original size/ shape after the force is removed 
(elastic region). The end of elastic region is marked by the ‘yield point’ in the stress- strain 
curve. The yield strength of a material is the strength after which a material begins to 
plastically deform where permanent and irreversible disfigurement of the material occurs (the 
plastic region) and after the yield point the material does not come back to its original state 
when the force is removed.     
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Figure 1.6. Defining basic mechanical properties of a material by uniaxial mechanical 
testing. The tensiometer setup is demonstrated in (A). The load- elongation curve produced 
by this test is demonstrated in (B) together with the change in appearance of the sample 
loaded to the tensiometer.  
 
 
The biomechanical integration of the implant with the host tissues is fundamental to its long 
term efficacy. The mechanical properties of the material are required to be comparable to that 
of the tissue of implantation. Assuming that the mechanical properties of the PPL mesh is 
stable in vivo over years, the mesh material can be characterized mechanically. Defining the 
engineering requirements for pelvic implants is rather difficult due to the complexity of the 
anatomical structures and the variability of the forces/ loading conditions acting on them in 
health and disease.  The uniaxial testing of the PPL mesh show that the PPL mesh is 5- 10 
times stronger than those of the healthy paravaginal tissues [72].  Thus the PPL mesh is 
probably far too strong to be used in the pelvic floor.  
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1.6.3. In- service failure of polypropylene mesh 
 
Plastic biological implants, can fail in service mechanically and/ or biochemically. 
Mechanical failure of an implanted biomaterial often results from an inaccurate estimation of 
the static and dynamic loads/ forces the material will undergo at the site of implantation 
during its lifetime. Defining the in vivo loading conditions and boundary conditions play a key 
role in the mechanical compatibility of the material and the tissue. For example, if the mesh is 
mainly bearing load, it needs to be tested in a certain direction by uniaxial testing whereas if it 
is working like an abdominal wall mesh it is better tested by its biaxial mechanical properties. 
It has been demonstrated that the same materials when tested by uni and biaxial mechanical 
tests can show significantly different mechanical properties [73]. Thus when defining the 
mechanical requirements of the mesh it has to be defined for a specific surgical application. 
Another possible mechanism for the failure of the PPL mesh can be due to cyclic stress that 
the mesh undergoes over weeks and months. When designing the mesh implant if the yield 
strength of the material is not calculated correctly, the material can start undergoing plastic 
deformation a little each time in response to a force more than its yield strength and this when 
repeated over time causes the material to  ‘strain harden’ [74]. Strain hardening indicates that 
the material will increase in stiffness over time resulting mechanical properties different to its 
original state.   
 
1.6.4. Initial design of the polypropylene mesh and improvements made to the initial 
design   
 
Ventral hernia occurs due to a defect in the fascia covering abdominal muscles and surgical 
treatments aim to repair the structural defect. Prosthetic materials have been used to treat large 
tissue defects that could not be closed with primary suture repairs or to reduce the chances of 
recurrence. It is attributed to Theodore Billroth (1829-1894) that “If we could artificially 
produce tissues of the density and toughness of fascia the secret of the radical cure of hernia 
would be discovered” [75].   
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The first prosthetic material used in hernia repair was made of silver, followed by tantalum 
(Figure 1.7). Tantalum wire mesh became quite popular at that time due to its inertness and 
ability to withstand infection however metals were inherently not suitable for soft tissue 
repairs as they were stiff and could fragment. After the plastics revolution materials made of 
nylon (polyamide) and dacron (polyester [polyethylene terephthalate (PET)]) started to be 
used [76]. Although the plastic meshes offered significant advantages over metallic meshes 
with their ductility and strength, the initial meshes were actually textile fabrics made of 
plastics which were boiled for sterilization before implantation. These plastics induced a 
dense fibrotic reaction and the infection rates were high.  
It was only after Usher, who is a hernia surgeon, started to design a fit- for- purpose material 
that the surgical mesh gained widespread acceptance. He used a high density polyethylene 
and used a new manufacturing method to ‘extrude’ it as a monofilament with a thread count 
of 42 by 42 to the inch [77]. He optimized the porosity, stretch-ability and tensile strength of 
the new mesh to allow fibroplasia while keeping the necessary tensile strength.  He then 
characterized the tissue response to the mesh in animal studies [78]. In 1962 Usher introduced 
an improved version of Marlex mesh made of polypropylene (PPL). PPL had improved 
material properties with higher heat resistance allowing sterilization with less compromise, it 
had high tensile strength with good flexibility and excellent resistance to infection [79]. PPL 
than became the standard of the modern mesh materials [80].  
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Figure 1.7. Milestones in development of the polypropylene mesh (PPL) as a material 
used in pelvic floor repair. (only mesh augmented incisional hernia repair procedures as 
they are related to mesh positioning are included here). 
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Over the next few years heavy weight meshes were replaced by medium to light weight 
meshes that reduced the bulk of the foreign material leading to less inflammation, foreign 
body reaction, fibrosis and the associated pain sensation [94]. Also the pore sizes were made 
larger (macropororus). The first study to demonstrate a relationship between the material 
properties and side effects associated with the mesh when used in hernia repair was published 
by Amid [92]. In this study the porosity of the mesh was suggested as the main determinant of 
biocompatibility of a mesh implant. Later on, animal studies comparing heavy and light 
weight meshes showed that light weight PPL mesh displayed a marked reduction in fibrosis 
and foreign body reaction compared to heavy weight PPL [95]. Also clinical studies 
comparing heavy and light- weight mesh materials implanted for inguinal hernia repairs 
demonstrated less pain and less sensation than of a foreign material with lighter meshes [96]. 
Thus the current PPL mesh has evolved over the years from a metal wire to fabrics of plastic 
and eventually to the current mesh with a range of bulk densities and pore sizes.   
When surgical mesh was first introduced it offered clear advantages over the previous 
prosthetic material made of metals. However, it also came with a new set of complications 
that were predominantly related to the use of plastics such as mesh contraction and 
colonization/ infection of the mesh. Modifications to the surgical technique of implantation 
were then made to avoid these complications (Figure 1.8). For example, the ‘inlay repairs’ 
where the mesh is placed in- between the edges of the fascia defect were replaced with ‘onlay 
repairs’ where the mesh was placed on top of the repaired fascia defect in a tension- free 
manner. Onlay repairs involved extensive subcutaneous tissue dissection and also a large area 
of the mesh implant stayed very close to skin increasing the chances of wound complications 
such as infection and seroma formation.  To overcome this a ‘sublay (retrorectus) technique’ 
was introduced where the mesh is put underneath a thick muscle tissue (retro- rectus) in-
between two fascial layers. Placement of the mesh onto a well vascularized wound bed and 
away from the skin were key factors in the success of this technique [97]. The ideal location 
of mesh in ventral hernia repair remains debatable and different methods are indicated for 
each specific case however it is certain that the surgical technique of implantation is a factor 
that has contributed to mesh related complications in hernia repair surgeries [98]. 
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Figure 1.8. Graphical demonstration of mesh positioning in relation to muscle and fascia in 
incisional hernia repair. (A) A cross section of anterior abdominal wall with a fascia defect 
causing herniation of the intestine.  (B) Inlay mesh implantation where the mesh fills in the 
gap created by the fascia defect. (C) Mesh onlay repairs where the mesh is on top of the 
fascia repair to reinforce it.  (D) In the sublay technique the mesh is placed on a well 
vascularized wound bed underneath the muscle and it is in- between two strong fascial 
layers. (E) The mesh underlay procedures are mainly used in laparoscopic hernia repair 
procedures, in this case a mesh with anti- adhesive properties would be preferable instead of 
a polypropylene mesh to prevent attachment of intra-abdominal organs.  
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Just like new materials necessitated new surgical approaches, developments in the surgical 
technologies also required modifications in material properties in hernia surgery. For 
example, recent widespread use of laparoscopy led to an ‘underlay’ repair technique where 
the mesh is placed on the inside surface of the abdominal wall in direct contact with 
intraabdominal organs. The mesh in these cases needed to have additional anti- adhesive 
properties, such as Teflon based materials, to prevent adhesion of intraabdominal organs [99]. 
Thus the material properties and surgical technique developed hand to hand over many years 
to obtain best outcomes for hernia repairs.    
 
1.6.5. Why did the polypropylene mesh fail in the pelvic floor? 
 
The PPL mesh failed in the pelvic floor both biologically and mechanically. The biological 
response to PPL has mainly been studied histologically in the context of hernia surgery. 
Experimental studies to evaluate the tissue response to PPL in  vaginal surgery started in 2007 
[100], showing that graft related complications (exposure and contraction) occurred more 
when the mesh is implanted to vagina rather than in the abdominal wall [101]. In transvaginal 
mesh implantation the material traverses a clean contaminant area and it is very hard not to 
get the mesh contaminated during insertion. Minutes after mesh is inserted into body a ‘race 
for the surface’ begins and if the host cells cannot win the mesh gets contaminated which can 
remain dormant without causing obvious problems for a long time. Also after mesh 
implantation an inflammatory reaction begins which leads to tissue remodelling or a persistent 
inflammatory response. In the background of chronic inflammation, colonization and 
mechanical failure events leading to chronic pain, mesh contraction and erosion can occur 
[102].   We cannot currently predict which patients will be affected more by mesh 
complications.  
Mechanically, the PPL mesh is now thought to be incompatible with the female pelvic floor. 
Essentially the PPL mesh is too strong and not elastic enough to be used in the pelvic floor 
[103], [104]. Other factors that have contributed to emergence of the vaginal mesh issue as a 
public health problem are listed in Tables 2 and 3.   
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Table 1.2. Problems that have occurred during development of meshes for pelvic floor 
repair 
1. Lack of necessary regulations for approval of medical devices  
a. Devices granted approval with no/ limited clinical data 
2. Lack of understanding of female pelvic floor disorders 
a. The female pelvic floor is structurally and functionally complex 
b. Pelvic floor biomechanics not well studied 
c. Targets for surgical treatment generally poorly defined, particularly in 
transvaginal POP repairs 
3. Problems related to the material  
a. Surgical mesh not designed for use in pelvic floor 
b. Limitations in available technologies and materials at the time 
c. Polypropylene considered inert however it undergoes surface degradation  
4. Factors related to surgical technique 
a. Proximity of large areas of mesh implant to skin wound 
b. Implantation of mesh on to a poorly vascularized wound bed 
5. Lack of relevant animal models of efficacy 
 
Table 1.3. Problems that have occurred after the mesh was made available for 
widespread clinical use. 
1. Lack of implementation of post marketing surveillance  
2. Poor patient selection 
a.  Poorly defined disease subgroups  
b. ‘One size fits all’ approach 
3. Factors related to operating surgeon 
a. Poor subspecialty training on management of all aspects of SUI and POP 
b. Minimally invasive operations perceived as ‘easy to do’ 
4. Extensive marketing  
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1.6.6. Current approaches to improve the polypropylene mesh 
 
Efforts to make further improvements to the current surgical mesh are still ongoing. It is now 
widely accepted that the new generation, light- weight, macroporous meshes with high 
porosities are desirable to ensure a better mesh remodelling and reduce complications such as 
fibrosis, pain and mesh failure. The knit pattern and geometry of the mesh can also be 
modified to obtain desired mechanical properties [105].   Another approach to enhance the 
biocompatibility of PPL is to apply a bioactive coating onto it with more biocompatible 
substances, such as natural extracellular matrix [106]. Titanium coated light weight 
polypropylene meshes was also used in a pilot patient group to improve the biocompatibility 
of the PPL mesh [107].  
There has also been research on degradable and hybrid degradable/ nondegradable mesh 
materials.  The main idea behind a degradable mesh was that it would be absorbed after a 
period of time by which time the patients’ own tissues would have at least partially recovered 
or regenerated and this would avoid the long term complications of permanent mesh like 
infection and fistula formation. The concept of using biodegradable scaffolds or support – 
often combined with patient cells to help regenerate tissues is well accepted in the world of 
tissue engineering and regenerative medicine [108] but has not yet been trialled clinically with 
respect to POP although there are materials in development. 
1.7. Tissue engineering to construct biomaterials for pelvic floor 
 
Advances in materials science and tissue engineering are finally being applied to designing 
novel materials specifically for use in the pelvic floor.  The first tissue engineered approach to 
construct an autologous fascia equivalent for POP repair was reported in 2010. In this study 
human vaginal fibroblasts were seeded on a PLGA knitted mesh before implantation into 
nude mice for 12 weeks and a well- organized new fascia with a high collagen I/III ratio was 
demonstrated [109]. A stronger tissue engineered material was also constructed from knitted 
silk mesh seeded with adipose derived MSCs in 2013 [110]. A gelatine coated- polyamide 
knit mesh seeded with endometrial MSCs that was designed for POP repair was also  shown 
to reduce inflammatory cell infiltration and increase neovascularization in a rat model in 2013 
[111].  
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1.7.1. Previous work from Sheffield group: Choice of material and manufacturing 
technique 
 
Our own group in Sheffield has also been developing biomaterials and tissue engineered 
substitutes to be used in pelvic floor repair over the last 8 years. 
With respect to choice of materials we think it is important to be able to consider a range of 
degradable and non- degradable materials. The Sheffield group has mainly produced work on 
a biodegradable material, Poly-L-lactic acid (PLA) and a nondegradable polymer of 
polyurethane.  PLA is known to have good biocompatibility and is commonly used in drug 
delivery applications [112]. Another promising material was polyurethanes with increased 
elasticity that can withstand cyclic mechanical distension in vitro [113]. The electrospun 
polyurethanes, together with electrospun ureidopyrimidinone- polycarbonate scaffolds,  led to 
a better host response compared to ultra- lightweight  PPL meshes after implantation in to 
sheep vagina  for 6 months [114]. Electrospun materials and ultra- lightweight PPL were 
similar in this model with regards to graft related complications, passive mechanical 
properties and their effects on vaginal contractility.         
Electrospinning is a widely used technique in tissue engineering that allows fabrication of 
scaffolds with micro/ nano sized fibres with different compositions and configurations. This 
technique can effectively be used to build scaffolds with several layers of different polymers 
in order to achieve desired biomechanical properties [115]. For example, transversely, 
obliquely and irregularly aligned  fibres can be electrospun in a tri-layer structure with 
ultrastructural and biomechanical properties similar to native fascia [30].  Also we have 
shown that PLA scaffolds with random fibres have mechanical properties close to those of 
healthy paravaginal tissue [116] while showing successful integration into native tissues in 
short term [117].  
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PLA as a material 
Polylactide (PLA) is a biodegradable polyester synthesized from the monomer ‘lactic acid’ 
which is made by bacterial fermentation of carbohydrates such as corn and potatoes. PLA has 
several chiral forms such as poly (L-lactic acid) (PLLA), poly (D-lactic acid) (PDLA) and 
poly (D,F-lactic acid) (PDLLA). PLLA is most commonly used and studied in biomedical 
applications.  Higher molecular weight PLLA can take more than 5 years to degrade. PLA is 
highly biocompatible and as a degradable polymer it is commonly used as a drug delivery 
material [112].  
Polymers have the obvious advantage of being strong enough and ductile especially for soft 
tissue regeneration.  The word polymer refers to huge macromolecules made of repeating 
structural units called monomers (‘polus’: many and ‘meres’: parts in Greek). For instance, 
polysaccharides are made of single sugar units or polypropylene is a polymer made of 
‘propylene’ monomers. Polymers can be natural or synthetic. Natural polymers can be derived 
from plants or animal sources and they share similar features with the extracellular matrix of 
humans. Therefore, natural polymers are recognized, metabolized and degraded by the tissues. 
Additionally, natural polymers are known to be stimulate less immunological reactions and 
toxicity compared to synthetic polymers. Commonly used natural polymers are chitosan, 
hyaluronic acid, gelatin and cellulose. The main limitations of natural polymers are variability 
in the material properties depending on the source of isolation, the risk of contamination with 
microorganisms, poor mechanical strength and unpredictable degradation pattern.  
Synthetic materials have the main advantages of being available ‘off the shelf’ and being 
synthesized at reproducible quality and purity. Additionally, synthetic materials can be 
produced into various shapes and surface properties. The material properties of synthetic 
polymers are continuously being improved in the last half of the century to tailor the 
degradation times and improve the tissue response to these materials. The chemical properties 
of the material are the main determinant of its’ biocompatibility. However, it appears that 
numerous issues related to the biochemistry of the materials have not been identified and 
addressed in in vitro and in vivo experiments before they are translated into clinical practice. 
This is especially true for biomaterials whose material properties change over time after 
implantation leading to a significantly different host response in the long term [118].       
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Polymers most commonly used for soft tissue regeneration are PolyLactic Acid (PLA), 
PolyGlycolic Acid (PGA) and PolyCaproLactone (PCL). All these polymers are approved by 
FDA for a variety of application mostly in suture materials. Basic physical properties of these 
polymers are listed in Table 4.  
 
Table 1.4. A summary of the physical properties of the polymers most commonly used in 
scaffolds for soft tissue regeneration (* polymers used in this thesis). 
Polymer Degradation time  Tg (°C) Tm (°C) Tensile modulus 
PLLA* >2 years 60- 65 175 2.7 GPa 
PGA 6- 12 months 35-40 >200 6 GPa 
PCL >2 years 54 55- 60 0.4 GPa 
PU* 12-18 months -35 180 1.31- 2.07 GPa 
PPL Non-degradable -10 165 800- 1300 MPa 
 
 
 
1.7.2. Design requirements for materials to be used in pelvic floor reconstruction 
 
The PPL vaginal meshes in current clinical use were never designed or tested specifically for 
use in pelvic floor. The best available material was empirically used in pelvic floor based on 
an assumption that if it worked well in the abdomen to reinforce hernia repairs it would work 
equally well to support vaginal prolapse repairs. It is now being recognized that this approach 
was inherently flawed as the microbial flora, pH, vascular supply and physiological 
mechanical requirements of the pelvic floor are different from that of the abdomen.   
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The search for an ideal graft material to be used in pelvic floor continues since mid- twentieth 
century. An ideal graft has been defined arbitrarily as being biocompatible, noncarcinogenic, 
nonimmunogenic, able to provide structural support until tissue healing is completed, pliable, 
sterilizable, readily available, inexpensive and have a minimal risk of infection. Additionally, 
any material used to support the pelvic floor needs to have defined characteristics of material 
deformation and load bearing as well as how it contributes to tissue remodelling once it is 
implanted in to the body.    
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Biocompatibility is the ability of the biomaterial to perform with an appropriate host response 
that is defined for a particular clinical application [119]. This definition is often criticized for 
not providing any insights on how to assess biocompatibility or how to improve it . A tissue 
response is expected to any biomaterial once in contact with the host and what is needed is a 
mutually acceptable co- existence of the biomaterial and the host tissues while the biomaterial 
exerts its desired function. There are very many different ways the materials and tissues can 
interact. Classically, any synthetic material implanted in the body will trigger an 
inflammatory reaction sequentially involving acute inflammation, chronic inflammation, a 
foreign body reaction and wound healing/ scar formation. Under normal circumstances all 
available biomedical implants will generate a similar foreign body reaction that leads to 
formation of a fibrotic capsulation reaction with a thin (50 to 200 µm), tough, collagenous and 
avascular tissue around the implant material [120]. The fibrous capsule often defined as a 
desirable outcome from a clinicians point of view when the implant performs desired 
functions without causing any adverse reactions. However, in some cases, such as pain and 
deformation seen in capsular contracture of breast implants, foreign body reaction is 
considered an undesirable outcome that can necessitates excision of the implant.    
 
Current understanding of biocompatibility defines a host response to the biomaterial that is 
more similar to normal wound healing where a healthy, vascularized tissue is formed in the 
biomaterial- tissue interface rather than the fibrous capsule. This could be achieved by 
reducing the capsule formation and increasing the vascularity around the implantation site 
[121].  Although the exact relationship between angiogenesis and foreign body reaction and 
biocompatibility of an implant material is not clearly defined, it was recently proposed that 
blood vessel density was directly correlated with the biocompatibility of an implant [122]. 
Therefore, a controlled increase in the angiogenesis in the surrounding tissues could be a 
strategy to increase the biocompatibility of the biomaterial.  
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1.7.3. Angiogenic properties of tissue engineered materials 
 
The growth of new blood vessels into a tissue engineered substitute is crucial to improve its’ 
tissue integration and to obtain a successful long term clinical outcome. It has been estimated 
that a distance of less than 200 µM from the supplying capillary is the critical distance for 
diffusion of oxygen and nutrients to any new tissue introduced into the body. Because of this 
the  survival of any 3- dimensional tissue graft relies on rapid development of new blood 
vessels to supply not only the centre but also the margins of the graft [123]. A specific 
consideration should be given to clinical scenarios where the wound bed accommodating the 
biomaterial is already poorly vascularized, such as pelvic floor tissues of postmenopausal 
women with SUI and POP [124].  Clinical studies have demonstrated that post- menopausal 
women and women with co-morbidities that can have a negative impact vascular supply to 
tissues (e.g. diabetes, smoking, previous surgeries)  were more likely to experience vaginal 
mesh related complications [125].  
All attempts to design tissue engineered repair materials need to include an understanding of 
angiogenesis.  Angiogenesis is the sprouting of capillaries from pre-existing blood vessels in 
vivo. This process involves a complex interaction between endothelial and non- endothelial 
cells as well as many enzymes, growth factors and adhesion molecules. Several strategies to 
promote angiogenesis of tissue engineered constructs have been described [126], these 
include: (1) engineering a scaffold that allows easy attachment and proliferation of endothelial 
cells, (2) designing the microstructure to aid the formation of capillaries, (3) providing 
angiogenic growth factors into the microenvironment within the biomaterial either directly by 
incorporating a growth factor into the scaffold material or indirectly by seeding a cell source 
that is able to synthesize angiogenic factors onto the material such as stem cells or genetically 
modified cells.  
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Accordingly, strategies for the introduction of clinically acceptable agents  that would 
stimulate neovascularisation and new extracellular matrix production by the patient's 
endogenous cells have been assessed in the current work. To this end, effective 
pharmacological functionalization of electrospun PLA scaffolds by incorporating clinically 
acceptable bioactive factors such as vitamin C and Estradiol without compromising structural 
and mechanical properties are being assessed  [127]. Estradiol and ascorbic acid were selected 
as a) both are already in use clinically which will make their regulatory approval less 
challenging, b) within the group it has been demonstrated that both can increase extracellular 
matrix (ECM) production as they are released from PLA scaffolds without compromising 
mechanical properties of these materials. To the best of our knowledge neither of these drugs 
has ever been investigated regarding their effects on the intrinsic angiogenic potential of a 
tissue engineered biomaterial.   
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1.8. Aims and Objectives 
 
Aim:  The aim of this project is to develop biocompatible synthetic materials for pelvic floor 
repair that can promote angiogenesis and improve tissue regeneration.  
 
The specific objectives to accomplish this are; 
 
1. To establish an in vivo bioassay to study the angiogenic potential of tissue engineered 
materials  
a. To explore the feasibility of running an ex ovo version of the traditional chick 
chorionic allantoic membrane (CAM) assay. 
b. To evaluate embryo survival rates in ex ovo cultures 
c. To find the best way of obtaining high quality images for image analysis 
d. To explore the best way of visualizing all macro and microvessels of the CAM 
e. To assess if any added value can be obtained from the ex ovo cultures of the 
chick embryo 
2. To evaluate the chick aortic ring assay as an organ culture assay to study endothelial 
cell sprouting  
3. To construct electrospun PLA scaffolds that release Vitamin C  
a. To determine the release characteristics of Vitamin C from the scaffolds 
b. To characterize the Vitamin C releasing scaffolds with regards to their 
ultrastructure and mechanical properties 
c. To assess how the scaffolds, affect proliferation and extracellular matrix 
production of cells (either fibroblasts or adipose derived stem cells) grown on 
these scaffolds  
d. To assess the angiogenic potential of Vitamin C releasing scaffolds on an ex- 
ovo CAM model. 
e. To assess the initial tissue response to the materials 
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4. To construct electrospun PLA scaffolds that release Estradiol  
a. To determine the release characteristics of Estradiol from the scaffolds 
b. To characterize the Estradiol releasing scaffolds with regards to their 
ultrastructure and mechanical properties 
c. To assess how the scaffolds, affect proliferation and extracellular matrix 
production of cells (either fibroblasts or adipose derived stem cells) grown on 
these scaffolds  
d. To assess the angiogenic potential of Estradiol releasing scaffolds on an ex- 
ovo CAM model. 
e. To evaluate the effect of Estradiol on the microvasculature of the CAM 
f. To assess the initial tissue response to the materials 
5. To analyse if stem cells can provide any added benefit when added to scaffolds to 
promote angiogenesis 
a. To find an appropriate cell carrier to keep the stem cells on the CAM 
b. To find the most effective concentration of stem cells to promote angiogenesis 
in a chick aortic ring assay    
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Chapter 2. Materials and Methods 
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2.1. Cells 
 
Two cell types were used in the experiments included in the current doctoral studies: human 
dermal fibroblasts and human adipose derived stem cells. Both cell types were isolated from a 
regular supply of donated skin and subcutaneous fat  of patients undergoing breast reduction 
and abdominoplasty. All patients had given informed written consent and all procedures were 
covered under a research tissue bank license by the Human Tissue Authority (number 
08/H1308/39). 
2.1.1. Fibroblasts 
 
After donated skin was received in the laboratory a split thickness skin graft was taken using a 
Watson knife by a named technician under laminar hood. Skin grafts were then cut into 0.5X 
0.5 cm squares and incubated overnight at 4°C in a solution of 0.4% trypsin plus 0.1% w/v D-
glucose in phosphate buffered saline (PBS) to enable easy separation of epidermal and dermal 
layers. After trypsinisation skin grafts were taken into a Petri dish and epidermal layer was 
peeled off the dermis using a forceps and scalpel. Dermal layer was used for fibroblast 
isolation. After washing with PBS the dermal pieces were minced thoroughly using a scalpel. 
Minced dermis was incubated overnight at 37°C in a 10 mL solution of 0.05% collagenase A 
in media. Next day the collagenase was neutralized, the resulting suspension was centrifuged 
at 1300 rpm for 10 minutes and the precipitate was resuspended in fibroblast growth media in 
T25 flasks. Fibroblast growth media consisted of Dulbecco's Modified Eagles's Medium 
(DMEM) (Gibco Invitrogen, Paisley, UK) supplemented with 10% foetal calf serum 
(Advanced Protein products, Brierly Hill, UK), 1% penicillin/streptomycin and 0.5% 
Fungizone (Gibco Invitrogen, Paisley, UK). After the first passage HDFs were cultured in 
T75 flasks and incubated at 37°C in the presence of 5% CO2 with fresh media changes every 
3–4 days. Regular inspections under inverted microscope were undertaken daily to visualize 
cell morphology of the growing cells and exclude any infections. For the experiments HDFs 
between passages 4- 9 were used.  
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Passaging was performed using incubating the cells with 4 ml of trypsin/ EDTA solution 
(Sigma- Aldrich, Dorset, UK) per flask for 4 minutes.  Thereafter, the trypsin was neutralized 
with media, cells counted using a haemocytometer and the cell suspension was centrifuged at 
1000 rpm. The pellet was than divided into 3-4 new T75 flasks at a density of 100.000 to 
1.000.000 cells per flask.   
2.1.2. Adipose derived stem cells 
All ADSC isolation and characterization experiments were performed in collaboration with 
Dr Sabiniano Roman. Small lumps of human subcutaneous fat was placed in Petri dishes 
containing 10 mL of PBS containing 1% penicillin/ streptomycin.  Initially the fat tissue was 
minced in a Petri dish using a sterile scissors and collected into a 50 mL centrifuge tubes. An 
equal volume of 0.1% collagenase type A solution in HANKS buffer was than added into the 
centrifuge tubes and incubated in 37°C for 40 minutes while shaking the tube every 10 
minutes to facilitate enzymatic digestion. The collagenase was then neutralized adding an 
equal amount of culture  media and centrifugation performed at 1300 rpm for 8 min. The 
supernatant containing all the undigested fat tissue is discarded and the supernatant (stromal 
vascular fraction) was resuspended in culture media. After the supernatant was washed with 
media and centrifuged again, the pellet was resuspended and cells were seeded in T25 flasks 
containing 4 ml of DMEM medium. Flasks were incubated in at 37°C and 5% CO2.  
Next day the media was removed and flasks were washed with PBS removing all the non- 
adherent cells. Regular inspections under inverted microscope were undertaken daily to 
visualize cell morphology of the growing cells and exclude any infections. Once the growing 
cells reached to a confluence of 80% passaging was performed using 2 ml of Trypsin/ EDTA 
(Sigma- Aldrich, Dorset, UK) per flask for 4 minutes. After the first passage cells were 
seeded into T75 flasks and for the experiments ADSCs between passages 3- 6 were used.        
Cryopreserved ADSCs were also used. Previously isolated and characterized ADSCs were 
resurrected from cryogenic frozen vials and were cultured in T75 flasks which were then 
incubated in at 37°C and 5% CO2. Regular inspections under inverted microscope were 
undertaken daily to visualize cell morphology of the growing cells and exclude any infections. 
Once the growing cells reached to a confluence of 80% passaging was performed using 4 ml 
of Trypsin/ EDTA (Sigma- Aldrich, Dorset, UK) per flask for 4 minutes. ADSCs between 
passages 3- 6 were used in all experiments. 
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2.2. Scaffolds 
 
Electrospun Poly- (L)-lactic acid (PLA) scaffolds were produced with electrospinning 
technique (Figure 2.1). Polymer solutions were made by dissolving 10% w/v PLA (Sigma- 
Aldrich, Dorset, UK) (density: 1.24 g/ cm3, Mw 55-90K) in Dichloromethane (DCM) 
overnight on a benchtop shaker. After homogeneous solutions of suitable viscosities for 
electrospinning are formed polymer solutions were loaded into 5 mL syringes each fitted with 
an 18 G  blunt tipped stainless steel needle (I&J Fisnar Inc.). Four syringes were loaded onto a 
programmable syringe pump (Aladdin 1000) attached to a purpose built electrospinning rig in 
a fume cupboard. The collector was wrapped with an aluminum foil and the distance between 
the tip of the blunt needle and the collector was arranged to be 17 cm. A copper plate 
punctured at 4 locations to form a diamond shape was fitted over the needles for equal 
distribution of electrical current. A crocodile clip that was connected to the voltage generator  
was than attached to the copper plate. The opposite charged end of the voltage generator was 
connected to the rotating collector with use of another crocodile clip.  The syringe driver was 
set at a constant rate of 40µl/ min.   The voltage generator was set at 15kV. During 
electrospinning the formation of Taylor’ s cone was observed at all times and excessive 
polymer solution that accumulated at the tip of the blunt needle was continuously removed 
with use of a sterile nonconductive rod. At the end of electrospinning the resultant sheet of 
scaffold was removed off the rotating collector along with the aluminum foil.       
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Figure 2.1. The electrospinning setup 
 
 
 
2.2.1. Preparation of drug releasing scaffolds 
 
In addition to the standard electrospinning procedure described above, blend electrospinning 
and emulsion electrospinning techniques were used to form drug releasing scaffolds. A list of 
electrospun PLA scaffolds studied in this thesis is given in Table 2.1. In case of 17β Estradiol 
a homogeneous solution of the lipophilic Estradiol in DCM could be formed. Hence, a blend 
electrospinning technique where the drug is simply dissolved in polymer solution was used. 
However, in case of Vitamin C, the high hydrophilicity of the vitamin did not allow 
dissolution in DCM (Figure 2.2). Therefore, a stable emulsion of Vitamin C in polymer 
solution was formed before electrospinning.  
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Table 2.1. A list of biomaterials produced 
Scaffold Acronyms used Technique of 
production 
Ingredients 
Electrospun PLA PLA Electrospinning PLA 
Estradiol releasing 
PLA 
PLA Estradiol Blend 
electrospinning 
PLA, Estradiol 
Emulsion 
electrospun PLA 
Vehicle scaffold Emulsion 
electrospinning 
PLA, Span80, Water  
Ascorbic Acid 
releasing PLA 
PLA_AA Emulsion 
electrospinning 
PLA, Span80, AA in 
Water 
Ascorbate-2 
phosphate  
releasing PLA 
PLA_A2P Emulsion 
electrospinning 
PLA, Span80, A2P in 
Water 
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Figure 2.2. Demonstration of preparation of stable emulsions from the polymer solution. In 
(A) phase separation of polymer solution when the water phase containing Vitamin C is 
added can be seen (red arrow). (B) is the stable emulsion obtained using the surfactant where 
water phase contains Vitamin C and oil phase contains PLA polymer. (C) control where only 
Vitamin C powder is mixed with polymer solution where the powder settles at the bottom 
and to the sides of the glass (blue arrow).   
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2.2.2. Emulsion electrospinning 
 
After PLA polymer was dissolved in DCM as described above, 50 µl of surfactant, Span80 
(Sigma- Aldrich), was added to the polymer solution while stirring at a rate of 250 RPM with 
the aid of a rotating magnet inside for 10 min. Two forms of Vitamin C were used: ascorbic 
acid (AA) and ascorbate-2 phosphate (A2P). Vitamin C was dissolved in 500 µl of distilled 
water and added drop wise into the polymer solution containing the surfactant while stirring at 
a rate of 1000 RPM. For control scaffolds (Vehicle scaffolds) distilled water without any drug 
was used to form an emulsion. The polymer solution was observed to turn into a milky, stable 
emulsion gradually. After a stable emulsion was formed all the emulsions were immediately 
electrospun.  The resultant electrospun fibres are known to result in a core- shell morphology 
where the hydrophilic Vitamin C is in the core while the hydrophobic PLA polymer formed 
the shell (Figure 2.3).   
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Figure 2.3. Graphical demonstration of preparation of the emulsion electrospinning solutions. 
The hydrophilic Ascorbic Acid (AA) and Ascorbate- 2 – phosphate (A2P) dissolved in 
distilled water (dH2O) were added into the polymer solution obtained by dissolving 
Polylactic acid (PLA) in dichloromethane (DCM). This emulsion forms a core- shell 
morphology upon electrospinning.  
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2.3. Characterization of scaffolds 
2.3.1. Scanning electron microscopy 
 
Scanning electron microscopy was performed to assess scaffold ultrastructure of plain 
scaffolds and to assess the deposited extracellular matrix on the cell seeded scaffolds.  
On plain scaffolds, fibre diameters and pore sizes were examined on the SEM images of 
electrospun scaffolds. Dry samples of scaffolds were cut into 1x1 cm pieces and directly 
underwent gold sputtering (Edwards Sputter Coater S150B, Crawley, UK). Images were taken 
using a Phillips XL- 20 scanning electron microscope (Cambridge, UK).   The software 
ImageJ (National Institutes of Health) was used for measurements. For each experimental 
group three scaffold samples were examined with SEM.  
For each piece of scaffold, four images were taken from the random sites within the scaffold. 
From each image taken, 10 fibres and 5 pores were randomly selected and the fibre diameter 
and pore sizes were measured. As a result, a total of 120 fibres and 60 pores were analysed 
per scaffold.  A pore was defined as areas of void space bounded by fibres on all sides at or 
near the same depth of field.  
For cell seeded scaffolds, the samples were fixed in 10% buffered formaldehyde solution for 
10-15mins. After sequential incubation with 0.1M cacodylate buffer and glutaraldehyde in 
cacodylate buffer each for 20 minutes samples were washed in 0.1M cacodylate buffer twice 
for 15 min each wash. The samples were then incubated in osmium tetraoxide for 2 hours and 
in 0.1M cacodylate buffer for 15 min.  Following these, samples were incubated in increasing 
concentrations of ethanol (75, 95, 100%) for 15 min each and were incubated for 30 min in 
100% ethanol dried over anhydrous copper sulphate. Finally, the ethanol was removed and 
hexamethlydisalazine was added to the samples for 30 minutes and the samples were left to 
dry overnight. Dry samples were then mounted on 12.5 mm stubs and underwent gold 
sputtering with approximately 25 nm of gold (Edwards Sputter Coater S150B, Crawley, UK). 
Samples were imaged with a Phillips XL- 20 scanning electron microscope (Cambridge, UK).    
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2.3.2. Evaluation of the hydrophilicity of the scaffolds 
 
The hydrophilicity of the scaffolds was mainly studied for Vitamin C releasing electrospun 
scaffolds as a significant change in hydrophilicity would be expected due to involvement of 
Vitamin C and the surfactant in the scaffolds. Hydrophilicity was studied by measurement of 
water contact angle and water uptake by the scaffolds.  
Water contact angle measurement 
Water contact angle measurement was performed by a contact angle goniometer (ramé- hart 
instrument co., NJ, USA). Scaffolds were cut into 1 cm x 1 cm squares and placed on the 
testing plate. Subsequently 0.03 mL of distilled water was carefully dropped onto the 
scaffolds and contact angles between water droplets and the scaffolds were   measured 
immediately after dropping. Six samples were used at each test and average value was 
reported with standard deviation (±SD). 
Water uptake measurement 
Water uptake by scaffolds was assessed by incubating weighed 1x 1 cm pieces of each 
scaffold in 10 mL of PBS. Six samples for each group were weighed using a digital scale. 
Scaffolds were put in PBS and incubated at 37 °C for a total of 21 days. At days 1, 2, 3, 7, 14 
and 21 scaffolds were carefully blotted with filter paper to remove surface water and weighed 
again. Water uptake of each scaffold was expressed as the percent increase in weight of the 
scaffold and calculated with the formula:  
(Weight wet –Weight dry)/ Weight dry x100.  
2.3.3. Mechanical testing 
Uniaxial mechanical testing on scaffolds was performed using a BOSE tensiometer (BOSE 
Electroforce Test Instruments, MN). Samples were cut into 0.5x1 cm pieces and the 
thicknesses measured using a handheld micrometer thickness gauge. A small 22 N load cell 
was used in measurements. Samples were vertically placed between two grids and a ramp test 
was applied at a rate of 0.5 mm/ sec. The first failure point and plateau was used to calculate 
the ultimate tensile strength (UTS) and the displacement at this point (strain). The initial 
linear gradient of a plot of stress versus strain was taken as the Young’s modulus (E).  
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2.4. Release of drugs from the scaffolds 
2.4.1. Measurement of Vitamin C 
Vitamin C was measured using two different methods: a spectrophotometric method and a 
UV- spectroscopic method. A spectrophotometric method was initially developed due to 
unavailability of other methods. As the UV- spectrophotometer become available in the Kroto 
S20 lab the release experiments were repeated.  The UV spectroscopic method was less time 
consuming and allowed more accurate readings.      
Spectrophotometric measurement of Vitamin C 
A previously defined method called the ‘Enzyme linked Ferric tripyridyltriazine 
spectrophotometric assay (EFTSA)’ was used [128], [129]. In this assay the EFTSA solution 
which consists of acetate buffer, TPTZ (2,4,6-tripyridyl-s-triazine) and ferric chloride 
(FeCl3.6H20) is used to form a coloured ferrous tripyridyltriazine complex with reduction of 
ferric ion to ferrous ion by ascorbic acid at low pH. The absorbance of the ferrous 
tripyridyltriazine complex was read at 593 nm. Of the two forms of Vitamin C, ascorbic acid 
was directly measured with this method whereas A2P was first enzymatically converted to 
AA [130]. 
Briefly, after 2 parallel samples from each solution of Vitamin C were incubated for 5 min in 
37°C water bath with or without 4 units/ mL of ascorbate oxidase (AO). Then in the presence 
of acetate buffer at pH 3.6, 8mM tripyridyltriazine (TPTZ) and 20mM Ferric chloride 
solutions were added.  After 5 min incubation at room temperature, the absorbance was 
measured at 593 nm in a colorimetric plate reader (Bio- TEK, NorthStar Scientific Ltd, Leeds, 
UK). The difference between AO negative and positive readings were related to the presence 
of AA (Figure 2.4). For A2P measurement, samples were first incubated 15 min at room 
temperature with acid phosphatase (25 mg/mL in 0.1 M citric acid buffer at pH 4.8) to convert 
AA to A2P.  The concentration of unknown solutions was determined with the aid of standard 
curves plotted for AA.   The standard curves obtained with this method is demonstrated in 
Figure 2.4. Solutions of AA in both distilled water and PBS between 0.3 and 600 µM were 
studied. The lower limit of detection of AA (>6 µM) with this method was found to be lower 
when it was dissolved in distilled water compared to PBS (>60 µM). This is due to oxidation 
of AA with the metal ions present in PBS.   
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Figure 2.4. An example of running parallel samples with EFTSA method for detection of ascorbic 
acid (A). Standard curves obtained with this method in PBS and distilled water (B).   
 
 
After construction of the standard curves, preliminary experiments were undertaken to detect 
AA released from scaffolds using the spectrophotometric method. For this scaffolds were cut 
into 3x3 cm square pieces and put into distilled water. On 8th, 24th, 48th and 72th hours samples 
were taken from distilled water and AA concentration was determined using the standard 
curve for the spectrophotometric assay. After the distilled water was either replaced or all the 
media was completely changed.  The preliminary release curves obtained using the 
spectrophotometric method was demonstrated in Figure 2.5. The amount of AA detected in 
media continuously decreased after 3 days when it went down to undetectable levels. This 
demonstrated that AA was not only oxidized by the metal ions in media but also with the 
oxygen in the environment and incubator. A2P could be measured to increase consistently for 
28 days when measured by sampling the media. A2P could not be measured after day 10 
when replacing the media most probably due to released concentrations below the lower limit 
of detection of this test.  
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Figure 2.5. The release of AA and A2P from electrospun PLA scaffolds as measured by the spectrophotometric method. 
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Therefore, AA could be detected as released from the electrospun PLA scaffolds using the 
spectrophotometric method however this had some important limitations. Firstly, the release 
could only be studied in distilled water to avoid interference with method of detection of AA 
with use of PBS. This is not ideal as the release studies are more relevant when performed in 
physiologically similar media and conditions. Secondly, even when distilled water was used, 
detection of AA, not A2P, was still very limited probably because AA oxidized immediately 
with oxygen in the air and became undetectable soon after it was released. Therefore, AA 
became undetectable after 72 hours whereas A2P was still detectable on day 28. Thirdly, the 
lower limit of detection for the spectrophotometric method was high (>30 µM) which 
precluded measurement of small changes in concentration. Thus the spectrophotometric 
method to measure AA release from the electrospun PLA scaffolds had significant limitations.   
UV- spectrophotometric method 
Vitamin C was also measured using a UV- spectrophotometer (Thermo ScientificTM Evolution 
220) at an absorbance wavelength of 252 nm. A calibration curve was constructed by 
measuring 8 concentrations of vitamin C (lowest: 10 nM and highest: 100 µM) prepared in 
distilled water (Figure 2.6). All solutions were freshly prepared and the absorbances were 
immediately measured.  The lower limit of detection for Vitamin C with this method was 300 
nM and upper limit of detection was 100 µM.  
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Figure 2.6. The standard curve for measurement of Ascorbic acid using UV- spectrophotometry. 
 
 
 
To detect release of Vitamin C from electrospun scaffolds a 1x1 cm piece of scaffold was 
placed in 4 mL of media and was kept in a dry incubator at 37°C.  At 2, 4, 6, 8, 10 hours and 
daily afterwards a sample was removed from the media and the concentration measured. A 
vehicle scaffold with neither AA nor A2P  was taken as a control. All the media was then 
removed and replaced with a fresh sample. These steps were repeated at each time point.    
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2.4.2. Measurement of Estradiol 
 
Measurement of Estradiol was performed initially by a spectrofluoremeter and subsequently 
by UV- spectrophotometer. The release experiments for a duration of 6 months was initially 
started by Dr Christopher Hillary. The release of Estradiol from PLA scaffolds constructed 
within the current PhD studies was mainly studied using UV- spectrophotometer for a 
duration of 28 days.  
Spectrofluorometric detection of Estradiol    
A concentration ranges of Estradiol between 10 nM and 100 µM in PBS were measured using 
(Kontron SFM 25 spectralflurometer) at λex277nm/λem310nm. Standard curves were 
constructed and used thereafter to determine an unknown concentration of the drug in solution 
during the release experiments (Figure 2.7).   
UV- spectrophotometric detection of Estradiol 
Estradiol was also detected using a UV- spectrophotometer (Thermo ScientificTM Evolution 
220) at an absorbance wavelength of 220 nm.  Standard curves were constructed using a 
concentration of 10 nM and 100 µM in PBS and used to determine an unknown concentration 
of the drug in solution during the release experiments.   
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Figure 2.7. The standard curves for measurement of Estradiol using the spectralflurometer (A) and the UV- spectrophotometer (B). 
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2.5. In vitro evaluation of scaffolds 
2.5.1. Evaluation of metabolic activity by resazurin assay 
 
In all experiments using cells in 2D or 3D cell metabolic activity was measured by a resazurin 
assay. A stock solution of resazurin sodium salt (Sigma-Aldrich, Dorset, UK)  was first 
prepared by dissolving 0.124g wt/v of resazurin in 100mL of phosphate buffer saline (PBS). 
Dilutions of this stock solution in 1:20 was used for experiments. After the culture media was 
removed from each well the cells were washed with PBS and resazurin solution was added   
into each well. Cells were incubated for 60 min at 37°C in 5% CO2 atmosphere. Then 100 µl 
of resazurin solution was pipetted out from each well and transferred into a 96 well plate. 
Absorbence was measured at 570 nm in a colorimetric plate reader (Bio- TEK, NorthStar 
Scientific Ltd, Leeds, UK). Culture wells without cells or cell free scaffolds in media were 
used as reagent blanks. Samples were then washed of the dye and either fixed with 3.7% 
formaldehyde or replaced with culture media if experiments were to be continued.  Each 
measurement was performed in triplicates.   
 
2.5.2. Measurement of total collagen with Sirius red staining 
 
Total collagen production by the cells in 2D and 3D were measured using Sirius red staining 
(Figure 2.8). Sirius red is an elongated birefringent molecule that contains six salt-forming (-
SO3H) sulfonic groups. It binds to a variety of molecules in tissues however when bound to 
collagen it attaches parallel to fibrillary collagen enhancing its natural birefringence. 
Birefringence refers to an optical property of a material that reflects the light in a manner that 
is dependent on the orientation of the molecule relative to the light hitting them. In other 
words optically anisotropic materials are referred to as being birefringent. The Sirius red 
staining relies on birefringent properties of the fibrillary collagen.  
When the Sirius red stained tissues are examined under bright field microscope, all the 
proteins in the tissue would be visualized as Sirius red binds all. Visualizing Sirius red stained 
tissues under polarized light allows effective identification of collagen networks and 
appreciation of potential collagen alterations. Therefore, Sirius red stained samples need to be 
visualized under polarized light to show collagen specificity. The method used in these 
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studies relies on eluting the Sirius red that is first bound to all extracellular matrix elements 
produced by cells grown on the scaffolds. This is than measured using spectrophotometry.      
Samples that were previously fixed in 3.7% formaldehyde were washed 3 times with PBS. 
Two mL of Sirius red stain (0.1% Direct Red 80 in saturated picric acid, Sigma- Aldrich) was 
added to each sample of monolayer cultured fibroblasts or fibroblasts grown on scaffolds. 
Samples were left to stain on a benchtop shaker for 16 hours. Afterwards excess stain was 
washed off with distilled water until the wash out water ran clear. Then specimens were left to 
dry under fume cupboard. Dry samples were pictured and weighed. The stain was then eluted 
with 2 ml 0.2 M NaOH: methanol 1:1 for 15 min. The absorbance was measured at 490 nm. 
Acellular scaffolds acted as controls for calculating collagen production. Results were 
expressed as Sirius Red stain per gram of PLA.    
 
 
 
Figure 2.8. An example of how the Sirius Red staining was used to measure total collagen production 
of human dermal fibroblasts in tissue culture plastic (2D) and on scaffolds (3D). Yellow arrow shows 
a scaffold on which no collagen was produced and blue arrow shows an obvious collagen production 
on the scaffold stained by the Sirius red.  In between a range of staining can be observed. 
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2.6. Evaluation of angiogenic properties of the scaffolds 
 
The angiogenic potentials of the bioactive factors incorporated into the scaffolds were 
assessed using the chick aortic ring assay whereas the angiogenic potential of the final 
scaffolds were evaluated in a chick chorioallantoic membrane (CAM) assay.  The aortic ring 
assay is an organ culture assay that allows studying a wide range of concentrations of 
bioactive factors whereas the CAM assay was used as an in vivo assay to test the angiogenic 
response to the final scaffolds as well as the initial tissue response to the biomaterial.    
 
2.6.1. Chick aortic ring assay 
2.6.1.1.Description of the methodology 
 
Incubation of fertilized eggs 
Pathogen-free fertilized white leghorn chicken eggs (Gallus gallus domesticus) were obtained 
from Henry Stewart Co. Ltd (UK). Care was consistent with the guidelines of the Home 
Office, UK. The fertilized eggs were incubated at 37°C in a humidified egg incubator for 12- 
14 days. Between embryonic development days (EDD) 12- 14 the eggs shells were cracked, 
embryos were taken out and sacrificed immediately by decapitation. A vertical incision on the 
chest wall was made on the midline and the heart of the chick was dissected out together with 
the aortic arches. The aortic arches, surrounding connective tissues and the heart of the chick 
embryo was placed in PBS. The remaining body parts were disposed of in line with Home 
Office requirements.   
Preparation of aortic rings for organ culture 
Under a dissection microscope placed inside a culture hood, the aortic arches were cleaned of 
the surrounding connective tissue using fine forceps and scalpel and the aortic arches were 
separated from the heart by cutting through the attachment of aortic roots at the ventricles of 
the heart. At the end of this procedure 3 aortic arches attached to a single common root and 2 
other arches attached to another common root was obtained (Figure 2.9). Further dissection of 
the connective tissues around the aortic arches was performed until the collagenous outer wall 
of the aorta (the adventitia) was exposed completely.  Thereafter each tubular branch of the 
aorta was cut into 1 mm rings under a stereomicroscope.  
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Figure 2.9. Dissection of aortic arches from the chick embryo. (A) The chest wall is opened to see the 
the heart and the aortic arches (arrows). (B) The aortic arches attached to the heart is next cut out. (C) 
The aortic arches of the chick embryo, dissected from all the surrounding connective tissues and 
ready to be sliced for the aortic ring assay. (scale bars 0.5 cm for all images) 
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Culturing the aortic rings 
Between 20- 25 aortic rings can be obtained from each embryo. Aortic rings were collected in 
PBS and immediately after the completion of the dissection aortic rings were embedded in 50 
µL of Matrigel® (Basement Membrane Matrix, Corning®) in a 24 well plate.  After 30 min 
of incubation in Matrigel allowing gelation of the Matrigel, MEM (supplemented with 2.5% 
FCS, 50 unit’s/mL penicillin and 50 μg/mL streptomycin, GIBCO, Carlsbad, CA) (2 mL) was 
added into each well. The aortic rings were incubated in a cell culture incubator at 37°C and 
5% CO2 for 3- 5 days. Normal growth of endothelial cell sprouts in the chick aortic arch assay 
is shown in Figure 2.10. 
If the experiments involved drug testing the required concentration of the drug was added into 
the culture media. In experiments where co- culture of aortic rings with different cell lines 
(e.g. ADSCs) was intended, a transparent tissue culture insert (Greiner Bio-One GmbH) was 
used to contain the desired component of co- culture. The endothelial sprouts were observed 
under an inverted microscope between days 3 and 5. The pictures taken at each time point and 
the longest sprout length for each sample was calculated. Endothelial cell sprouts had a 
typical appearance of long, micro tubular elongations originating from the inside of the aortic 
ring and forming endothelial cell lacunae as if they were forming blood vessel lumens 
between themselves (Figure 2.11). Endothelial cells were further characterized by 
immunofluorescence staining with Griffonia Simplicifolia Lectin I, isolectin B4 (Vector 
Laboratories, Burlingame, USA) that stained endothelial cells (Figure 2.12).  
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Figure 2.10. Normal growth of the endothelial cell sprouts from day 3 to day 5 in the chick aortic ring assay. The tubular endothelial cell sprouts 
can be seen in close view (red arrows) and the endothelial cell branches connect with each other to form a lumen (yellow arrow). (black scale 
bar: 1 mm; yellow scale bar: 0.2 mm) 
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Figure 2.11.  Observation of the endothelial cell sprouts in the chick aortic ring assay. Firstly, 
endothelial cell sprouts appearing like long microtubules appear on day 3 of organ culture assay (red 
arrows in A). The tubules than start branching (B) and the branches then connect with each other to 
form the typical vessel lumen- like structures (red arrows in C & D) that can only be fully seen 
adjusting the focus as they are on 3D matrix.      
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Figure 2.12.  Characterization of the endothelial cell sprouts in the aortic ring assay. Staining with 
isolectin B4 (A) for endothelial cells, DAPI (B) for the cell nuclei and the combined images (C- D). 
Endothelial cell membranes appear green with isolectin B4 staining (A) and all cell nuclei appear 
blue with DAPI staining (B). Combining the two images allows visualization of endothelial sprouts. 
Error bar in A represents 200 µm and is applicable to all images.    
 
 
 
 
 
 
91 
 
2.6.1.2. Optimizations in the chick aortic ring assay 
Use of collagen as an extracellular matrix in the chick aortic ring assay 
The endothelial cells need a 3D extracellular matrix to facilitate formation of the typical 
endothelial morphology in cell culture. For the aortic ring assay although classically Matrigel 
has been chosen as the ECM to embed the rings into [131], some literature suggested use of 
other ECM elements such as collagen and fibrin. Therefore, in the preliminary work, collagen 
type I was used as an ECM to grow the aortic rings in (Figure 2.13). This had led to extremely 
suboptimal results because with collagen matrix the endothelial cell sprouting was very 
difficult to observe under light microscopy. This could be for 2 reasons: i) the collagen matrix 
facilitated growth of fibroblastic/ dendritic cells along with endothelial cell sprouts making 
the endothelial cell sprouts invisible, ii) after day 3-4 days of the organ culture assay the 
collagen matrix started degrading resulting in formation of empty spaces in the matrix which 
also led to displacement of the aortic ring inside the gel. It appears that the ideal extracellular 
matrix to stimulate formation of endothelial cell sprouts and micro tubular structures should 
contain basement membrane proteins [132]. Therefore, use of collagen type I in aortic ring 
experiments was abandoned and Matrigel was used as a standard ECM for aortic ring assay.  
Use of mouse aortic rings 
The aortic ring assay was initially described and performed on the rodent aortic rings [133]. 
Using rodent tissues could have several advantages over using chick tissues. Firstly, the 
rodents are genetically more similar to humans and secondly the range of proteins and 
markers that could be used with mouse tissues are more widely available compared to those of 
chickens. Therefore, during the course of this PhD studies mouse aortic rings were obtained 
from freshly sacrificed mouse aortic tissues (biological Services, The University of Sheffield) 
and dissected under the microscope within 4 hours of scarification. The rings were cut into 1 
mm thick slices and embedded in Matrigel as described above for the chick aortic ring assay. 
The maximum endothelial cell sprout growing from the mouse samples are shown in Figure 
2.14.  Out of 42 samples obtained from 2 different experiments measurable endothelial cell 
sprouts can be obtained only from 4 of the mouse aortic rings at 8 days of culture even with 
supplementation of media with fibroblast growth factor and vascular endothelial growth 
factor. Therefore, the mouse aortic ring was not as responsive as the chick aortic ring in the 
preliminary experiments. An obvious reason was that the embryonic tissues would have more 
regenerative capacity compared to adult tissues (aortic rings of the adult mice).   
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Figure 2.13. Using collagen as a matrix to grow chick aortic rings.  Starting from day 3 the collagen matrix degrades leaving empty spaces around the 
aortic ring (red arrows) and pushing the ring to the side of the circular collagen collagen matrix.     
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Figure 2.14. Preliminary findings of mouse aortic ring experiments. The most commonly encountered 
response at day 8 of organ culture with mouse aortic rings (A). Average response of the 4 samples 
where a measurable endothelial sprout could be observed (red arrow) (B). The maximum response as 
obtained by supplementation of the culture media with fibroblast growth factor (C) (Scale bar 0.2 
mm). 
 
   
The chick embryo metatarsal assay 
Another organ culture assay that could have been used is the chick embryo metatarsal assay. 
Although this methodology had not been defined before, the mouse embryo metatarsal assay 
has been described previously [134]. The same methodology was used to create a culture of 
chick metatarsal/ phalangeal bones of the developing chick embryo on embryonic 
development days 12- 14. The preliminary results are shown in Figure 2.15. Although this 
assay was feasible the dissection of the surrounding connective tissues from the bones of 
chick metatarsal bones were difficult and required more delicate instruments. Furthermore, 
the phalanges were easier to dissect and could have given better results however this needed 
to be defined as a methodology first requiring further set of intense experiments. Therefore, 
this methodology was also abandoned.  
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Figure 2.15. The preliminary findings of the chick embryo metatarsal assay. The chick embryo 
metatarsal bones embedded in Matrigel can be seen in the upper row images. A closer view shows 
the endothelial cell sprouts growing from the periosteum  on day 3 of the culture (red arrows) (Scale 
bars 0.2 mm).  
 
    
 
 
2.6.2. The chick chorioallantoic membrane assay 
The CAM assay methodology is   presented in the next chapter. 
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2.7. Statistical analysis 
Statistical analysis was performed with SPSS v. 17.0.  The differences between percentages 
were compared using Chi- square test.  Differences between two group means were analysed 
with Student’ s T test when the data was normally distributed and with Mann Whitney U test 
otherwise. Survival of the chick embryos were analysed with Kaplan Meier method. 
Correlation between two continuous variables was assessed by Pearson correlation test.   A p 
value of <0,05 was considered statistically significant.    
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3.1. Chapter Introduction 
 
The chorioallantoic membrane (CAM) of the chick embryo forms by the fusion of the 
allantois of the developing chick embryo with the mesodermal layer of the chorion (Figure 
3.1). It first appears as the allantoic vesicle on embryonic development day (EDD) 4 after 
which it enlarges rapidly until EDD 10 and fuses with the chorion [135] (Figure 3.2). The 
blood vessels located in the mesodermal layer of the CAM give rise to a capillary plexus that 
grows rapidly between EDD 8- 11 to mediate gas exchange with the environment. Therefore, 
the CAM is an extraembryonic membrane that functions as an organ for gas exchange 
between the embryo and the environment. It is rich in blood vessels and because it stays on 
top of the developing embryo it is easily accessible for experimental interventions.  
 
 
Figure 3.1. Graphical demonstration of extraembryonic membranes of the chick embryo.  
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The CAM assay has been used as a well- established in vivo assay to study angiogenesis since 
the 1970s. The CAM model has indeed made fundamental contributions to understanding of 
tumour related angiogenesis. It was first demonstrated experimentally in the CAM assay that 
growth of solid neoplasms was always accompanied by neovascularization and that the 
formation of new blood vessels in this context was more vigorous and continuous than that 
observed in wounds and inflammation [136]. Today inhibition of angiogenesis is one of the 
main strategies used when developing targeted therapies for cancer. Additionally, cancer cell 
lines are commonly grown on the CAM to test the efficacy of anticancer drugs in pre- clinical 
studies.  
The in ovo [137] and ex ovo culture methods have been used to grow chick embryos for use in 
research [135], [138]. The in ovo culture method was established first. In this method 
fertilized chicken eggs are placed in an incubator at 37°C with constant humidity to start 
embryogenesis. On day 3 of embryonic development 2-3 ml of albumen is removed from 
inside of the egg using a needle attached to a syringe. Removal of the albumen detached the 
CAM from the egg shell and increases the distance between the egg shell and the CAM 
allowing experimental intervention without damaging the vascular structures and embryo. 
After removal of the albumen, a small square window is opened on the egg shell which is than 
closed and sealed until further experimental interventions are done. The main advantage of 
this technique is that it allows a more physiological environment for development of the chick 
embryo. Also it is known that the egg shell itself is a source of calcium for the developing 
embryo which could be important when studying bone physiology. For example, when 
studying bone regeneration it may be a good idea to grow in vivo cultures to allow absorbance 
of calcium from the egg shell. It has also been suggested in earlier literature that the survival 
rates of in ovo cultures were higher however there is recent evidence against this suggestion.       
The ex ovo method is where the embryo is grown outside of the egg shell for most of the 
embryonic life. This represents a useful modification of the classical in ovo CAM assay 
offering a few unique advantages. With use of the ex ovo CAM assay the growing embryo and 
the vascular structures can be better observed. Additionally, a larger area of the CAM can be 
used for experiments. The main concern with this technique is related to the survival and 
maintenance of the chick embryos outside of the egg shell [139]. There is literature to support 
both arguments suggesting a decreased [139] and unchanged [140]–[142] survival of ex ovo 
cultures.  
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Figure 3.2. The development of the CAM after first appearing on embryonic development day (EDD) 5 (black arrows) and growing up to cover the 
whole surface of the square weighing boat on EDD 9 (Black and red scale bars represent 1 cm and 5 mm, respectively).    
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3.2. The ex ovo CAM assay protocol 
3.2.1. Assay planning 
 
All the experiments were planned beforehand as this is a ‘bioassay’. The fertilized eggs that 
were laid on the same day of dispatch were received next day. The date of dispatch and the 
date received in the egg laboratory were recorded following the Home Office guidelines. 
After fertilized eggs were received they were stored at 10°C up to 10-12 days until the 
incubation is started.  
The day of incubation of fertilized eggs started was embryonic development day (EDD) 0, 
followed by cracking the eggs on EDD 3, start of experimental intervention EDD 7 and 
sacrifice of the embryos on EDD 14 (Figure 3.3).  
Practically, it was most convenient to receive 6 dozen of eggs at a time and to start incubation 
on a Friday (day 0), crack the eggs on a Monday (day 3), implant the test samples on the next 
Friday afternoon (day 7) and sacrifice the embryos on the third Friday (day 14).  This allowed 
image acquisition during the weekdays when necessary. 
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Figure 3.3. The timeline of the ex ovo CAM assay. The incubation of the eggs starts at embryonic 
development day (EDD) 0, the ex ovo cultures start at EDD 3. The experimental intervention is done 
late on the EDD 7 and the angiogenic response can be evaluated anytime between EDD 10 and 14.    
 
 
 
102 
 
3.2.2. Incubation of fertilized eggs 
 
The internal parts of a rotating egg incubator was cleaned by spraying IMS (70%) and left to 
dry inside the laminar flow cabinet. The fertilized eggs were removed from the fridge and the 
egg shells were wiped with tissue paper and 20% IMS under the laminar flow cabinet. The 
eggs were then placed in the rotating egg incubator lying on their horizontal axis. Eggs were 
incubated at 37- 38° C and 40- 60% humidity for 3 days.  
 
3.2.3. Starting the ex ovo cultures 
 
At EDD 3 the upper surface of the horizontally lying eggs were marked with a pen and the 
rotating incubator was put in a stationary state for at least 10 min. In the meanwhile, plastic 
weighing boats are dipped into 70% alcohol for disinfection and left to dry. Additionally, a 
1% solution of Penicillin/ Streptomycin in PBS was prepared and 2 ml of the antibiotic 
solution is pipetted in each weighing boat (Figure 3.4). The eggs were taken out of the 
incubator and inside the laminar flow cabinet each egg was cracked from below (opposite to 
the marked line) by hitting it on a hard surface.    
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Figure 3.4. The preparation of the setup before cracking the eggs. The horizontally lying eggs are first 
marked on the top surface (insert). Inside the laminar hood, sterilized plastic weighing boats, antibiotic 
solution, Petri dishes, racks to hold the eggs, a beaker to use to collect the waste and a small heater to 
help keep the embryos warm.   
 
 
The chick embryo was gently transferred into a plastic square weighing boat by separating the 
two halves of the egg shell (Figure 3.5). Successful embryo transfer was confirmed by 
observation of the beating heart in the developing embryo and an intact egg yolk. A sterile 
petri dish was covered as a lid on the weighing boat and the ex ovo cultures were put in a 
stationary sterile incubator 37- 38°C with 60% humidity immediately.  Survival and normal 
development of the ex ovo cultures were checked daily afterwards. Any dead embryos were 
disposed of immediately following the Home Office procedures.  
 
104 
 
Figure 3.5. The start of ex ovo cultures on embryonic development day 3. The egg cracking technique is 
demonstrated with confirmation of a successful embryo transfer with intact egg yolk and the live 
embryo (5 & 6). Here a Petri dish is used instead of a weighing boat for better demonstration.  
 
 
 
 
3.2.4. Start of experimental intervention 
 
On EDD 7 the ex ovo cultures from incubator and placed in laminar flow cabinet. The 
biomaterials to be implanted were prepared beforehand. Scaffolds were cut into circular 
shapes with a diameter of 7- 10 mm using a laser cutter and sterilized for 40 min under UV 
radiation. Using a sterile forceps samples were placed in between two large vessels halfway 
between the embryo and the outer border of the CAM (Figure 3.6).  It is important to 
delineate the borders of the CAM on EDD 7 and not to place the sample outside of the CAM 
to avoid growth of the CAM over the test sample (Figure 3.7). Daily checks of embryo 
survival and development continued.  
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Figure 3.6. Correct placement of the test sample on the CAM. The dashed arrows show the borders 
of the CAM which will grow further to cover all surface of the square weighing boat in a few days. 
Coloured circles show the preferred places for placement of the sample on the CAM.  
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Figure 3.7. An example of correct and incorrect placement of the test samples on the CAM. 
In embryonic development day (EDD) 7 the CAM does not completely cover the surface of 
the square weighing boat leaving areas devoid of the CAM. The sample 1 is placed outside of 
the CAM whereas sample 2 is placed correctly on the CAM the borders of which can be 
followed by close inspection (arrows).   The area where sample 1 is placed is not the CAM 
but the yolk sac. Following up this sample for 2 more days in the embryonic development it 
could be observed that sample 1 blocks normal expansion of the CAM which is clearly seen 
to accumulate behind the sample at EDD 9. Sample 2 grows and expands together with the 
CAM. (Scale bars 10 mm for all images). 
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3.2.5. Evaluation of angiogenic response to scaffolds 
 
Angiogenic responses to the scaffolds were evaluated between EDD 10- 14. In the case of 
ascorbic acid releasing scaffolds the angiogenic response was evaluated at EDD 11 whereas 
for Estradiol releasing scaffolds experiments were continued until EDD 14. This was because 
with ascorbic acid an anti- angiogenic dose of the drug was being demonstrated which was 
most evident at EDD 11, in preliminary studies. 
A digital camera fixed at a constant height was used to take images (Figure 3.8). All samples 
were imaged while being trans illuminated with light coming from below. Additionally, two 
side lamps were also used when necessary. To obscure the unnecessary background due to 
presence of chick embryo body parts or egg yolk a 20% solution of oil in water emulsion was 
injected just beneath the test sample (Figure 3.9). For some samples, injection of the contrast 
underneath the test samples makes a significant difference (Figure 3.10). Standard procedures 
were consistently applied in all experiments to obtain standard, high quality images for 
subsequent image analysis.  
Figure 3.8. The imaging unit used to take pictures of the CAM- biomaterial complex at the 
end of the experiments. The digital camera (yellow arrow) fixed at a constant height and a 
transillumination box (red arrow) are key to take high quality images consistently. 
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Figure 3.9. Demonstration of how an emulsion is injected underneath the CAM- biomaterial complex to obscure the unnecessary background. First the 
injectors containing the contrast agent is inserted between the two layers of the CAM (1-2). Than by rotating the petri dish the tip of the needle is 
brought underneath the area of interest containing the implanted scaffold and the contrast injection is started (3-4). After adequate amount of contrast 
is injected evenly the sample is ready for image acquisition (5-6).  
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Figure 3.10. Comparison of images obtained before and after injection of the contrast. Here two 
contrast agents with different colours are compared. In the upper raw, a white contrast provides 
effective visualization of the blood vessels whereas in the lower raw the blue contrast obscures the 
small blood vessels. Error bars represent 400 µm.   
 
 
3.2.6. Sacrifice of chick embryos 
The CAM is an extraembryonic structure and does not contain any nerve endings. However, 
nerve endings occur in the developing chick embryo starting from EDD 11. Therefore, this 
point was considered during all stages of experimental planning. Current experiments did not 
involve any noxious stimulus or intervention to the chick embryo and only implantation of 
biomaterials onto the CAM surface was performed. Therefore, no prior sedation or 
anaesthesia was performed during the experiments following the Home Office guidance 
statement ‘a prior sedation or anaesthesia should be carried out before humane killing unless 
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to do so would be likely to cause greater distress than using the same method of killing 
without sedative or anaesthetic’.   
On EDD 14 immediately after images were taken, the chick embryos were sacrificed by 
bleeding. The CAM- biomaterial complex was excised using tissue scissors and forceps with 
a margin of 1 cm. Samples were fixed in 3.7% formaldehyde for histologic examination. 
 
3.3. Setting up control scaffolds for angiogenesis 
 
The preliminary experiments on evaluating the angiogenic potential of a biomaterial proved to 
be challenging due to lack of data on what constitutes a pro- angiogenic material and what 
defines an anti- angiogenic material. Although there is data in the literature on the testing of 
certain drugs on the ex ovo CAM assay there was no data for biomaterials.  A further 
complication when studying angiogenesis with biomaterials is that any foreign material 
placed on the CAM could potentially induce an antigenic reaction that can then be confused 
with an angiogenic response. Therefore, every material placed on the CAM needs to have its 
own set of controls.   
3.3.1. A negative control for electrospun PLA scaffold 
 
Incorporating antiangiogenic substances into the electrospun PLA scaffolds was chosen as a 
strategy to construct an anti- angiogenic PLA scaffold as a negative control for angiogenesis 
experiments. Among available options hydrocortisone releasing PLA scaffold was chosen as a 
negative control scaffold for several reasons: i) hydrocortisone has several derivatives that 
allow it to dissolve in water and oil phases, ii) it is known to have antiangiogenic properties, 
iii) its release can easily be demonstrated using the UV- spectrophotometer and iv) it is cheap 
and widely available.      
Hydrocortisone (Sigma Aldrich, Dorset, UK) was dissolved in 500 µl of distilled water and an 
emulsion of hydrocortisone in 10% PLA solution was formed as described earlier in Chapter 
2.  Electrospun PLA scaffolds containing 0.01 gram of hydrocortisone per gram of PLA were 
constructed. Release of hydrocortisone was measured at an absorbance wavelength of 242 nm 
using UV- spectrophotometer. The calibration curve for hydrocortisone and release of 
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hydrocortisone from PLA scaffolds is demonstrated in Figure 3.11. Release of hydrocortisone 
from the scaffolds was only studied for 3 days.  
Concentrations of hydrocortisone of up to 1 gram of hydrocortisone per gram of PLA can be 
used to observe more angiostatic effects by dissolving the lypophilic formulation of 
hydrocortisone in the polymer solution. However increased dosages reduced the embryo 
survival at EDD 10.   
 
Figure 3.11.   The standard curve to determine the concentration of hydrocortisone in an unknown 
solution and the release of hydrocortisone from electrospun PLA scaffolds for 3 days.  
 
 
 
3.3.2. A positive control for electrospun PLA scaffold 
 
Constructing a positive control where a pro- angiogenic drug is released from electrospun 
PLA scaffolds proved to be more difficult. Known pro- angiogenic substances such as VEGF, 
FGF and EGF were all protein structures that could not go into polymer solutions for 
electrospinning. A strategy to incorporate heparin into the PLA scaffolds by layer- by- layer 
coating was performed within the group previously [143] this was technically very 
challenging. Therefore, PLA scaffolds seeded with tumour cell lines were constructed with 
the idea that tumour cells would secrete pro- angiogenic factors.  
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To do this, the human melanoma cell line (C8161) available in the MacNeil lab (isolated from 
an abdominal wall metastasis from a recurrent malignant melanoma) was cultured in 
melanoma culture medium consisted of EMEM media (Sigma-Aldrich) supplemented with 
FSC (10%v/v), L-glutamine (2uM), Penicillin (100U/mL), streptomycin (100ug/mL) and 
Fungizone (0.625ug/mL).  A total of 1 million C8161 cells were seeded on an electrospun 
poly (lactic acid) (PLA) scaffolds. After culturing in vitro overnight the scaffolds seeded with 
tumour cells were controlled for attachment and viability using the resazurin assay. Scaffolds 
seeded with tumour cells were then implanted on CAM at EDD 7 to constitute a positive 
control (Figure 3.12).  
 
Figure 3.12.  Demonstration of negative and positive controls to use when assessing the angiogenic 
potential of a biomaterial. An angiostatic effect is evaluated at embryonic development day (EDD) 10 
whereas a proangiogenic response is best evaluated at EDD 14. Scaffolds constructed with an 
intention to act as positive controls have led to pathologic bleeding and probable hypercoagulation 
(arrows) eliminating use of this strategy to construct positive controls. (scale bars represent 200 µm)    
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3.4. Evaluation of results 
3.4.1. Evaluation of embryonic survival and development 
 
Normal development of the ex ovo cultures are checked and recorded daily. The survival of 
the embryos, the presence of any developmental arrests and/ or presence of any infection were 
reported for each experimental group. 
 
3.4.2. Evaluation of angiogenic response to biomaterials 
 
The angiogenic response to biomaterials was analysed using digital images. A previously 
described methodology was used to calculate the ‘vasculogenic index’ [144]. All discernible 
vessels including capillaries, arterioles, venules that are within an imaginary circle drawn 
around the scaffold with a 1 mm margin were counted provided that they form an angle of 
less than 45° with a line radiating from the centre (Figure 3.13). Vessels branching within the 
annulus are counted as 1 vessel, whereas those branching outside the annulus are considered 
to be 2 vessels. 
 
 
Figure 3.13. An example of how the ‘vasculogenic index’is calculated. Original image and contrast 
injected image are shown together with demonstration of blood vessel counting. On the processed 
grayscale image (on the right hand side) all discernible vessels growing towards the scaffold in a 
spoke- wheel pattern are counted (Scale  bar 2 mm) 
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Another method of quantification was also used when evaluating the angiogenic response to a 
transparent hydrogel. In this case transparency of the hydrogel allowed observation of blood 
vessels underneath the biomaterial itself. In this semi- automated quantification method, the 
free online plug in for Image J software, Neuron J, was used (Meijering et al., Cytometry Part 
A 2004;58A:167–176; http://www. imagescience.org/meijering/software/neuronj/). The 
digital images were converted to grayscale (8- bit) and sharpened twice. Afterwards all 
discernible vessels in the image were traced using the Neuron J tracing tool. An advantage of 
this method is that it allowed calculation of other parameters in addition to number of blood 
vessels, such as total vessel length and the total number of blood vessels.  
The angiogenic responses have also been quantified in histologic sections of the CAM- 
biomaterial complex. Standard Haematoxylin &Eosin (H&E) sections allowed observation 
and counting of medium to large sized blood vessels on the CAM in cross sections (Figure 
3.14). The feasibility of demonstration of blood vessels by immunohistochemical or 
immunofluorescence staining has also been studied. The blood vessels on the CAM could 
effectively be stained by fluorescent labelled α-SMA (Figure 3.15). Although effective 
staining could be performed on the CAM, in the presence of the biomaterial, which is PLA in 
this context, the autofluorescence of the material prohibited effective use of this method to 
quantify vessels that were in between the fibres of the material.  
Figure 3.14. Quantification of angiogenic response by counting the blood vessels on Haematoxylin 
&Eosin (H&E) stained sections. The scaffold implanted on the surface of the CAM can be observed 
followşng the normal CAM tissues on the sides of the implanted scaffold. The blood vessels on the 
CAM are labelled with blue arrows. The scaffold on the left contains more blood vessels in the CAM 
tissue underneath the scaffold (therefore is more angiogenic) compared to the scaffold on the right. 
(Scale bars 100 µm) 
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Figure 3.15. Staining properties of the CAM with antibody to alpha smooth muscle actin (α-SMA). 
The normal CAM has a trilayer structure with blood vessels in the mesodermal layer.  Larger blood 
vessels (arrows) give the best results for staining with α-SMA.  (scale bar 200 µm). The mounting jelly 
appears like an artefact in all images. 
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To overcome this limitation, another method was developed. A rhodamine labelled lens 
culinaris agglutinin [LCA], a member of the lectin family, was injected into the circulation of 
the CAM before sacrifice. The LCA is known to attach to the endoluminal surface of the 
CAM vessels by an agglutination reaction. With this method selective labelling of all blood 
vessels regardless of their size and shape was achieved (Figure 3.16).  
 
 
 
 
 
Figure 3.16. Staining properties of the CAM with the lens culinaris agglutinin (LCA). Larger blood vessels (arrow head) appear more prominently 
stained with the LCA compared to smaller ones both in the CAM only samples and CAM+ PLA scaffold samples. In the samples with the scaffold, 
smaller blood vessels sectioned in different directions can be detected (arrows). (scale bars 1 mm for all images). 
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3.4.3. Evaluation of initial tissue response to biomaterials 
 
All implanted materials placed on the CAM surface were evaluated for their biocompatability 
and engraftment by daily observations. Additionally the tissue sections with H&E staining 
were assessed for the amount of inflammatory cell infiltration in and around the material.  
 
3.4.4. Evaluation of angiogenic potential of drugs in the CAM assay 
 
Before the drug releasing scaffolds were placed on the CAM, each drug was tested by 
applying them onto the CAM surface. This was achieved by labelling the area where the 
drugs would be applied using a 100 µm thick plastic ring that was cut from using a6.5 mm in 
diameter soft needle cover using cryosectioning. Solutions of drugs (Estradiol, VEGF and 
Sunitinib) with various concentrations were prepared in PBS. Between EDD 7 and EDD10 
drugs were applied onto the CAM delineated by the plastic ring. Two doses per day were 
given to each area with an application  volume of 30 µl each time (Figure 3.17-1).  
Angiogenic responses were evaluated by observation of macrovessels and microvessels.  
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Macrovessels 
Images of the area of drug application were taken at EDD 10 using a digital microscope. 
Using Image J software images were first converted to grayscale and then adaptive 
thresholding was performed. Finally, noise removal was performed by obtaining the binary 
images that went to analysis. From each image ‘the percentage area covered by blood vessels’ 
was calculated. A similar protocol was described by other authors previously [22] (Figure 
3.17-2).  
Microvessels 
The microvasculature was imaged by confocal microscopy on fixed tissues of the CAM. The 
CAM vasculature was labelled using a rhodamine conjugated LCA by injecting it into chick 
circulation at EDD 10. On the top planar view, the microvasculature was found by focusing 
on the area just above the larger blood vessels of the CAM (Figure 3.17-3). The 
microinjection technique is demonstrated in Figure 3.18. A Zeiss LSM 510 META confocal 
upright microscope with Zeiss LSM Image Browser software (version 4.2.0121) was used for 
image acquisition. EC-plan Neofluar 5X and 10X objective lenses were used. For 
visualization of rhodamine LCA following parameters were used: excitation 543nm and 
emission 615nm; optical images were taken at every 25 μm interval, confocal settings (frame 
size 512 x 512, scan direction (single), scan speed (4), data depth (8 bit), pinhole (1 Airy 
unit), laser power and detector gain were all kept constant for all samples.  These parameters 
were arranged initially with the help of Dr Ahtasham Raza and the same settings were used 
for all samples. 
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Figure 3.17. The process of application of drugs directly on the CAM, injection of the lens culinaris agglutinin (LCA) and imaging the 
vasculature on confocal microscopy.    
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Since there is no hierarchy in the microvasculature, mainly the degree of endothelial cell 
hypertrophy was assessed in all samples. This was calculated on processed images 
constructed using Image J software. Original images were converted to grayscale, ‘enhance 
contrast’ applied, band pass filter applied and images were ‘thresh holded’ to be most 
representative of original images. The total area covered by endothelial cells in a frame was 
calculated. The frames were taken from randomly selected areas of the CAM within and 
around the plastic ring.    
Figure 3.18. Demonstration of microinjection technique. A 30G hypodermic needle attached to 1 ml injector is used. A cotton swab is used to 
stabilize the CAM when injecting. A bifurcation in one of the vitelline veins is chosen for injection (arrow heads in 1 and 2). The needle first 
punctures the membrane with a 45-degree angle and then goes as horizontal as it can be to lie parallel to the membrane. Once inside the vein, a small 
flush demonstrates clearing of the vessel content for a few seconds (arrows in 3, 4 and 5) which confirms successful injection into the vitelline vein.  
After the injecting the needle is removed while pressing with the swab. 
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3.5. Chapter discussion 
 
Developing the ex ovo technique to culture the chick embryos in our laboratory was one of the 
main achievements of the current doctoral studies. The current work builds on previous work 
of Dr Giulia Gigliobianco who first setup the necessary procedures with the in ovo CAM 
assay. Although the ex ovo culture method was described previously, developing the 
necessary equipment and the standard operating procedures in house for this assay was the 
main challenge addressed within these doctoral studies. As a result, this assay is now being 
taken up and used by a wider community of researchers within the department. 
The ex ovo CAM assay can be used as a readily available bioassay to study the angiogenic 
potential of and initial tissue responses to biomaterials. The main advantages of the ex ovo 
(shell- less) modification is that a larger surface area of the CAM is available for all 
experimental interventions where up to 3-4 samples can effectively placed on a single embryo 
culture. Also the developing chick and the vascular structures are clearly visible to the 
researcher without effort. This could have particular importance for material testing as 
toxicity of some materials or their constituents can be detected.  
Recently the CAM assay proved to be a useful in initial in vivo assessment tool to test 
biomaterials.  Biomaterials comprise a wide range of natural and synthetic materials that are 
often combined with a range of bioactive molecules, proteins and/ or cells. The 
biocompatibility testing has to examine each of these constituents separately and in various 
combinations. This creates a demand for reproducible and technically simple bioassays that 
allow higher throughput screening of biomaterials prior to animal testing. The 3Rs principles 
inevitably limit the use of animals for high- throughput screening of biomaterials. Vigorous 
testing of biomaterials in in vivo assays during pre- clinical development is key to their 
subsequent success in clinical studies. Therefore, the CAM assay stands out as a technically 
simple bioassay where biomaterials can be assessed for their biocompatibility and angiogenic 
potential prior to animal testing.    
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The CAM assay is increasingly being used as a pre in vivo test to assess biomaterials [145]. 
The CAM has been effectively used as a short term host for grafted materials, organs and 
tissue samples where the angiogenic response and their safety and biocompatibility can be 
studied [142]. Also the CAM assay has recently been demonstrated to produce data that is 
comparable to mouse assays in testing bio-distribution and in vivo stability of 
radiopharmaceuticals [146].    
Other advantages of the ex ovo technique is that it allows direct visualization of sprouting and 
intussusceptive angiogenesis in vivo which can be of particular importance when studying the 
mechanisms of angiogenesis.   Other available in vivo models are expensive, do not allow 
high throughput screening and require expertize and sophisticated instruments (e.g. the dorsal 
skin fold assay).  Another unique feature of the CAM assay is that it allows visualization of 
the capillary plexus in a top planar view under a fluorescent microscope after a fluorescently 
tagged lectin (lens culinaris agglutinin [LCA]) is injected into the circulation of the chick 
embryo.  This capillary plexus is a very responsive in vivo system where the effect of an 
experimental intervention on the microcirculation can be studied.  
The main disadvantage of the ex ovo technique has commonly been cited as decreased 
survival rates associated with it. However, throughout these studies survival rates of above 
80% were consistently obtained. Nevertheless, there is a learning curve when conducting ex 
ovo cultures. This may explain the apparently inconsistent reports in the literature.  Within the 
MacNeil group my research experience has accumulated and been shared with several 
researchers.  
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Within the context of this work, mainly biomaterials without cellular components have been 
implanted onto the CAM. However, the CAM is known to accept xenogeneic grafts that 
contain cells and/ or proteins in the initial stages of embryonic life. The immune system of the 
chick embryo starts developing later in the embryonic life after embryonic development day 
11. First mononuclear phagocytes are detected in the chick embryo at EDD 9 [147] and 
functional macrophages which are responsible for the initiation of acute inflammatory 
response, were detectable in the circulation at EDD 14, the number of which suddenly 
increased at EDD 19 [148]. The lymphoid cells that constitute the cellular (T cells) and 
humoral immunity (B cells) were detected after EDD 11 and EDD 12, respectively [147].  
The chick embryo is considered immunocompetent only after EDD 18.   
Under our institutional regulations, the embryos can be cultured for only up to 14 days (other 
centres are known to have licenses for longer durations) this assay has been found useful to 
assess the initial in vivo tissue response to biomaterials. Therefore, other tissue engineered 
constructs, such as tissue engineered skin, can also be implanted and cultured on the CAM 
making use of the in vivo environment. However, it should be considered that this model on 
its own cannot be adequate in characterizing the biocompatibility and immunogenic potential 
of the biomaterials. Further animal studies would still be needed to achieve a complete 
understanding.  
Other in vivo assays have also been used to study angiogenesis. Among these the mouse 
dorsal skin chamber (DSC) assay allows direct visualization of blood vessels at all times 
during the experiment with use of intravital microscopy [149]. This model can also accept 
xenogeneic grafts if nude mice are used and it can provide information on the dynamics of 
blood vessel development. The main limitation of mouse DSC assay is that it requires 
significant expertise and sophisticated equipment that may not be available in most 
laboratories. Furthermore, for biomaterials testing implantation of the biomaterial will be 
difficult as the chamber lies vertically at the back of the mouse. Therefore, the ex ovo CAM 
assay stands out as an inexpensive, reproducible and technically less challenging bioassay to 
allow screening of materials. 
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4.1. Chapter Introduction 
 
During and after pregnancy there is extensive connective tissue remodelling in the pelvic 
floor. This remodelling occurs as a result of a complex interplay between the synthesis and 
degradation of main components of the extracellular matrix, mainly collagen and elastin 
[150].  Defects in the remodelling of the ECM during and after pregnancy have been 
suggested as one of the mechanisms leading to development of pelvic floor disorders 
including SUI and POP.  
The main component of ECM is collagen. Collagen accounts for 30% of all proteins in human 
body. Collagen fibrils allow connective tissues to withstand tensile forces. To date 27 
different collagen types have been identified each of which is coded by a specific gene [151].  
Most commonly encountered collagen types are collagen I and III constituting 80-90% of the 
collagen in human body. Collagen is synthesized as procollagen and after being secreted to 
the extracellular space procollagen acquires a triple helical structure and assembles into the 
highly ordered fibrillary collagen [152].   
Collagen turnover is mediated by a balance between collagen synthesis and degradation. 
Collagen degradation is mainly driven by a family of matrix metalloproteinases (MMP). The 
action of these enzymes is regulated by interefering with their synthesis, activation and 
activity inhibition at the tissue (tissue MMP inhibitors) at multiple levels. On the other hand 
collagen synthesis is followed by a series of  post- translational modification reactions which 
eventually lead to formation of a mature,  high tensile strength double helix of collagen that 
can provide structural support.  
 
 128 
 
4.1.1. The role of defective ECM production in POP and SUI 
 
In women with SUI and POP, anatomical defects and/ or biochemical dysfunctions of the 
pelvic floor support structures have been suggested as the possible etiological factors. 
Changes in biochemical composition of ligaments, paravaginal tissues and vaginal wall have 
been reported with decreased levels of collagen I and III that can lead to reduced tensile 
strength of these structures [153], [154].  Also elevated levels of MMP and reduced activity of 
MMP inhibitors were found in paravaginal tissues [155]. Furthermore, impaired healing of 
tissues following pelvic floor surgery leading to recurrencd has been suggested to be due to 
the underlying primary defect in connective tissue metabolism. It has been reported that in 
women with altered collagen I and III metabolism risk of recurrence of POP after surgery was 
significantly higher [156]. Nevertheless it is not clear whether the observed changes in ECM 
composition and organization are the cause or the effect of the underlying POP [32]. 
Therefore defects in collagen synthesis and turnover appear to be a part of the disease process 
in women with SUI and/or POP but the exact pathophysiological pathways are not clear.  
4.1.2. The effect of Vitamin C on collagen metabolism 
Vitamin C is historically known to be the single most crucial vitamin to play a role in collagen 
biosynthesis. Deficiency of Vitamin C is  called ‘scurvy’ and it has been associated with 
sailors who go on lengthy voyages without access to fresh fruit. Scurvy  manifests itself as a 
severe connective tissue disorder characterized by  swollen bleeding gums, non- healing 
wounds, edematous legs with soft tissue heamorrhage and bruising together with other 
constitutional symptoms.   
 Vitamin C exerts its effects on collagen synthesis and post-translational modification at 
multiple levels: (1) acting as a co- factor for the enzyme prolyl hydroxylase which is 
responsible for crosslinking of collagen fibrils thus forming the triple helix structure [157], (2) 
stimulating collagen gene expression via malondialdehyde [158] and (3) activation of 
collagen gene transcription and stabilization of procollagen mRNA [159], [160].   Vitamin C 
is absorbed in the small intestine and its blood concentrations is regulated by renal excretion. 
Humans rely on a continuous supply of Vitamin C in their diet. 
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4.1.3. Effect of Vitamin C on angiogenesis 
 
Vitamin C can influence blood vessel formation through its effects on collagen III and IV 
which are the main types of collagens forming the blood vessel wall and basement membrane. 
Ascorbic acid is an essential co- factor in expression, maturation and deposition of collagen in 
ECM of cultured fibroblasts, vascular smooth muscle cells and endothelial cells [161], [162]. 
Some contradictory results have been reported on the effects of Vitamin C on angiogenesis. 
Some studies evaluating the effect of ascorbic acid on CAM demonstrated angiostatic effects 
for ascorbic acid [163] whereas others reported ascorbate-2- phosphate to be significantly  
proangiogenic [164]. This variability can be due to different experimental setups and dosages. 
4.1.4.Vitamin C and POP/ SUI 
Although a strong association between collagen metabolism and Vitamin C and changes in 
collagen structure and biochemical composition and pelvic floor disorders are known, the role 
of Vitamin C in pathophysiology of SUI and POP is not known.  A recent study however 
suggested that Vitamin C supplementation during pregnancy in rats resulted in increased type 
I and III collagen content in cardinal and uterosacral ligaments [165]. In a cross sectional 
study of 96 women with and without POP, smokers with POP were found to have lower 
levels of Vitamin C and higher levels of MMP-9 compared to non- smokers with POP 
suggesting smoking can effect development of POP via depleting vitamin C levels [166]. In a 
population based cross sectional study between 2002 and 2005, the Boston Area Community 
Health survey, adult women who had high- dose Vitamin C  intake were more likely to report 
storage type lower urinary symptoms. However normal intake of vitamin C from food and 
beverages decreased lower urinary tract symptoms [167].  Nevertheless the evidence is very 
limited to suggest Vitamin C deficiency as a cause of any pelvic floor disorder as well as a 
positive effect of Vitamin C supplementation in prevention of SUI and POP.  
Therefore Vitamin C is a potent stimulator of collagen production and can have positive 
effects on new blood vessel formation. In this section Vitamin C is incorporated in 
scaffolds with the aim of improving tissue integration of the materials by  increasing 
ECM production and by stimulating angiogenesis.   
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4.1.5. Incorporation of Vitamin C into Tissue Engineered scaffolds 
 
Ascorbic acid (AA) is the naturally occurring and metabolically active form of Vitamin C in 
humans.  It has been used since 1970s as a supplement in culture media to increase the 
collagen production of fibroblasts [168]. AA is easily oxidizable and is not stable in aerobic 
culture conditions [169] therefore a variety of AA derivatives such as Ascorbate-2-phosphate 
[A2P] and ascorbate sodium salt have been synthesized. A2P has been the most widely used 
synthetic form of AA with its good chemical stability (Figure 4.1) with the same activity  as 
AA [170], [171]. Nevertheless there are a few direct comparisons of AA analogs [172], [173] 
in terms of their effects on collagen production by fibroblasts. A continuous supplementation 
of either AA or A2P in culture media so as to mimic a sustained release state from a 
biomaterial, has not been studied. This can be important because if a continuous supply of AA 
can be achieved it would abolish the need for using a more stable derivative such as A2P.      
A2P was previously incorporated into PLGA scaffolds using the solvent- casting, particulate 
leaching technique achieving a sustained release [174]. Using the electrospinning spinning 
technique, substances with high hydrophilicity often fail to form stable solutions with the  
hydrophobic polymer solutions [169].  To overcome this the technique of ‘emulsion 
electrospinning’ was described. In this technique a surfactant is used to form a stable 
emulsion where hydrophilic substances are in the water phase and hydrophobic polymer 
solutions are in the oil phase.  Upon electrospinning, the hydrophillic phase constitutes the 
core of the electrospun fibres whereas the hydrophobic phase forms a shell around the 
hydrophilic core [175], [176]. Successful encapsulation of  vascular endothelial growth factor 
[177], Rhodamine B [178] and human nerve growth factor [179] with the emulsion 
electrospinning technique have been reported previously.     
The aims of this section were to construct emulsion electrospun PLA scaffolds that are able to 
release  vitamin C derivatives (AA and A2P) and assess the effects of these scaffolds on 
collagen production and angiogenesis.  
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Figure 4.1. The chemical formula of L- ascorbic acid (AA) and ascorbate-2 phosphate (A2P). AA 
can easily oxidize whereas A2P is more stable.  
 
 
 
4.2. Effect of Vitamin C on collagen production of human dermal fibroblasts 
 
The effects of Vitamin C on collagen production of human dermal fibroblasts (HDFs) were 
evaluated on proliferating cultures of HDFs and confluent cultures of HDFs. HDF cultures 
were supplemented by two forms of AA in these experiments:  AA and A2P.  Furthermore, to 
mimic a continuous release state of the drugs, as would be expected to occur with sustained 
release from the biomaterials, AA and A2P were supplemented in cell culture media freshly 
every day which was compared to routine supplementation in culture media.  The flowchart of 
this experimental design is shown in Figure 4.2. 
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Figure 4.2. Flowchart of the experimental design to assess collagen production of human dermal 
fibroblasts on tissue culture plastic when ascorbic acid (AA) and ascorbate- 2 phosphate (A2P) are 
supplemented daily to mimic a continuous release state. 
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4.2.1. Effect of Vitamin C on collagen production of ‘proliferating cultures of 
fibroblasts’ 
 
Human dermal fibroblasts (HDFs) were seeded in 12 well plates at a concentration of 50,000 
cells per well. Supplementation of AA and A2P in media started next day for ‘proliferating’ 
cultures. Cell culture media consisting of DMEM supplemented with 10% FCS and 1% 
penicillin/streptomycin was used to prepare the following concentrations of AA and A2P in 
media: 0, 10, 100, 300 and 600 µM. Media was prepared freshly and changed every day for 
14 days in the ‘media changed daily group’. For the ‘media changed every 3-4 days’ group’ 
the media was replaced every 3-4 days for 14 days. The results of collagen production in this 
section were presented as a percent (%) increase in collagen production compared to collagen 
production of fibroblasts grown in non-supplemented media.  
Daily supplementation of proliferating fibroblasts with 10, 100, 300 and 600 µM 
concentrations of either AA or A2P resulted in a dose dependent increase in collagen 
production up to a maximum of 100% by 14 days of culture.  Compared to supplementation 
every 3-4 days, which resulted in a maximum of 50% increase in total collagen production, 
daily supplementation of AA at a concentration of 600 µM and daily supplementation of A2P 
at concentrations of 100, 300 and 600 µM resulted in significantly more collagen production 
(Figure 4.3.).   
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Figure 4.3. Total collagen production of proliferating fibroblasts supplemented with either ascorbic 
acid (AA) or ascorbate- 2 phosphate (A2P) daily or routinely (every 3-4 days) after 14 days of 
culture (*p<0.05 and **p<0.005, compared to every 3-4 days’ group).   
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4.2.2.Effect of Vitamin C on collagen production of ‘confluent cultures of fibroblasts’ 
 
Human dermal fibroblasts (HDFs) were seeded in 12 well plates at a concentration of 50 000 
cells per well. Supplementation of AA and A2P in media started 3 days after seeding for 
‘confluent’ cultures. Cell culture media consisting of DMEM supplemented with 10% FCS 
and 1% penicillin/streptomycin was used to prepare the following concentrations of AA and 
A2P in media: 0, 10, 100, 300 and 600 µM. Media was prepared freshly and changed every 
day for 7 days in the ‘media changed daily group’. For the ‘media changed every 3-4 days’ 
group’ the media was replaced every 3-4 days for 7 days. The results of collagen production 
were presented as a percent (%) increase in collagen production compared to collagen 
production of fibroblasts grown in non-supplemented media.  
Daily supplementation of proliferating fibroblasts with 10, 100, 300 and 600 µM 
concentrations of either AA or A2P resulted in a dose dependent increase in collagen 
production up to a maximum of 60% at 7 days of culture was observed with significantly 
more collagen production at all concentrations in the daily supplemented groups (Figure 4.4.).     
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Figure 4.4. Total collagen production of confluent cultures of fibroblasts supplemented either with 
AA or A2P daily or once every 3-4 days for 7 days (*p<0.05 and **p<0.005, compared to every 3-
4 days group). 
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4.3. Production of Vitamin C releasing PLA scaffolds 
 
Scaffolds containing 3 different concentrations of AA and A2P were prepared: 0.0001, 0.001 
and 0.01 grams of either AA or A2P per gram of PLA (summarized in Table 4.1). AA and 
A2P were first dissolved in 500 µl of distilled water and with the aid of the surfactant an 
emulsion with the polymer solution was prepared for electrospinning.  Additionally, polymer 
solutions containing neither AA nor A2P but only 500 µl distilled water to make the emulsion 
was also prepared (Vehicle scaffolds) (Figure 2.3).  All emulsions were freshly prepared and 
electrospun immediately.  
Table 4.1. Summary of all scaffolds produced in this section. 
Scaffold Acronym Production 
method 
Ingredients 
PLA PLA Electrospinning PLA 
Emulsion electrospun 
PLA 
Vehicle 
scaffold 
Emulsion 
electrospinning 
PLA+ surfactant+ distilled 
water 
AA releasing emulsion 
electrospun PLA 
AA scaffold Emulsion 
electrospinning 
PLA+ surfactant+ distilled 
water + AA 
     0.0001 g AA/ g of PLA AA_0.0001   
     0.001 g AA/ g of PLA AA_0.001   
     0.01 g AA/ g of PLA AA_0.01   
A2P releasing emulsion 
electrospun PLA 
A2P scaffold Emulsion 
electrospinning 
PLA+ surfactant+ distilled 
water + A2P 
     0.0001 g A2P/ g of PLA A2P_0.0001   
     0.001 g A2P/ g of PLA A2P_0.001   
     0.01 g A2P/ g of PLA A2P_0.01   
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4.3.1. Demonstration of release of Vitamin C from PLA scaffolds 
 
All measurements of AA and A2P were performed using a UV- spectrophotometer (Thermo 
ScientificTM Evolution 220) at an absorbance wavelength of 252 nm. A previously constructed 
calibration curve (Figure 2.6) was used to determine the concentration of AA and A2P in a 
given solution.  
Release of AA and A2P from scaffolds were studied in distilled water. Three pieces of AA 
and A2P scaffolds (mean weights: 0.0199± 0.002 and 0.0176± 0.002, respectively) were 
placed in 4 mL media and were kept in a dry incubator at 37°C.  A vehicle scaffold was taken 
as a control. At 2, 4, 6, 8, 10 hours and 1, 2, 3, 7, 14, 21 and 28 days a sample was removed 
from the media, the absorbance measured and the concentration was determined with use of 
the calibration curve. All the media were then discarded and replaced with fresh media. 
Experiments were repeated three times.  
Release characteristics 
The sustained release of both AA and A2P over 28 days (Figure 4.5). Percentage release of 
the drug at each point was calculated based on the actual drug content. For AA releasing PLA 
scaffolds a burst release of 77% of AA in the first 2 hours was followed by the release of 90% 
of the actual drug content in the first 10 hours. Afterwards AA was not measurable after 72 
hours. For A2P releasing PLA scaffolds a burst release of 34% was followed by the release of 
60% of the actual drug content in 14 days which continued gradually until 28 days.   
Therefore, AA had a significant burst release compared to the more sustained release of A2P 
from electrospun PLA scaffolds. The released AA from the scaffolds were depleted after 72 
hours whereas A2P continued to be released over 28 days.  
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Figure 4.5.  Cumulative release of AA and A2P over 28 days. 
 
 
 
Encapsulation efficiency  
The indicated concentrations of AA or A2P in scaffolds are the amount of vitamin C put into 
the polymer solution that went into electrospinning. This is called the ‘theoretical drug 
content’. During the electrospinning process the amount of polymer and the vitamin that go 
into the electrospun fibrous mat can be disproportional. Therefore, the ‘actual drug content’ 
that is encapsulated within the micro/ nanofibers of the electrospun PLA scaffolds can be 
different to the ‘theoretical drug content’.  This can be studied by calculating the 
‘encapsulation efficiency’.  
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The electrospun scaffolds were dissolved back and vitamin content was extracted. An 
accurately weighed 20 mg piece of AA and A2P releasing electrospun PLA scaffold was 
dissolved in 10 mL of DCM. On top of the polymer- vitamin solution a 5 mL volume of 
distilled water was added and the suspension was vigorously vortexed intermittently for 30 
min the extract all the hydrophilic vitamin C into the water phase. The suspension was then 
left to stand still for 60 minutes to facilitate separation of the water and oil phases. The water 
phase containing vitamin C was than pipetted out and absorbances were read using UV 
spectrophotometer. The encapsulation efficiencies for AA and A2P were calculated to be 
46.8% (± 6.45) and 44.06% (± 7.14).  
The encapsulation efficiency (%) was calculated using the following formula:   
(Actual drug content/ Theoretical drug content) x 100.  
 
4.4. Characterization of Vitamin C releasing PLA scaffolds 
4.4.1. Ultrastructure 
 
The effect of incorporation of AA and A2P on the ultrastructure of electrospun PLA scaffolds 
was studied using SEM.  The SEM images of the AA and A2P releasing scaffolds are shown 
in Figure 4.6.  The mean fibre diameter and the mean pore size for AA, A2P and Vehicle 
electrospun PLA scaffolds were 0.99 (±0.60); 1.04 (±0.56) and 1.11 (±0.63) and 5.66 (±3.18); 
5.76 (±2.76) and 5.47 (±3.52), respectively.  For PLA only scaffolds the mean fibre diameter 
and the mean pore size was 1.06 (±0.72) µm and 5.65 (±4.61) µm, respectively.  Therefore, 
neither the incorporation of the surfactant (Span-80) nor the incorporation of AA or A2P in 
electrospun PLA scaffolds had an effect on scaffold ultrastructure.   
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Figure 4.6. The ultrastructure of ascorbic acid (AA) and ascorbate- 2 phosphate (A2P) releasing 
electrospun PLA scaffolds (scale bar represents 20 µm for all images).  
 
 
4.4.2. Wettability 
 
The water uptake of AA, A2P and vehicle scaffolds was significantly higher than that of pure 
electrospun PLA scaffolds (Figure 4.7).    The water uptake (% increase in weight) of 
scaffolds containing AA were significantly higher in the first 7 days compared to vehicle 
scaffolds (355.84 [±140.36] vs 274.84 [±108.21] at day 1, p=0.005; 407.69 [±62.38] vs 
299.76 [±92.2] at day 2, p=0.001; 397.74 [±53.3] vs 328.76 [±80.31] at day 3, p=0.001 and 
363.64 [±45.32] vs 304.31 [±65.59] at day 7, p=0.001) whereas those of A2P containing 
scaffolds were significantly lower at all-time points compared to vehicle scaffolds (161, 1 
[±116.36] vs 317.55 [±62.25] at day 14, p=0.001).  
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The wettability of AA and A2P scaffolds containing different concentrations of the drug was 
also evaluated. For AA scaffolds there was no difference in the wettability between AA 
releasing scaffolds of 0.0001 g, 0.001 g and 0.01 g of AA per gram of PLA concentrations 
(mean percentage increase in weight was 350.52 [±192.54], 325.41 [±191.72] and 321.06 
[±186.65], respectively [p=0.49]). A2P releasing scaffolds with 0.001 g per gram of PLA 
were slightly more hydrophilic (mean percentage increase in weight being 72.84 [±64.24], 
174.02 [±153.54] and 79.46 [±84.71] for 0.0001 g, 0.001 g and 0.01 g of A2P per gram of 
PLA concentrations, respectively [p=0.03]).  
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Figure 4.7. The wettability of emulsion electrospun PLA scaffolds. (A) Representative images of 
scaffolds at day 1 of water uptake experiment showing partial wetting of all AA, A2P and vehicle 
scaffolds when PLA only scaffolds were wetting at all (B) Percent increase in weight of the emulsion 
electrospun scaffolds upon incubation in PBS over 21 days (*p<0,005 compared to vehicle scaffolds) 
(C) Correlation of percent increase in weight (PIW) and  Ultimate Tensile Strength 
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4.4.3.Mechanical properties 
 
This was studied both in dry and wet scaffolds. Also the effect of water uptake on mechanical 
properties was studied. Since the water uptake of our scaffolds occurred gradually the 
mechanical properties in the wet state were evaluated at days 3, 7, 14 and 21 after the 
scaffolds were placed in PBS in incubator.   
In their dry state, all emulsion electrospun scaffolds (AA, A2P and Vehicle scaffolds) had 
higher UTS, strain and YM values compared to pure PLA scaffolds (Figure 4.8). On the other 
hand, there was no difference in the mechanical properties of the emulsion electrospun PLA 
scaffolds.  
In their wet state, the UTS and strain values of AA and Vehicle scaffolds further increased, 
whereas the Young’ s modulus were variable. The mechanical properties of A2P scaffolds did 
not change significantly when wet compared to when dry.  The UTS of AA scaffolds were 
significantly higher than Vehicle scaffolds only at day7 (Table 4.2).  There was a statistically 
significant correlation between the percent increase in weight and the UTS of wet scaffolds at 
day 3, 7, 14 and 21 (Pearson r= 0, 64 [p<0,001], 0, 78 [p<0,001], 0, 67 [p<0,001] and 0, 85 
[p<0,001], respectively), the strongest correlation was observed at day 21. 
 145 
 
Figure 4.8. Mechanical properties in dry and wet states for all scaffolds. (The values in the y axis are mean of days 3, 7, 14 and 21). 
 
Table 4.2.  Mechanical properties of AA and A2P releasing scaffolds at days 3, 7, 14 and 21 in in vitro culture conditions. Values are 
mean (standard deviation). (+p<0.05 and ++p<0.005 compared to PLA; *p<0.05 and **p<0.005 compared to Vehicle scaffolds)  
 Dry Wet (day 3) Wet (day 7) Wet (day 14) Wet (day 21) 
 UTS  Strain  YM  UTS  Strain  YM  UTS  Strain  YM  UTS  Strain  YM  UTS  Strain  YM  
AA 
scaffolds 
1.39++.** 0.43++ 16.46++.** 2.37++ 0.66++ 20.07++ 2.93++.** 0.77++ 24.06++ 2.36++ 0.73++ 13.57++ 2.26++ 0.59++ 21.78++.* 
  (0.30) (0.06) (5.99) (0.45) (0.15) (7.81) (0.55) (0.08) (8.06) (0.44) (0.12) (4.70) (0.39) (0.17) (5.60) 
A2P 
scaffolds 
1.54++ 0.41++ 23.08++ 1.49++.** 0.48 14.76++ 1.28++.** 0.44** 9.62+.* 1.52++.** 0.37** 15.49++ 1.27++.** 0.31+.** 16.56++.* 
  (0.41) (0.15) (12.07) (0.38) (0.48) (10.81) (0.48) (0.09) (7.03) (0.37) (0.18) (10.29) (0.46) (0.15) (12.75) 
Vehicle 
scaffolds 
1.76++ 0.45++ 25.68++ 2.36++ 0.58++ 20.97++ 2.10++ 0.71+ 
  
16.93++ 2.23++ 0.66+ 14.18++ 2.45++ 0.47++ 27.08++ 
  (0.25) (0.07) (9.03) (0.34) (0.17) (6.42) (0.57) (0.12) (6.51) (0.66) (0.17) (5.54) (0.35) (0.07) (4.56) 
PLA 0.66 0.22 9.17 0.71 0.40 3.56 0.34 0.45 1.80 0.54 0.36 2.75 0.30 0.40 1.70 
  (0.36) (0.05) (4.20) (0.23) (0.11) (2.12) (0.10) (0.16) (0.73) (0.09) (0.15) (1.86) (0.04) (0.05) (0.79) 
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4.5. Effect of Vitamin C on collagen production of fibroblasts seeded on scaffolds 
 
The SEM images showed continuous coverage of the scaffold surface by fibroblasts and 
extracellular matrix which was more intense in AA and A2P containing scaffolds (Figure 4.9). 
Although lower concentrations of AA and higher concentrations of A2P seemed to work 
better, no single concentration of either AA or A2P proved to be significantly different than 
other concentrations.   
 
Figure 4.9. SEM images showing the ECM produced by the human dermal fibroblasts seeded on 
the scaffolds and corresponding DAPI staining of the cell nuclei of fibroblasts grown on scaffolds 
for 14 days (scale bar represents 50 µM for all images). 
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Scaffolds were cut into 8x8 mm squares using sterile forceps and scissors. A total of 500.000 
HDFs were seeded and cultured on the scaffolds for 14 days. The metabolic activity of HDFs 
grown on scaffolds was assessed on days 3, 7 and 14 (Figure 4.10A).     
Total collagen production of HDFs grown on scaffolds was assessed by Sirius red staining. 
HDFs produced significantly more collagen at all concentration of AA and A2P scaffolds 
compared to Vehicle scaffolds (Figure 4.10B).  The mean corrected absorbance values (Sirius 
red stain/gram of PLA) were 5.44 (±0.50); 5.26 (±0.46); 4.44 (±0.49) and 4.41 (±0.41); 5.32 
(±0.55); 5.50 (±0.51) for AA and A2P scaffolds with concentrations of 0.0001; 0.001; 0.01 
grams of either AA or A2P per gram of PLA. respectively. Corresponding values for Vehicle 
and PLA scaffolds were 3.86 (±0.43) and 3.39 (±0.43), respectively. 
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Figure 4.10.  Metabolic activity of fibroblasts grown on scaffolds over 14 days (A) and total collagen production by Sirius red staining (B).  
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4.6. Angiogenic properties of Vitamin C releasing PLA scaffolds 
4.6.1. Day of evaluation of angiogenesis 
 
After the electrospun scaffolds are placed on the CAM at EDD 7. The angiogenic response 
could be evaluated between EDD 10 and 14. To determine the best time point to evaluate the 
angiogenic response to vitamin C releasing PLA scaffolds initial experiments were conducted 
by taking serial images daily starting from EDD 10 (Figure 4.11). By EDD 11 the scaffolds 
started to contract with the underlying CAM making it more difficult to assess a possible anti- 
angiogenic effect. Therefore the angiogenic responses to vitamin C releasing scaffolds were 
all assessed on EDD 10.  
 151 
 
 
Figure 4.11. Daily follow up of the scaffolds implanted on CAM starting from EDD 10. Scaffold 
start contracting starting from EDD 11 obscuring a negative angiogenic response to scaffolds if 
evaluated after EDD 10. (scale bar represents 200 µm for all images).  
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4.6.2. Angiogenic Response to vitamin C releasing PLA scaffolds 
 
A hydrocortisone releasing electrospun PLA scaffold was used as a negative control in these 
experiments. For both AA and A2P scaffolds containing two different concentrations of the 
drug were used: 0.01 gram (low concentration) and 0.1 gram (high concentration)  of AA or 
A2P per gram of PLA. Compared to Vehicle scaffolds. hydrocortisone releasing PLA 
scaffolds were angiostatic with a vasculogenic index of 11.4 (±2.6) (p=0.001) compared to 
21.7 (±3.4) for the vehicle scaffolds. AA releasing scaffolds were proangiogenic at low doses 
(AA_0.01 g) with a vasculogenic index of 32.3 (±6.0) but angiostatic at higher doses (AA_0.1 
g) with a vasculogenic index of 13.4 (±3.6) compared to Vehicle scaffolds. A2P releasing 
PLA scaffolds did not different from Vehicle scaffolds either at high (A2P_0.1) or low 
(A2P_0.01) doses of the drug (Figure 4. 12).   
 
Figure 4. 12. Total data for the comparison of low (0.01 g per gram pf PLA) and high (0.1 g per gram of PLA) doses of AA and A2P as released from 
PLA scaffolds. Negative control is a hydrocortisone releasing PLA scaffold. The hydrocortisone releasing PLA scaffolds (1) decreased the number of 
blood vessels around the scaffold compared to controls (2). Ascorbic acid 0,01 releasing PLA scaffolds (3) stimulated angiogenesis whereas the others 
(4, 5 and 6) were no different to controls  (scale bars represent 200 µm for all images). 
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4.6.3. Initial tissue response to vitamin C releasing PLA scaffolds 
 
The initial tissue response was only evaluated for AA releasing scaffolds as they were most 
proangiogenic. Both Vehicle scaffolds and AA releasing scaffolds induced a mild to moderate 
inflammatory response on the CAM adjacent to the scaffold with infiltration of the scaffolds 
by the host cells. Their appeared to be more blood vessels growing around the scaffold 
releasing AA in cross sections of the histologic images (Figure 4.13).   
 
Figure 4.13. The initial tissue response to AA releasing PLA scaffolds.The interface where the PLA 
scaffolds integrate into CAM are shown with dotted line. Underneath the dotted line blood vessels 
growing underneath the scaffolds can be observed in cross section (black arrows). More blood 
vessels are observed in the CAM tissue adjacent to AA releasing scaffolds. Error bars represent 200 
µm. 
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4.7. Chapter discussion 
 
In this section PLA scaffolds with desired mechanical properties that could release AA and 
A2P were synthesized and assessed for for their ability to stimulate new collagen production 
and new blood vessel formation. The ultimate aim was to improve the tissue integration of 
pelvic floor repair materials once they are implanted into the host.    
Firstly, these experiments showed that both derivatives of vitamin C. AA or A2P. could 
effectively be incorporated into biodegradable PLA scaffolds using a modification of the 
commonly used electrospinning setup. The first milestone in these experiments was to 
develop the emulsion electrospinning technique which had not been performed within the 
MacNeil  group before. This technique allowed formation of stable emulsions of hydrophilic 
and hydrophobic solutions that could then be electrospun with use of a surfactant. Previous 
evidence demonstrated that upon electrospinning the surfactant delineates a core in the 
electrospun fibre that contains the hydrophilic phase whereas the hydrophobic polymer 
solution remains outside of the core forming an outer shell in the fibre.  
The emulsion systems need to have defined concentrations and viscosity in order to be  
electrospun successfully  [180]. The first requirement is the formation of a stable emulsion. 
For this purpose a surfactant (Span 80) was used and the emulsion was created by slowly 
pipetting  droplets of water phase into the oil phase while mixing with use of rotation 
magnets. The resultant emulsion was stable without any phase seperation for 6 hours. During 
electrospinning of the emulsion. the oil phase containing the solvent rapidly evaporates 
leaving the high viscosity polymer to the outside of the fibre while the aqueous phase 
migrates to the centre of the jet.  The electrostatic properties of the electrospinning solution 
are known to be affected by the inclusion of surfactant [181] however systematic studies do 
not exist on which combination of the surfactant- polymer combination will produce the 
desired fibre characteristics. Therefore in these experiments the non- ionic surfactant Span 80 
was used at a minimum concentrations to acheive the minimum amount of an aqeuous 
solution containing vitamin C in the emulsion. This did not affect fibre diameter or pore sizes 
of the electrospun scaffolds.      
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Another technique of electrospinning, co- axial electrospinning, could have been used to 
contain bioactive substances in a core- shell morphology within the electrospun fibres [182]. 
The co- axial electrospinning has the advantage of not requiring a surfactant to separate water 
and oil phases. Instead phases are carried to the tip of the needle in separate channels which 
only mix together in the Taylor’ s cone. However it requires a special setup using a 
specifically designed co- axial electrospinning needle. This technique was not used as we 
lacked this equipment. 
The core- shell fibre structure formed by the emulsion electrospinning has also been 
suggested as a means to achieve a sustained release of bioactive factors encapsulated in the 
core of the fibres.  For AA and A2P releasing PLA fibres, a successful encapsulation of the 
drugs was demonstrated that is consistent with the previous literature reporting encapsulation 
efficiencies of between 17- 90% [183]–[186]. The difference in the encapsulation and release 
pattern of AA and A2P can be explained by the difference in their chemical structure. 
With regards to release of AA and A2P from electrospun PLA fibres. a burst release of 30- 
70% of both drugs occurred within the first 10 hours. Previously. the same core- shell 
morphologies of hydrophilic drugs have been reported to produce burst release rates between 
20- 73% with different drug- polymer combinations [179], [185], [187]. A limitation of the 
current release studies relates to use of distilled water as a medium in which to study drug 
release. Distilled water is not an ideal medium when conducting an in vitro release experiment 
as it is not similar to physiologic fluids. However, distilled water was the only option when 
studying AA release as PBS rapidly oxidized AA with the metal ions it contained within it 
making it impossible to detect the released amount of AA. AA could also be oxidized by the 
oxygen in air even when distilled water is used however this did not happen immediately 
(after 6 hours in our experiments) allowing us to carry out the experiment at 2 hourly 
intervals. Nevertheless, ideal release experiment would be expected to be conducted in an 
environment devoid of oxygen which was not possible in the given circumstances.   
 
 157 
 
AA is well documented for its effect in stimulating collagen production in in vitro cultures of 
fibroblasts. Among the various derivatives of it.  A2P appeared to be the most commonly used 
derivative due to its increased stability in culture conditions. However, achieving a sustained 
release of AA could abolish the need for A2P. Therefore, the comparative effectiveness of 
AA and A2P on collagen production of cultured fibroblasts in 2D was first evaluated in these 
experiments. No such comparative data was available in the literature.  The results 
demonstrated that when a continuous release state was mimicked in culture conditions both 
AA and A2P increased collagen production of fibroblasts to a similar extent in a dose 
dependent manner. The toxic concentration of AA was 600 µM whereas there was no toxicity 
for  A2P up to the highest concentration studied in these experiments.  
The next step was to test the effect of the AA and A2P releasing PLA scaffolds on cell 
viability and collagen production of fibroblasts seeded on them. This was done using 
scaffolds containing three different concentrations of each drug.  Overall, a significant 
increase in collagen production of fibroblasts up to about 60% was observed with both AA 
and A2P  scaffolds compared to controls. It was important to note that the scaffolds 
containing the highest concentration of AA was least effective, although better than the 
control scaffolds. This could be due to higher local concentration of the drug that may have 
occured in micropores of the scaffold resulting in a similar toxicity to that observed in 2D 
experiments.  
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With regards to scaffold ultrastructure. incorporation of neither the surfactant nor either of the 
bioactive factors, AA and A2P, changed the fibre diamater and pore size of the electrospun 
fibres. However, all emulsion electrospun PLA scaffolds became more hydrophilic compared 
to control PLA electrospun scaffolds.  Among the emulsion electrospun scaffolds AA 
releasing PLA scaffolds were the most hydrophilic followed by Vehicle scaffolds and A2P 
releasing scaffolds. Furthermore, AA and Vehicle scaffolds became stronger with higher UTS 
values and more elastic as they became wet whereas there was no difference between dry and 
wet states for the A2P scaffolds. Also there was a positive correlation between water uptake 
and the ultimate tensile strength when all emulsion electrospun were taken into account. 
Therefore both the addition of surfactant and a combination of AA and surfactant appear to 
have a plasticizing role [35].  Other surfactants such as polyethylene glycol and glucose 
monoesters. are reported to have acted as plasticisers [36]. 
The mechanical properties of the candidate materials are of particular importance when 
producing materials for use in female pelvic floor. Although the design requirements in terms 
of mechanical properties are not clearly defined for the pelvic floor. the range of normal 
female pelvic floor tissues is reported as  a mean maximum tensile strength of  0.79±0.05 
Mpa and Young’ s modulus of  6.65±1.48 Mpa for pre-menopausal tissues  [28]. Therefore, 
the AA and A2P releasing scaffolds are slightly above this target.   
The introduction of AA into electrospun scaffolds not only stimulated more collagen 
production but also exerted a proangiogenic effect. Particularly AA scaffolds secreting lower 
concentrations of AA appeared to be signigicantly better than control scaffolds at stimulating 
new blood vessel formation. Surprisingly a higher concentration of AA was angiostatic 
porbably due to local acidic effects of AA. On the other hand scaffolds releasing A2P did not 
cause any change in blood vessel formation at  any concentration. This raises the question of 
the chick embryos ability to convert A2P to AA which is performed in humans by the enzyme 
acid phosphatase on the cell membrane.    
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Taken altogether, among the scaffolds constructed in this section electrospun PLA scaffolds 
releasing lower concentrations of AA appear to be the best candidate to take into further 
analysis with their ability to stimulate new collagen formation and angiogenesis. Initial tissue 
responses studied on the CAM for 5 days of impantation shows a moderate cell infiltration of 
the scaffolds which is promising however these scaffolds needs to be further evaluated in 
relevant animal models with regards to their efficacy and safety.   
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5.1. Chapter Introduction 
 
Another potential drug that could be incorporated into the electrospun PLA scaffolds to 
improve the tissue integration is Estradiol. Estradiol is the major estrogen secreted by the 
premenopausal ovary to act not only on the female reproductive organs but also on many 
other non- reproductive organs such as the skeletal, cardiovascular, nervous and immune 
systems.   
The three most abundant forms of estrogens in females are estrone (E1), estradiol (E2) and 
estriol (E3). Estrogens are steroid hormones synthesized from cholesterol most of which 
comes from the plasma low density lipoprotein derived from dietary cholesterol. Human 
adrenal gland can also synthesize cholesterol from acetate. Steroid biosynthesis is mainly 
derived by two enzymes: cytochrome P450s or hydroxysteroid dehydrogenases [188]. These 
enzymes are expressed highly in ovaries of premenopausal women, placenta in pregnant 
women and adipose tissue in both postmenopausal women and men.  Estradiol is synthesized 
by the aromatization of testosterone. It can be converted to estrone with the enzyme 17β 
hydroxysteroid dehydrogenase while estrone can also be synthesized from androstenedione 
(Figure 5.1).  In premenopausal women, estradiol is mainly synthesized in the ovaries to act 
on target tissues all over the body.  After the menopause small amounts of estradiol are 
produced mainly at extragonadal sites including adipose tissue, bone, vascular endothelial and 
smooth muscle cells to act locally [189].  
Estrogens exert their effects via several well defined pathways. One of the ways estrogens 
function is via binding of the hormone to the intracellular estrogen receptors (ER- α and β) 
which then modulate transcription of target genes.  ER-α is mainly expressed in the uterus, 
mammary gland, ovary (thecal cells), bone and adipose tissue whereas ER- β is present in 
ovary (granulosa cells), immune system, colon and bladder. Both receptor subtypes can be 
found in the cardiovascular and central nervous system [190]. Therefore, the physiological 
functions of estrogens can also be controlled by modifying the receptor expression. Sex 
steroid receptors have been investigated for their role in the development of POP (reviewed in 
[191]) however there is limited data to reach to a conclusion.     
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Figure 5.1. The chemical formula and synthesis of Estradiol and its two main derivatives.   
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5.1.1. The role of Estradiol in the pathophysiology of pelvic floor disorders 
 
Estrogens play vital roles in normal structure and functions of female genital and lower 
urinary tract organs [192], [193]. Estrogen receptors are present in the tissues of female 
urethra, bladder neck, vagina and all connective tissues of the pelvic floor including smooth 
muscles and ligaments. Although estrogen deficiency is recognized as one of the main factors 
leading to the occurrence of SUI and POP the exact mechanisms are not completely known. 
One possible mechanism of estrogens influencing  the female urogenital tract is through 
modifying collagen metabolism.  The total collagen content of the vaginal mucosa was 
significantly reduced in premenopausal women with POP compared to controls.   
Furthermore, their MMP activity was significantly higher [193].  Estrogen levels can also 
affect the pathophysiology of POP by differential expression of estrogen- related genes.  
Recent microarray studies identified expression changes of transcriptional response and signal 
transduction genes associated with estrogens in the uterosacral ligaments of women with POP 
[194].   
Another mechanism by which estrogens relate to development of SUI and POP could be via 
changing the blood flow to pelvic organs. Estrogens are known to be involved in many other 
physiologic and pathologic processes characterized by neovascularization such as lupus, 
Takayasu’s arteritis and menstrual bleeding [195]. The relationship between angiogenesis and 
development of pelvic floor disorders is much less studied. However a measurable decrease in  
vaginal blood flow has been demonstrated in postmenopausal women which improved 
significantly with exogenous estrogen replacement [124].  Additionally, recent work has 
suggested that Estradiol can be involved in pathophysiologic processes leading to 
development of many pelvic floor disorders via its effects on vaginal microcirculation [196], 
[197].   
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Estrogen replacement was shown to increase the collagen content of skin by 48% in 
postmenopausal women compared to controls [198]. The role of estrogen replacement therapy 
in the regulation of collagen metabolism in female pelvic tissues is less clear. It is well known 
that topical estrogen treatment increases the vaginal epithelial thickness and promotes 
revascularization [199]. The change in collagen content in the subepithelial tissues in response 
to estrogen supplementation has been studied in animal models. In ovariectomized rhesus 
macaque vaginal estrogen treatment increased collagen gene transcription in the vaginal 
connective tissues indicating an increase in total collagen production [200]. In ovariectomized 
rats low doses of vaginal estrogen replacement resulted in increased vaginal weight, increased 
collagen I/ collagen III ratio and increased distensibility of the vaginal wall. Low dose vaginal 
treatment was superior to high dose vaginal treatment regimen and systemic supplementation 
[201].  
Currently there is evidence to support the effectiveness of vaginal estrogens in the treatment 
of vaginal atrophy [202] however there is no clinical evidence to support the use of vaginal 
estrogens for prevention or management of POP [203]. With regards to SUI, exogenous 
replacement of estrogen does not necessarily lead to an improvement of SUI symptoms. It 
was shown that estrogen replacement reduced total collagen concentration, decreased collagen 
cross- linking and increased collagen turnover. Also estrogen supplementation increased 
collagen to smooth muscle ratio in the lower urinary tract that may lead to reduced bladder 
compliance and storage symptoms. Therefore, systemic estrogen treatment although it has 
historically been used, can have negative impact when treating SUI.  Nevertheless there is 
some evidence to support the use of vaginal estrogens for treatment of SUI [204]. Clinical 
guidelines recommend use of vaginal estrogens to treat SUI only when it is associated with 
vaginal atrophy [38].    
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5.1.2. The effect of Estradiol on angiogenesis 
 
In adult organisms angiogenesis is normally absent unless there is tissue injury and repair or 
tumours. An exception to this is in the female reproductive tract where physiologic 
neoangiogenesis takes place monthly in menstruating women. This suggests that sex steroids 
influence neovascularization [195]. Additionally estradiol prevents endothelial dysfunction 
and promotes vascular endothelial repair and angiogenesis [205], [206]. Both estrogen 
receptors alpha and beta are expressed in vascular endothelium. Estradiol has direct actions on 
endothelial cells including accelerating endothelial cell migration, proliferation and 
organization of endothelial cells in vitro [205], [207]. Estradiol can directly stimulate vascular 
endothelial cells through the estrogen receptors [208].  Vascular endothelial growth factor 
(VEGF) is a potent stimulator of angiogenesis. Estrogen receptor elements are thought to be 
responsible for direct activation of VEGF gene transcription [209].  Also in vivo experiments 
showed bovine corpus luteum to increase neovascularization in the CAM assay [210].  
In this section, it was hypothesized that estradiol could effectively be introduced to 
electrospun PLA scaffolds and that it could stimulate neovascularisation as released from the 
scaffolds. Incorporating drugs into tissue engineered constructs is a well- established strategy 
to improve the intrinsic angiogenic potential of a tissue engineered materials [126].   Estradiol 
has been shown to be a potent stimulator of angiogenesis as released from electrospun 
materials [72], [138]. Clinically its pro- angiogenic properties are used in disease states such 
as cardiac ischaemia [211] and wound healing to improve tissue vascularization. Additionally 
topical Estrogen treatment is also believed to improve post- operative wound healing and it is  
a common practice among surgeons to use topical vaginal  estrogens before and after vaginal 
surgery especially in the presence of vaginal atrophy [212].  
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5.2. The effective concentrations of Estradiol to stimulate collagen production 
 
This was studied on monolayer cultures of human dermal fibroblasts (HDFs). HDFs were 
isolated from consented donors as described in Chapter 2. A total of 100. 000 cells were 
seeded on each well of a 12 well plate. After overnight incubation the culture media was 
replaced with same media supplemented with different concentrations of Estradiol. First a 
dose finding experiment was conducted using the following concentrations: 10 nM, 100 nM, 1 
µM, 10 µM and 50 µM.   Collagen production was assessed with Sirius red staining and 
expressed as percentage increase in collagen production compared to non-supplemented 
controls.   Concentrations of Estradiol above 100 nM decreased collagen production and 
concentrations of 50 µM reduced collagen production. Additionally as the concentration 
increased there appeared to be a reduction in cell metabolic activity (Figure 5.2).  
 
Figure 5.2. Dose response study for the effects of Estradiol on cell metabolic activity (A) and  
collagen production (B) of human dermal fibroblasts. 
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Therefore, a second set of experiments were conducted using the following concentrations: 2 
nM, 5 nM, 10 nM, 25 nM and 50 nM. Within this concentration range cell metabolic activity 
increased for all concentrations from day 7 to day 14. The most effective concentration for 
Estradiol to stimulate collagen production appeared to be 2 nM and 5 nM (Figure 5.3).   
 
 
Figure 5.3. The effect of different concentrations of Estradiol on cell metabolic activity (A) and 
collagen production (B) of human dermal fibroblasts. 
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5.3. The effective concentrations of Estradiol to stimulate endothelial cell proliferation 
and sprouting 
 
The effect of different concentrations of Estradiol on endothelial cell proliferation and 
sprouting was assessed using the chick aortic arch assay. Chicken embryos were sacrificed 
between EDD 14, aortic arches removed from aortic branches were cut into 1 mm rings under 
a stereomicroscope.  Aortic rings were embedded in 50 µL of Matrigel® (Basement 
Membrane Matrix, Corning®) in a 24 well plate.   Cell culture media, DMEM (supplemented 
with 2.5% FCS, containing 0, 1, 10, 30, 50 and 100 nM of 17-β Estradiol were added into 
wells.  Vascular endothelial growth factor (VEGF) at a concentration of 100 nM was used a 
positive control in this assay.  The endothelial sprouts were observed under an inverted 
microscope on the 5th day of culture. The longest sprout was measured on the digital images 
using Image J software (U. S. National Institutes of Health, Bethesda, Maryland, USA). The 
mean sprout length was calculated for each sample (Figure 5.4). 
The aortic arch assay was used to effectively demonstrate a significant difference in the mean 
sprout length between the control and VEGF supplemented groups, mean sprout length 211 
(±24) µM and 315 (±21) µM, respectively (p=0,003).  Estradiol stimulated endothelial cell 
sprouting at concentrations of 1, 10 and 30 nM, mean sprout length 358 (±34), 362 (±42) and 
357 (±26) µM, respectively (all p values >0,05 compared to control). Estradiol concentrations 
of 50 and 100 nM did not increase endothelial cell sprouting with mean sprout lengths of 215 
(±34) and 131 (±19) µM, respectively.   The number of samples included in this analysis for 
each group were as follows: control (n=19), Estradiol 1 nM (n=8), Estradiol 10 nM (16), 
Estradiol 30 nM (n=11), Estradiol 50 nM (n=14), Estradiol 100 nM (n=9) and VEGF 100 nM 
(n=20).   
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Figure 5.4. The effect of different concentrations of Estradiol on endothelial cell sprouting. 
Concentrations of Estradiol between 1- 30 nM appear to stimulate longer endothelial cell sprouting 
compared to controls whereas a concentration of 50 nM seems to result in shorter endothelial cell 
sprouts. The VEGF is used as a positive control (scale bars 200 µM).  
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5.4. The effect of Estradiol on angiogenesis in the CAM assay 
 
Macrovessels 
Another way of evaluating the effect of Estradiol on new blood vessel formation was applying 
the drug solution to the CAM. For this purpose, a 2 mm thick plastic ring was cut from a soft 
30G needle cover was placed on the CAM. A 50 nM solution of Estradiol in PBS was 
prepared together with positive and negative controls of VEGF (100 nM) and Sunitinib (50 
µg/ ml). The solutions were prepared freshly for each experiment and an injection volume of 
30 µl was pipetted slowly onto the CAM marked by the plastic ring. The drugs were given 
twice every day between EDD 8 to 11. Each group contained 6 eggs for each experiment. 
EDD 11 the CAM area around the plastic ring was imaged. 
The macrovascular response to VEGF and Sunitinib could effectively be observed on the 
CAM images (Figure 5.5). Especially with Sunitinib the decrease in the number and intensity 
of the blood vessels is very dramatic. However, the response to Estradiol never appeared as 
dramatic as it was in the in vitro assays. This could be due to the difficulty in achieving a 
positive effect with twice daily applications of the drug.  
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Figure 5.5. The comparative effectiveness of Estradiol on macrovessels in the CAM assay (Scale bar 
represents 500 µM for all images).  
 
 
Microvessels 
After imaging the macrovessels, a rhodamine labelled lens culinaris agglutinin (LCA) (Vector 
laboratories) (50 µL of a 5µg/ mL of) was injected into one of the major vitelline veins of the 
chick embryo using a 30G hypodermic needle attached to a 1 mL syringe. A maximum of 100 
µl of LCA solution was injected into each embryo. Embryos were then sacrificed and the area 
of the CAM involving the plastic rings were cut by wedge resection and fixed immediately in 
3.7% paraformaldehyde (Sigma Aldrich, USA) in PBS. These samples were used for confocal 
imaging to visualize the microvasculature.  When imaging the microvasculature Estradiol 
effects appeared more quantifiable. Estradiol resulted in a response similar to that of VEGF 
with endothelial cell hypertrophy with smaller lacunar spaces (Figure 5.6).  The percentage 
areas covered by endothelial cells were 52.6±14.3, 87.0±3.7, 87.1±3.5 and 11.7±5.7% 
respectively in control, Estradiol, VEGF and Sunitinib groups (all p values < 0.005 compared 
to controls for all three). 
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Figure 5.6. The comparative effectiveness of Estradiol on the microvasculature on the CAM. The 
normal honey- comb like appearance of the CAM microvasculature can be observed in PBS treated 
samples. With application of Estradiol and VEGF, endothelial cell hypertrophy with smaller lacunar 
spaces are observed. Sunitinib resulted in loss of endothelial cell coverage with larger lacunar spaces. 
Error bars represent 50 µm. 
 
 
In summary, Estradiol at concentrations between 1- 50 nM stimulated endothelial cell 
proliferation and sprouting in vitro. In the CAM assay, although the microvasculature could 
easily quantify the Estradiol effects, the effect of Estradiol on macrovasculature was not 
clearly observable. Therefore, a continuous release system for Estradiol was investigated next.     
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5.5. Achieving a sustained release of Estradiol from a hydrogel 
 
To achieve a sustained release of Estradiol a hydrogel was used as a carrier. This hydrogel 
was constructed as described previously by a visiting researcher (Dr. Gözde Eke) and 
supplied in a ready to use powder form. Briefly, methacrylated gelatin (GelMA) and 
methacrylated hyaluronic acid (HAMA) were synthesized as described previously [140].  
GelMA (15%, w/v) and HAMA (1%, w/v) were mixed with cell culture media containing 
photoinitiator (Irgacure 2959, 0.3% w/v). Estradiol was added into this solution at a 
concentration of (10 µg/1 mL). After complete dissolution at 37°C, 100 µL of hydrogel 
solution was placed on to a petri dish and immediately photo- crosslinked by exposing to UV 
light at a wavelength of 365 nm for 40 sec (Omnicure s1000) (Figure 5.7). The release of 
Estradiol from the hydrogels were confirmed for three days. 
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Figure 5.7. Graphical demonstration of construction of a UV- crosslinkable, transparent hydrogel 
system to achieve a sustained release of Estradiol. (A) The hydrogel is constructed from methacrylated 
gelatin and methacrylated hyaluronic acid which are first dissolved in media, then the photoinitiator and 
Estradiol are added. The final solution was crosslinked by exposing to UV light for 40 seconds. (B) The 
final hydrogel can easily be handled by a fine forceps. (C) A summary of the physical properties of the 
hydrogel has been described previously. 
 
 
The Estradiol releasing and control hydrogels were placed on CAM on EDD 7 and incubated 
for 8 days. On EDD 14, the hydrogels and surrounding CAM area were imaged by digital 
microscope. Digital images were analysed and the vasculogenic index calculated. Estradiol 
releasing hydrogels resulted in a significant increase in the number of newly formed blood 
vessels growing towards the hydrogel in a spoke wheel pattern compared to control 
hydrogels. The vasculogenic index was 35.0±4.6 and 21.3±3.5, respectively for control and 
Estradiol releasing hydrogels (p: 0.005) (Figure 5.8).  
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Figure 5.8. Angiogenic response to the Estradiol releasing hydrogel in the chick chorioallantoic 
membrane (CAM) assay. Micrographs of the control and Estradiol releasing hydrogels taken on day 14 
of embryonic development demonstrate a significant increase in the mean vessels count with Estradiol 
releasing hydrogels compared to controls (n= 6 for each group) (Scale bar 500 µm). 
 
 
Therefore, a sustained release of Estradiol from a hydrogel resulted in an increase in the 
number of blood vessels growing around the hydrogel. This hydrogel had two main 
advantages in this experimental set up. Firstly, it did not trigger an inflammatory response that 
could have interfered with the angiogenetic process. Secondly, because it was transparent all 
the blood vessels underneath the hydrogel were clearly visible during the experiment.   
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5.6. Construction and characterization of Estradiol releasing PLA scaffolds 
 
A total of 50 mg of Estradiol was dissolved in 10 mL of DCM into which 1 gram of PLA 
added to produce a homogenous solution of PLA and Estradiol. This solution was then 
electrospun. Micro/ nanoporous scaffolds of Estradiol incorporated PLA with a mean fibre 
diameter of 0.71±0.28 µm and a pore size of 4.25±2.04 µm were produced. Control PLA 
scaffolds without any Estradiol had a fibre diameter and pore size of 0.65±0.30 µm and 
4.26±2.29 µm, respectively (Figure 5.9).    
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Figure 5.9. The ultrastructure of Estradiol releasing PLA scaffolds as shown by scanning electron 
microscopy. There was no difference in the fibre diameter and pore sizes of both scaffolds. Scale bar 
represent 10 µm.  
 
 
Mechanical testing of scaffolds was previously performed by Dr. Chris Hillary demonstrating 
no significant change in mechanical properties of PLA scaffolds with incorporation of 
Estradiol, apart from a slight increase in UTS and Young’s modulus. Therefore, the 
mechanical testing was not repeated here.    
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Release of estradiol from scaffolds over 5 months 
Scaffolds were cut and standardised by mass to equate to 1% of the entire electrospun mat.  
All scaffolds were washed and incubated in 1ml/well of Phosphate buffered saline (PBS) in a 
12-well tissue culture plate.  The relative fluorescence of PBS was measured intermittently 
(Kontron SFM 25 spectrofluorimeter) at λex277nm/λem310nm, with fresh PBS replaced 
following each sampling over a 5- month period.  New standard curves were prepared at each 
sampling time-point.   
 
Figure 5.10. The release of Estradiol from PLA scaffolds over 133 days in a concentration 
dependent manner. (This experiment was conducted by Dr. Chris Hillary) 
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The concentration of estradiol released from each of the 3 scaffold groups (10mg (1% wt/vol), 
50mg (5% wt/vol) and 100mg (10% wt/vol)) was measured fluorimetrically against solutions 
of known concentration (n=6 per group).  The cumulative release of estradiol increased for 
each time-point, until no further estradiol was released (at 133 days) as demonstrated in 
Figure 5.10. The total released estradiol from the scaffolds was equivalent to 2.5%, 1.4% and 
2.45% of the estradiol present in the polymer solution for the 10mg, 50mg and 100mg 
estradiol scaffolds respectively prior to the electrospinning process, while 40%, 50% and 40% 
of estradiol was released over the initial 14 days for each of the 3 scaffold groups 
respectively; the rate of release was proportional to the amount of estradiol present in the 
scaffold and reduced over time.   
 
5.7. Assessment of angiogenic potential of Estradiol releasing electrospun PLA scaffolds 
 
This was assessed by both co- culturing the scaffolds with chick aortic rings and by 
implanting the scaffolds on the CAM.   
Co- culture of scaffolds with chick aortic rings 
Three 1x1 cm piece of control and Estradiol releasing PLA scaffolds were cut and placed in 
transparent tissue culture inserts (Greiner Bio-One GmbH). Chick aortic rings were embedded 
in Matrigel  in 48 well plates and co- cultured with scaffolds for 5 days. Estradiol releasing 
scaffolds stimulated more endothelial cell sprouting compared to controls, with a sprout 
length/radius of 1.6 (±0.51) and 1.0 (±0.44), respectively (P=0.01) (Figure 5.11).   
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Figure 5.11. The effect of estradiol on endothelial cell proliferation and sprouting as released from 
PLA scaffolds. Representative images are shown in (A) showing increased endothelial cell sprouting 
at 5 days of culture compared to controls. (B) Fluorescent microscopy images of immunological 
staining.  Lectin IB4 - endothelial cells stained green, nuclear components stained blue (DAPI).  C) 
Sprout length/radius results taken from 11A, * P=0.01.  (Scale bars represent 50 µm). 
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Implantation of scaffolds on the CAM 
PLA scaffolds with or without Estradiol were cut into 0.65 cm circles with use of an Epilog 
Laser Cutter (Clevedon, UK), placed in 1 mL PBS for pre-wetting and kept under UV light 
for 30 min for sterilization. At EDD 7 pieces of circular scaffolds were placed on the CAM 
and incubated for 8 days. At EDD 14 pictures of scaffolds and surrounding CAM were taken 
with a digital camera. A 20% emulsion was injected just underneath the CAM when 
necessary. For better visualization of blood vessels on histologic sectioning, the LCA was 
injected into one of the vitelline veins before sacrificing the embryo cultures. The embryos 
were sacrificed by cutting their vitelline arteries, scaffolds were resected from the CAM 
surface together with a rim of membrane and samples were fixed.   
On the digital images ‘vasculogenic index’ was calculated.  Estradiol releasing scaffolds (50 
mg/ gram of PLA) resulted in a significant increase in the number of blood vessels growing 
towards them in a spoke- wheel pattern compared to control PLA scaffolds. The mean vessel 
counts were 25.0 (±5.29) and 10.67 (±2.64), respectively (P<0.001) (Figure 5.12).    
Initial tissue response to Estradiol releasing PLA scaffolds 
Retrieved scaffold- CAM complexes were fixed in paraformaldehyde and were placed into 
moulds for cryo-sectioning filled with OCT solution (Leica, Germany). They were left to 
freeze at 80°C and 10 µm sections were cut with the cryostat Leica CM1860UV (Leica 
Germany). Slides were then stained with haematoxylin & eosin solutions (H&E), according to 
the standard protocol for frozen slides. Slides were then covered with DPX (Sigma-Aldrich, 
USA) and a glass coverslip to be imaged with a light microscope (Motic, China) (Figure 
5.13). 
Both estradiol releasing PLA and control PLA scaffolds became infiltrated with host tissues 
(CAM interstitial cells) together with a moderate inflammatory reaction.  The CAM tissue 
adjacent to the estradiol scaffolds demonstrated more blood vessels compared with PLA only 
scaffolds.  Moreover, a greater proportion of blood vessels were observed in between the 
fibres of the estradiol releasing PLA scaffolds as compared to controls (Figure 5.13).   
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Figure 5.12. Angiogenic potential of estradiol releasing PLA scaffolds compared to control PLA 
scaffolds. A normal distribution of blood vessels was observed with the control PLA scaffolds whereas 
with the estradiol releasing scaffolds resulted in a significant increase in the number of blood vessels 
growing towards the scaffold (A). The mean vessel count of estradiol releasing meshes was double 
that of the PLA meshes (B) and the embryo survival rate was the same between the two groups (C).   
(Scale bars represent 3mm). 
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Figure 5.13. Histologic evaluation of tissue- mesh interface. A mild inflammatory reaction together 
with a normal distribution of blood vessels on the CAM adjacent to the PLA mesh (upper raw) can be 
observed compared to a significantly increased number of large blood vessels in response to Estradiol 
releasing PLA mesh (lower raw) at day 14, Haematoxylen &Eosin (H&E) staining (left side). Also on 
higher magnification several small blood vessels could be observed in between the PLA fibers which 
were more abundant in the presence of Estradiol (middle). On the right endothelial cells lining all 
sizes of blood vessels appear stained Rhodamine- conjugated Lens culinaris agglutinin and cell nuclei 
are stained with DAPI.  Scale bars represent 100 µm. 
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5.8. Chapter discussion 
 
In this set of experiments, estradiol was first confirmed as a potent stimulator of collagen 
production and endothelial cell proliferation and sprouting. Next, an estradiol releasing 
electrospun PLA scaffold with desired ultrastructural and mechanical properties was 
constructed. The most striking finding of this section was the ability of estradiol releasing 
scaffolds to stimulate new blood vessel formation around itself in the CAM assay. Finally, the 
initial in vivo tissue response was assessed in the CAM assay.   
Despite the association of pelvic floor disorders with estrogen deficiency and increasing age, 
the exact role of estradiol in the pathophysiology of pelvic floor disorders is not clear. Here, 
estradiol was not used for the purposes of estrogen replacement but to improve the tissue 
integration of the biomaterial by stimulating new ECM production and new blood vessels 
formation. Estradiol is a known stimulator of collagen production. Previously, effective 
concentrations of estradiol to stimulate collagen synthesis were reported to range between 1 
nM- 10 µM [213], [214]. Additionally, inhibitory concentration of estradiol to suppress 
collagen production were found to be above 10 µM [214]. These are all in line with our 
findings demonstrating a significant decrease in collagen production by human dermal 
fibroblasts with supplementation of more than 10 µM of estradiol.  
For evaluation of collagen production by HDFs, donated skin from anonymous donors were 
used. The source of the donated skin to the laboratory was mostly the Plastic surgery unit and 
the vast majority of the donated skin and fat were obtained from breast reduction and 
abdominoplasty surgeries. Therefore, most patients would be expected to be females. Yet the 
gender of the patient is not known to the researchers in this set up. This could potentially be 
important when assessing the effect of estrogens on cellular functions. Males are known to 
express estrogen receptors in their reproductive as well as non- reproductive organs such as 
liver, muscle, kidney [215]. However, the affinity of these receptors could differ in male and 
females which could have increased the variability in the presented results.       
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Estradiol is also known to be an effective stimulator of endothelial cell proliferation and tube 
formation in vitro and in vivo [216], [217]. The effective concentrations of estradiol in 
endothelial cultures were between 1- 10 nM [216], [218]. Angiogenesis is a process where a 
complex interaction between endothelial and non- endothelial cells as well as many enzymes, 
growth factors and adhesion molecules are crucial and for this reason the widely used, 
traditional monolayer cultures of endothelial cells are limited. In this section, the angiogenic 
properties of estradiol were studied in an organ culture assay, the chick aortic ring assay, and 
an in vivo CAM assay both of which allowed the study of the process of angiogenesis with all 
the elements playing a role in it. In this section it has been demonstrated that the effective 
concentration for estradiol to stimulate endothelial cell proliferation, sprouting and tube 
formation was 1- 30 nM. Interestingly, estradiol had obvious negative effects on endothelial 
proliferation and sprouting at concentrations of 100 nM. The chick aortic arch assay was 
found to be a very responsive assay and could effectively be used to screen various 
concentrations of drugs. A limitation of this assay is that the cultured organ is an embryonic 
tissue with a high proliferative capacity. Even in the absence of a pro- angiogenic factor 
endothelial cell sprouting can be observed. Additionally, a common limitation to all of the in 
vitro experiments with estradiol might be the interference with the estrogens that are naturally 
present in the fetal calf serum (FCS). There is approximately 0.05 pM of estradiol in the FCS 
[219]. This value may vary between batches and that could potentially interfere with the 
results.  
In addition to confirming the findings reported in the literature previously, a direct 
comparison of Estradiol with the well- known pro and anti- angiogenic drugs was also 
included in the current studies. Using the CAM assay, the pro- angiogenic (VEGF) and anti- 
angiogenic (Sunitinib) were compared with estradiol. In this experimental set up, a 
biomaterial was not used to allow observation of the drug effect only. Although the positive 
and negative controls worked stunningly well, particularly the negative control, estradiol did 
not work as was expected. This could have been due to its administration via a the twice- 
daily dosage. Therefore, we postulated that a sustained release system for estradiol might 
prove more effective.  
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Among the available drug carriers, a photocrosslinkable transparent hydrogel appeared to be a 
reasonable carrier for this experiment. The estradiol releasing hydrogel was therefore used to 
achieve a continuous release of estradiol. This proved that a sustained release state of the drug 
appeared to produce more obvious results. 
Another dramatic effect of estradiol was on microvasculature. The absence of a hierarchical 
organisation of the vasculature allowed more accurate assessments and easier quantification 
of angiogenesis on the microvasculature. The CAM assay offers an experimental system 
where the microvasculature can be studied. Although the CAM microvasculature would be 
expected to have differences to the microcirculation of mammals, it could be used in initial 
screening. Methods to assess vaginal microcirculation have recently been developed with 
unknown efficacy and uptake by the scientific and clinical community [220]. The role of 
vaginal microvasculature in the pathophysiology of pelvic floor disorders such chronic pelvic 
pain and pelvic organ prolapse is increasingly being studied [196], [221].   Poor vaginal 
microcirculation can be the final common pathway where all factors that are related to 
development of pelvic floor disorders such as aging, birth trauma, smoking, poor 
estrogenization and previous surgeries meet to result in the clinical presentation of these 
conditions. The current findings cannot suggest a relationship between estradiol and vaginal 
microcirculation but only shows a potential effect of the drug on microcirculation.  
After determination of the effective concentrations of estradiol to stimulate collagen 
production and angiogenesis the blend electrospinning technique was used to construct 
estradiol releasing electrospun PLA scaffolds. Estradiol is highly lipid soluable and could 
effectively be dissolved in polymer solution before electrospinning. The drug would be 
blended in the polymer fibres and be expected to be released as the polymer degrades. The 
release of estradiol from electrospun PLA scaffolds continued for nearly 5 months. Estradiol 
releasing biomaterials have previously been described for a variety of clinical applications.  
An estradiol releasing polyurethane- dextran nanofibrous mat was introduced as a wound 
dressing for post- menopausal women. In this study a higher concentration of estradiol (2 
wt%) was incorporated into the scaffolds and in an in vivo wound model estradiol releasing 
mats were shown to accelerate cutaneous wound healing [222].  However, in this study the 
angiogenic effects of the scaffolds were not studied. In another study, estradiol was 
demonstrated to stimulate endothelial cells to produce VEGF when cultured on collagen 
based scaffolds in the presence of estradiol [25]. Here we demonstrate for the first time that 
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estradiol as released from an electrospun scaffold could dramatically stimulate new blood 
vessel formation in and around the material.  Although we have designed this material for use 
in pelvic floor repair, we believe it can have wider applications in all areas of tissue 
engineering as a pro-angiogenic scaffold.    
The most striking property of this Estradiol releasing hydrogel is its ability to stimulate and 
attract new blood vessel formation.  Adequate blood supply to the wound is critical to ensure 
good wound healing. This could be even more important in women when the blood supply to 
the vaginal tissues are already compromised after menopause or as a result of other medical 
conditions such as diabetes, previous pelvic surgeries and radiotherapy.  A severe mesh 
related complication is mesh erosion (extrusion) which is described as ‘vaginal mesh being 
visualized through the separated vaginal epithelium’. This most commonly occurs in the 
midline where the surgical incision is made as if there was a wound dehiscence [1] implying a 
poor wound healing process. With use of the current mesh material, previous studies have 
demonstrated the presence of a maladaptive remodelling response [223] and triggered an 
unfavourable macrophage response [106] however the effect of surgical mesh on vaginal 
wound healing has not been investigated before. Nevertheless, when mesh erosion occurs 
clinically, a common practice among surgeons is to apply topical estrogen creams for the 
initial treatment of smaller mesh erosions. Taken all together, the estradiol releasing PLA 
scaffolds appear to be good candidates to stimulate angiogenesis and wound healing at the site 
of implantation. This needs to be studied further in relevant animal models.   
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The current results will need to be taken into account considering that so far only the 
chorioallantoic membrane of chick embryos were used to study angiogenesis. The CAM assay 
is a well- established method to evaluate angiogenesis in vivo and it allows direct 
visualization of the newly forming vessels in a cheap, quick way that can be readily available 
to most laboratories.  Furthermore, this method can be used as a rapid, simple and low cost 
screening tool to test the initial tissue response to biomaterials, as a pre in vivo method. The 
presented results show that CAM tissues can penetrate the scaffold and blood vessels can 
grow in between the fibres of the electrospun PLA scaffolds which was observed to be more 
prominent in case of estradiol releasing PLA. One limitation of relying on this model to 
characterize the immune response to the implanted material is related to the fact that the 
immune system of the chick embryo develops after day 11 of embryonic life, thus these 
results need to be confirmed on animal models. Therefore, these promising results now need 
to be confirmed in relevant animal models.  
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6.1. Chapter Introduction 
 
Another way of improving the tissue integration of biomaterials designed for use in pelvic 
floor could be to incorporate cell sources that can stimulate tissue regeneration and 
angiogenesis into the biomaterials.  Mesenchymal stem cells (MSCs) have long been  
recognised to play a vital role in normal tissue regeneration/repair.  
MSCs, were first isolated from bone marrow. This was followed by isolation of MSCs from 
almost all adult tissues including adipose tissue, skeletal muscle and central nervous system. 
MSCs are characterized by their ability to self- renew and to differentiate into other 
phenotypes (multipotency) [224].  Although a standard definition for an MSC has been 
established and widely used by the scientific community, there is a lot of discussion around 
the limitations of such a definition. The main limitation about the current definition of an 
MSC is about the multi differentiation capacity of MSCs which currently is only proven for 
bone marrow derived MSCs in vivo [225].  In other words, although MSCs has been shown to 
differentiate into other lineages in vitro, the expectation of replacement of damaged tissues by 
these cells in vivo has not yet been met.  Nevertheless, a therapeutic effect of MSCs has 
consistently been demonstrated in in vivo studies that may not necessarily relate to their 
ability to differentiate into other lineages to replace damaged tissue.  
MSCs achieve their therapeutic effects by producing a wide range of bioactive molecules.  
This is known as paracrine action of MSCs and up to now paracrine actions of MSCs involve 
stimulation of angiogenesis, modulation of immune and inflammatory responses, inhibition of 
apoptosis and trophic effects such as stimulation of mitosis, proliferation and differentiation 
of intrinsic stem/ progenitor cells [226]. Most paracrine actions of MSCs are exerted as part of 
a ‘homing’ process. These cells are known to follow the biochemical cues to migrate to sites 
of tissue damage caused by ischemia, inflammation, trauma or tumour invasion when 
delivered systemically. Just like the well- defined leukocyte adhesion cascade, MSC 
trafficking involves migration within the blood stream (chemotaxis),  cell attachment and 
rolling in vessel lumen and finally transmigration of MSCs across the endothelium and 
invasion into the tissue stroma [227].  
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Chemotaxis is migration of MSCs to the sites of tissue injury following the chemical signals 
pooled at the sites of injury. This process is facilitated by the chemokine receptors classified 
as G- protein coupled receptors for CXC, CC, C and CX3C chemokines [228]. MSCs are 
demonstrated to express CCR1- 10, CXCR1- 2, CXCR4- 6 and CX3CR1 receptors with a 
high variability depending on the tissue of isolation, passage number of cells analysed and 
different isolation/ cultivation protocols [229]. A well- studied chemokine- receptor 
interaction both in vivo and in vitro is CXCL12 (or stromal cell derived factor [SDF]-1)- 
CXCR4 [230], [231]. It was shown in vitro that MSCs express increase their expression of 
CXCR4 upon stimulation by cocktails containing IGF- 1 [232] and TNF- α [233], [234]. After 
attachment of MSCs to the vascular endothelium migration occurs following several 
coordinated steps involving rolling along the endothelium by selectins and their ligands, firm 
adhesion after activation of integrins by chemokines, diapedesis across the endothelial tight 
junctions and basement membrane and finally invasion through extracellular matrix.  
6.1.1. Paracrine effects of mesenchymal stem cells 
Most effects of MSCs are attributed their rich secretome, known as paracrine action, and  
involves modulation of immune and inflammatory responses, inhibition of apoptosis and 
trophic effects such as stimulation of mitosis, proliferation and differentiation of intrinsic 
stem/ progenitor cells and stimulation of angiogenesis [226].   
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Immunomodulation 
MSCs can adopt pro-inflammatory or anti- inflammatory phenotypes within their 
microenvironments. MSCs acquire an immune-suppressive phenotype in the presence of high 
levels of TNF- alpha and IFN- gamma levels in the microenvironment. On the other hand, low 
levels of these cytokines induce a pro-inflammatory phenotype [235]. The cell surface 
receptors on MSCs, the Toll like receptors (TLR), are thought to contribute to differentiation 
into either of these phenotypes via stimulation of either TLR- 3 and TLR- 4 receptors to 
derive an anti- inflammatory (MSC 2) or pro- inflammatory (MSC 1) phenotype, respectively 
[236]. In analogy to macrophage polarization, this process of MSCs is called the MSC 
polarization to which interactions with other cells of the innate immune system such as 
monocytes are also reported to contribute. Conclusively, MSCs play a regulatory role in 
several phases of immune response through diverse mechanisms of actions and on various cell 
types.  
Angiogenesis 
Angiogenesis involves a complex interaction between endothelial and non- endothelial cells 
as well as many enzymes, chemokines, growth factors, matrix metalloproteinase and adhesion 
molecules.  A defective angiogenesis is implicated in many disease states such as ischemic 
heart disease, peripheral vascular disease and all defective wound healing processes. MSCs 
have demonstrated to secrete a wide variety of pro- angiogenic factors such as vascular 
endothelial growth factor, fibroblast growth factor 2, interleukin- 6 that are shown to act in 
each step of the angiogenesis (endothelial cell proliferation, migration and tube formation 
[237].  The secretion of pro- angiogenic factors by MSCs has been shown to be increased 
significantly by exposing the cultured MSCs to hypoxia (hypoxic pre conditioning) [238] 
resulting in better regenerative capability in vivo [239]. 
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Tissue growth and regeneration 
Another important property of MSCs is to secrete growth factors and other chemokines to 
induce cell proliferation and tissue regeneration in many organ systems including peripheral 
nerves. Some of the important growth factors that have been shown to be included in the 
secretome of the MSCs are NGF (nerve growth factor), BDNF (brain-derived neurotrophic 
factor) and GDNF (glial cell line-derived neurotrophic factor) [240], [241].   MSCs also 
modify the microenvironment in a pro- proliferative way, by secreting anti- apoptotic proteins 
and by direct cell- to- cell communications.  On MSC co- culture experiments, MSCs 
improved survival of ischaemic cardiac cells via direct cell- cell connections and intercellular 
nanotube formation [242]. The secretome of MSCs also contain anti- apoptotic factors [243], 
[244] as MSC- conditioned medium without any cells have shown to decrease Caspase-3 
activity in the myocardium and improved functional outcomes in pig models [245].  
Therefore, MSCs can provide beneficial effects on tissue regeneration and integration of the 
tissue engineered products by secreting factors that promote tissue regeneration and new 
blood vessel formation.    In this section, the effect of stem cells on new blood vessel 
formation was first investigated. Than the added effect of combining a drug releasing scaffold 
with stem cell implantation is investigated.   
 
6.2. Effect of adipose derived stem cells on angiogenesis 
 
In these experiment a hydrogel was used as a stem cell carrier to be able demonstrate a 
measurable paracrine effect of MSCs both in aortic ring assay and the CAM assay a high 
number of cells would need to be concentrated in a small surface area which required a three 
dimentional structure. For example, when testing the effects of stem cells on endothelial cell 
sprouting in the chick aortic ring assay a 24 well plate was used which was necessary to 
ensure minimal dilution of the growth factors that naturally existed in the piece of the cultured 
organ. The culture insert that could go with a 24 well plate to achieve a co- culture system 
could only accommodate   100.000 cells at confluency which did not allow demonstration of a 
measurable difference in endothelial cell sprouting using this set up.  
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The feasibility of implantation of cells directly on the CAM was also investigated in the 
preliminary experiments. Similar to the experimental set up used to test the effect of estradiol 
on CAM a plastic ring was placed on the CAM at EDD 7 into which a suspension of 100k 
cells were seeded. Human dermal fibroblasts were first used as cellular controls and 
melanoma (C8161) cells were planned to constitute positive controls for ADSCs. When the 
cells were directly seeded on a circumscribed area on the CAM, the maximum measurable 
angiogenic response was not considered to be ideal. This could have been due to invasion of 
the CAM stroma by the tumour cells and failure of these cells to get concentrated on a single 
spot or the number of cells would not have been enough to allow a visible change in 
angiogenesis. Therefore, a hydrogel system was used as a carrier of more cells.  The 
preliminary experiments demonstrated that up to 1000k cells could be encapsulated into the 
hydrogels resulting in more dramatic increase in angiogenesis (Figure 6.1). However, the 
blood vessels in tumour induced angiogenesis appeared tortuous and disordered. Therefore, 
although the the hydrogel system worked well to concentrate enough number of cells on a 
singke area on CAM, the tumour cells were abandoned as a positive control as they induced a 
pathological neovascularization.  
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Figure 6.1. Preliminary experiments to establish control groups for testing angiogenic potential of 
adipose derived stem cells (ADSCs). Here human dermal fibroblasts (HDFs) were used as 
cellular controls whereas melanoma (C8161) cell line was included as a possible positive control. 
Both cell types were first implanted directly on CAM (upper raw) which did not result in an 
obvious change in vascularization at the site of implantation. After HDfs and C8161 cells were 
encapsulated in a hydrogel (lower raw) tumour cells resulted in an increase in vascularization 
however this time the blood vessels were tortuous as would be expected with tumour cells.    
 
 
 196 
 
Construction of the hydrogel cell carrier 
A bicomponent hydrogel was constructed using methacrylated gelatin and methacrylated  
hyaluronic acid by UV- crosslinking. This hydrogel was designed and synthesized in 
BIOMATEN Center of Excellence in Biomaterials and Tissue Engineering, Middle East 
Technical University, Ankara, Turkey by Dr. Gozde Eke and Prof Vasif Hasirci. Previously 
synthesized and characterized powders of lyophilized gelatin and hyaluronic acid were 
received in Kroto Research Institute which were than weighed, dissolved and crosslinked in 
house. The main characteristics of the hydrogel has been published previously [140] and 
summarized in Figure 6.2.  
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Figure 6.2. Graphical demonstration of synthesis, assembly and basic in vivo evaluation of the 
hydrogel used to encapsulate adipose derived stem cells (ADSC) in these experiments.  Synthesis 
of components of the hydrogel by methacrylate groups (upper raw). Assembly of hydrogel can be 
easily performed by crosslinking a solution of methacrylated gelatin (GelMA) and methacrylated 
hyaluronic acid (HA-MA) using UV irradiation (middle raw). In vivo testing of biocompatability 
of the hydrogel by demonstrating growth and DNA synthesis over 21 days in the hydrogel (lower 
raw). More detailed information in reference [140].  
 
Briefly, gelatin and hyaluronic acid were methacrylated by dropwise addition of methacrylic 
anhydride with degree of methacrylations of  63% and 25%, respectively, as detected with 
NMR analysis. Methacrylated polymers were dialyzed against distilled water and than 
lyophilized. The lyophilized polymers were weighed and dissolved in media at a ratio of 15:1 
(w:w) together with a Photoinitiator (Irgacure 2959, 0.3% w/v). The solution was than placed 
into molds and  exposed to 365 nm UV (Omnicure s1000) for 40 seconds resulting in a solid 
mass. The final hydrogel had a highly porous structure with an average pore size of 120±76 
µm and 79% porosity. Once in media, the hydrogels further absorbed water to reach to 200% 
of their original weight equilibrating at 48 hours.  The proliferation of adipose derived stem 
cells in the hydrogels were assessed by quantification of DNA with Picogreen staining. 
ADSCs in the hydrogels proliferated at a rate similar to that in their growth on tissue culture 
plastic increasing throughout the 21 days of incubation as quantified by the measurement of 
increase in the amount of DNA. ADSCs appeared mostly encapsulated in the hydrogel in the 
first 3 days. On Day 14 of in vitro culture, ADSCs appeared more elongated and spreading.   
In summary, this hydrogel was used as a cell carrier to test the effects of ADSCs on 
angiogenesis and was not considered as a candidate material for use in pelvic floor 
repair.  
Chick aortic ring assay 
The effect of three different concentrations of ADSCs encapsulated in the hydrogel (250k, 
500k and 1000k) was assessed in the chick aortic ring assay by co- culturing the hydrogels 
together with the aortic rings via a transparent tissue culture insert. The results were evaluated 
at day 5 of culture and results were expressed as mean sprout length for each group. The 
endothelial cell sprouts were significantly longer with increasing concentrations of ADSCs. 
The mean sprout length for control, 250k, 500k and 1000k ADSC encapsulated groups were 
84 (±6.1), 11.2 (±19.3), 203 (±25.3) and 397 (±96.2), respectively (Figure 6.3). Additionally 
the endothelial cell sprouts were characterized by staining positively with the endothelial cell 
marker Isolectin B4.   
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Figure 6.3. Assessment of endothelial cell proliferation and sprouting in response to different number 
of ADSCs loaded hydrogels. Hydrogels were  co-cultured with chick aortic rings for 5 days. 
Characterization of endothelial cell sprouts (arrows) by lectin IB4 (green) and cell nuclei with with 
DAPI (blue) (A). The change in the length of endothelial sprouts with the seeding density of ADSCs 
(B) and representative images (C). (scale bars 250 µm). 
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CAM assay  
One million ADSCs were put into the hydrogel solution containing methacrylated gelatin and  
hyaluronic acid and photoinitiator that was warmed up to 37°C beforehand. After gentle 
pipetting, 100 µl of this solution was pipetted on to Petri dishes and immediately exposed to 
UV light for 40 seconds. The ADSC containing hydrogels were implanted on to the CAM at 
EDD 7. Hyrogels without any cells and hydrogel containing 100 ng of VEGF was used as 
controls (Figure 6.4).  Three parametres were calculated on digital images using the Image J 
software and the Neuron J plugin: the total vessel count, the total vessel length and the 
vasculogenic index (Table 6.1). 
 
Figure 6.4. Evaluation of the angiogenic properties of ADSCs encapsulated into the hydrogel in the 
chick chorioallantoic membrane (CAM) assay. Micrographs (upper row) and semi-automatic 
processed images (lower row) of the hydrogel, hydrogel containing ADSCs and hydrogel 
containing VEGF (positive control), taken on day 14 of embryonic development.  
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Table 6. 3. The summary of CAM assay findings comparing hydrogels with and without 
adipose derived stem cells (ADSCs).  (*p<0.05 compared to control hydrogels; +p<0.05 
compared to VEGF hydrogels) 
 Control hydrogels ADSC hydrogels VEGF hydrogels 
Total vessel count 
(mean± SD) 
59.2 (±15.1) 93.2 (±12.7)* 117.6 (±14.3)* 
Total vessel length 
(mean±SD) 
97.6 (±16.3) 136.0 (±16.7)*, + 168.6 (±11.5)* 
Vasculogenic index 14.6 (±1.8) 21.0 (±2.7)*,+ 27.0 (±3.8)* 
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Histology 
On EDD 14 the hydrogel- CAM complex were gently resected and fixed in formaldehyde. 
The first observation was that unlike fibrous scaffolds the hydrogels could easily be detached 
from the CAM. The H&E staining confirmed this showing almost no tissue integration into 
the hydrogels.  Additionally the hydrogels did not induce any inflammatory reaction on the 
underlying CAM tissue (Figure 6.5.). This made it easier to count the blood vessels on the 
adjacent  CAM.    The angiogenic response to the hydrogels were quantified by measuring the 
area stained positive for α-SMA on fluorescent images. Therefore, histologic examination of 
CAM-hydrogel complex have confirmed a significantly increased area of α-SMA positive 
blood vessels in CAM tissue under and adjacent to the VEGF loaded hydrogel compared to 
the hydrogel alone whereas ADSC loaded hydrogel was associated with a moderate increase 
in the number of blood vessels. Also there was almost no cellular/ inflammatory cell 
infiltration in the CAM underneath the hydrogel.   
In conclusion ADSCs on their own appeared to stimulate angiogenesis through their 
paracrine effects. Compared to VEGF, ADSCs have mild to moderate pro- angiogenic 
properties.     
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Figure 6.5. Histological evaluation of angiogenic properties of ADSCs encapsulated in hydrogels. 
A) Normal appearance of CAM structure on Haematoxylin &Eosin (H&E) staining and 
fluorescence staining of CAM vessels with alpha-smooth muscle actin (α-SMA) and 4′,6-
diamidino-2-phenylindole dihydrochloride (DAPI). B) Area coverred by blood vessels (stained 
positive for  α-SMA) (**: p<0.01; ***: p<0.005). C) Representative images from each group 
demonstrating more blood vessels in the area adjacent to the hydrogels. Additionally hydrogels 
caused a mild inflammatory response on the CAM. (Scale bars: 100 µm). 
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6.3. Combining electrospun scaffolds with ADSCs to improve tissue integration 
 
In this section a polyurethane scaffolds used to follow on the work within the group 
suggesting PU material could have beneficial mechanical properties with improved elasticity.  
All the work presented in this section was a part of the masters thesis of Miss Sarah Shafaat 
which has been published [72]. The PhD scholar has direct contribution to all satges of the 
experiments at all levels including planning, conducting and results evaluation.  
Briefly, polyurethane (PU) Z3 (Biomer technologies, Cheshire, UK) was dissolved  (8% w/v) 
in a mixture of 70% v/v N,N-Dimethylformamaide and 30% v/v tetrahydrofuran. Into the 
polymer solution 50 mg of Estradiol was added and electrospun. Eight milliliters of 10% PLA 
was first electrospun as a sacrificial layer. Electrosinning parameters were rotation at a rate 
for collector of 265 rpm, 20 cm of distance from the tip of the needle to the collector, feed rate 
of 40 µl/min and an accelerating voltage of 17.4 kV. Estradiol was released from these 
scaffolds gradually after an initial burst release of 30-40% in the first 10 days as measured by 
UV-spectrophotometer at a wavelength of 272nm. Incorporation of estradiol into the PU 
scaffolds did not effect scaffold ultrastructure but increased total collagen production by 
ADSCs compared to PU only scaffolds. 
Evaluation of mechanical properties of PU scaffolds 
The main advantage of PU materials is related to their inherent elasticity. The mechanical 
properties of electrospun PU scaffolds were evalauted by both uniaxial and cyclic mechanical 
testing. The cyclic mechanical testing is performed to demonsrate a deformation of the 
material by repeated loading and unloading (Figure 6.6).  
 205 
 
 
Figure 6.6. Graphical explanation of using a cyclic mechanical testing to demonstrate material 
deformation. (A) The BOSE tensiometer for uniaxial testing. (B) The stress- strain curve produced by 
uniaxial tensile testing. The change in the appearance of the sample during the test is shown in the 
inset. (C) Demonstration of deformation of the material in cyclic mechanical testing applying a 25% 
displacement (strain) to the material. The deformation of the material can be measured by the lack of 
stress starting from the second cycle. 
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In uniaxial testing, incorporation of estradiol significantly increased the ultimate tensile 
strength (UTS) (N/mm2) and Young’ s modulus (YM) (N/mm2) of PU scaffolds compared to 
controls, UTS and YM were 5.79± 0.336 and 3.26±0.46 (p<0.005) and  11.5±1.6 and 9.8±0.7 
(p<0.005), respectively (Figure 6.7).  These values were  30-40% higher than the reference 
range for the healthy native fascia (YM 6.4-10.1 N/mm2). In the cyclic mechanical testing, all 
PU scaffolds underwent deformation from cycle 1 to cycle 2, with reduced YM values for 
estradiol releasing PU scaffolds from  20.2±2.4 in the first cycle to  14.7±1.4 in the second 
cycle (Figure 6.8).   
 
Figure 6.7. Mechanical testing of PU only and Estradiol releasing PU scaffolds on uniaxial 
mechanical testing. 
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Figure 6.8. Cyclic mechanical testing on PU only and estradiol releasing PU scaffolds to 
demonstrate material deformation (*: p<0.05). 
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In another study conducted within the group in collaboration with Dr. Sabiniano Roman, the 
deformation of various mesh materials under cyclic mechanical testing was compared to two 
other electrospun materials. This has shown that all materials underwent plastic deformation 
after cyclic loading mainly between cycle 1 and cycle 2. However it appeared that the 
commercial meshes demonstrated significantly higher deformation compared to electrospun 
meshes after 10 cycles. The percentage deformation for commercial meshes were 6.69% 
(±0.75), 8.51% (±0.47), 4.77% (±1.08) and 3.60% (±0.52), respectively for Gynemesh®, 
Restorelle®, DynaMesh-ENDOLAP® and DynaMesh-PR4®. In contrast the percentage 
deformation for electropun meshes (UPy-PC and PU) were 1.92% (±1.19) and 0.58% (±0.32) 
(Figure 6.9).    
 
 
Figure 6.9. Comparison of electrospun polyurethane (PU) scaffold with available meshes currently 
used in the treatment of SUI and POP.  (This experiment performed by Dr. Sabiniano Roman) 
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Evaluation of scaffold and stem cell constructs for their effects on angiogenesis 
PU scaffolds with and/ or without estradiol were cut into 1x1 cm squares and were UV 
sterilized. ADSCs between passages 3 and 8 were seeded on the estradiol releasing PU and 
control scaffolds at a density of 250k and incubated at 37 °C and 5% CO2 until they were 
implanted onto the CAM next day. HDFs were used as a cellular control in these experiments. 
The scaffolds were then implanted on the surface of CAM by placing the cell seeded surface 
in direct contact with CAM tissue. 
Estradiol releasing PU scaffolds were significantly more angiogenic compared to controls, 
vasculogenic index 33.5 (±7.2) and 15.8 (±3.5), respectively (p<0.05). When ADSCs were 
seeded on the estradiol releasing and control scaffolds the vasculogenic index went up to 55.2 
(±7.2) and 43 (±3.6), respectively. Therefore ADSCs increased the vasculogenic potential of 
PU scaffolds compared to PU only scaffolds (Figure 6.10).     
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Figure 6.10. The effect of incorporating ADSCs into the tissue engineered constructs on the 
angiogenic potential of estradiol releasing PU and control scaffolds. (scale bars represent 200 µm; 
*p<0.05 compared to PU only scaffolds). (This experiment was performed by Miss Sarah Shafaat) 
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Evaluation of tissue integration of scaffold- ADSC constructs 
Histologic examination of the ADSC seeded PU scaffolds resulted in good tissue integration 
into the CAM tissues after 8 days of implantation. There was no significant difference 
between estradiol releasing and PU only scaffolds (Figure 6.11). A mild inflammatory 
response in the CAM tissue adjacent to tissue engineered constructs could be seen in all 
samples.  
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Figure 6.11. The effect of incorporating ADSCs on tissue integration of estradiol releasing 
and control scaffolds. Haematoxylin and Eosin (H&E) staining of CAM- scaffold complexes 
after 8 days of incubation.  Scale bar represents 100µm and applies to all images 
(PU=Polyurethane) (*CAM tissue, ** implant/scaffold). (This experiment was performed by 
Miss Sarah Shafaat) 
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6.4. Chapter discussion 
 
Mesenchymal stem cell (MSC) therapy   has emerged in the last 10 years as an important 
cellular source to stimulate tissue regenration and promote angiogenesis with several cell 
based therapeutic applications being tested in clinical trials [246]. In this section, the added 
effects of incorporating stem cells inthe tissue engineered constructs designed for pelvic flor 
repair is evaluated. The data presented shows that stem cells alone have a mild to moderate 
effects on stimulating new blood vessel formation in the CAM assay and combination of 
electrospun matrices with stem cells can have an added effect when stimulating angiogenesis. 
Nevertheless the involvement of cellular components in the tissue engineered constructs 
would mean more complicated routes when translating into clinic compared to biomaterials 
without cells.  
From a regulatory perspective, regenerative medicine refers to methods to replace or 
regenarate human cells, tissues or organs to restore or establish normal function. This includes 
cell therapies, tissue engineering, gene therapy and biomedical engineering techniques as well 
as more traditional treatments involving pharmaceuticals, biologics and devices. On the other 
an advances medicinal therapy product (ATMP) is a medicinal product which is either a gene 
therapy medicinal product, a somatic cell therapy medicinal product or a tissue engineered 
product [247].   Among these gene therapy medicinal products and somatic cell therapy 
medicinal products have legal definitions, a tissue engineered product rather more difficult to 
define due to the extent and complexity it encompassess. For medicinal products that do not 
contain viable cells the mode of action is primarily by physical means. However if they 
contain viable cells or tissues, regardless of the role that the material component play,  the 
primary mode of action of the combined product should be considered to be a function of the 
pharmacological, immunological or metabolic effects of the cells. Hence the regulatory 
evaluation of ATMPs often require very specific expertise covering the areas of 
biotechnology and medical devices. 
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Under the new EU directive, a tissue engineered product is defined as “a product that contains 
or consists of engineered cells or tissues and is presented as having properties for, or is used  
in or adminisered to human beings with a view to regenerating, repairing or replacing a 
human tissue” [247]. An ‘engineered cell’ is defined as “a cell that fulfil at least one of hte 
following: i) the cells or tissues have been subject to substantial manipulation  so that 
biological characteristics, physiological functions or structural properties relevant for the 
intended regeneration, repair or replacement are achieved” [247]. Article 2(1)(c) of the 
directive defines specific procedures that are not considered as substantial manipulations. 
These are: cutting, grinding, shaping, centrifugation, soaking in antibiotic or antimicrobial 
solutions, sterilization, irradiation, cell separtion, concentration or purification, filtering, 
lyophilization, freezing, cryopreservation, vitrification ; ii) the cells or tissues are not intended 
to be used for the same essential function or functions in the recipient as in the donor. 
Therefore adipose tissue derived cells, even if not substantially manipulated, will be 
considered an ATMP when used to serve functions other than being adipose tissue. This 
means that the necessary regulatory approval before translation of these products would be 
difficult.        
The main challanges that lie ahead of the clinical translation of MSCs for many applications 
are related to lack of a more specific definition of an MSC, the uncertainties about the 
mechanisms of actions, reproducable manufacturing of adequate amounts of MSCs, 
distribution and costs.  The widely accepted minimal criteria to define a mesenchymal stem 
cell [224], although useful to have one, covers a hugely diverse cell population that could 
result in high variability among result findings. Also,  the in vivo fade of MSCs at the site of 
tissue injury is not clear. It has been shown that after intravenous injection most of the MSCs 
are trapped in the lungs initially, however they eventually home to sites of tissue injury and 
finally 0.1% to 2.7%  of MSCs can be found engrafted to the sites of injury after 2 weeks 
[248]. Furthermore, in most pre- clinical research the MSCs are used without pre- labelling 
and the fate was not tracked. Instead it has been a common practice to report efficacy of stem 
cells based on functional outcomes. This has also been referred to as ‘the beneficial effects 
given as a reason to move fast from insufficient science to translation or therapy are not 
clearly defined’ [225].     
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In addition, the efficacy and bioavailability of stem cells as a function of the method of 
delivery is highly variable and not comparatively studied. For example, most pre- clinical and 
clinical research on using MSCs for treatment of erectile dysfunction applied stem cells  by 
intracavernousal injections where the main tissue damage was actually in the cavernous nerve 
in the pelvis [246], [249]. This assumes an effective homing of MSCs to the sites of tissue 
injury however this has not been assessed in many studies. The bioavailability and efficacy of 
any therapeutic agent is affected by its method of delivery.  A direct comparison of 
intravenous, intracoronary and endocardial injections of MSCs in a swine model of acute MI 
demonstrated a better engraftment of MSCs in  intracoronary and endocardial injections 
compared to IV delivery [250].  In the context of pelvic floor repair materials, the MSCs is 
envisaged to be seeded on scaffolds before implantation. Hence they will be implanted at the 
site of the intended tissue repair  however the fate of the MSCs in this scenario still needs to 
be studied. 
Some of the above challanges can be overcome by innovative methods of cell labelling and 
together with use of non- invasive imaging technologies. The detection of MSCs in fixed 
tissue samples requires scarification of groups of animals at several time points and harvesting 
organs for histologic sectioning. These disadvantages led to development of dynamic imaging 
modalities. The non- invasive dynamic imaging studies include MR imaging of magnetic 
particle labelled cells [251]–[253], single photon emission computed tomography (SPECT) 
imaging of radioisotope (111In oxine, 99mTc) MSCs [254] and quantum dot labelling [255]. 
Each of these non- invasive imaging modalities have their own advantages and limitations 
however they are very likely to become an integral part of stem cell based therapies and 
further improvements in this area needed.        
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Another issue that is addressed within this section is related to the cyclic mechanical 
properties of the biomaterials designed for pelvic floor reconstruction. Looking back critically 
on the currently used mesh materials, mainly PPL, it appears that many authors agree on the 
biological and mechanical incompatability of the PPL mesh to the pelvic floor. Briefly, it is 
known that the host response to PPL mesh is more representative of a chronic inflammation 
resulting in poor tissue integration and significant fibrosis around the implant [256]–[258], 
especially in cases of vaginal implantation rather than abdominal [101]. This unfavourable 
biological response to PPL mesh, is much less studied compared to its mechanical failure. It 
has been commonly suggested that the mesh is too strong and too stiff for applications in the 
female pelvic floor. Theoretically, this can lead to a phenomenon called ‘stress shielding’ 
which is more commonly used for orthopaedic implants. Stress shielding is when a strong 
material carries all the load and depriving the adjacent issues of mechanical stimuli that 
eventually results in defective extracellular matrix production in the tissues adjacent to the 
implant. The same phenomenon can explain the poor tissue healing and erosion associated 
with vaginal mesh implant surgeries.  
Furthermore, PPL mesh is probably not only too strong but also it can mechanically fail when 
exposed to cyclic distension at the site of implantation. The cyclic loading experienced by the 
materials are known to lead to plastic deformation of the material a little at a time when they 
are exposed to loads above their yield point. This can contribute to material failure and/ or 
change in its mechanical properties overtime [74]. The available evidence on the effects of 
cyclic loading on mechanical properties of the PPL mesh is not well studied. Cyclic uniaxial 
loading studies are conducted to study the deformation of the material under repetitive sub- 
failure loads [259]. Previous studies have shown the results when such tests were run for up to 
10 cycles [259], [260] and despite showing ‘deformation’, they were not planned to 
demonstrate ‘failure’. Fatigue testing of materials for longer durations of cyclic mechanical 
loading under simulated physiological conditions can show material failure. These tests have 
been commonly performed for biomedical implants such as heart valves and stents however 
they were never considered for evaluation vaginal meshes.  
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Mechanical testing studies within the pelvic floor research group in the Kroto Research 
Institute, have led to describing a simple protocol that could be used as a fatigue testing to 
demonstrate the mechanical failure of the materials starting from early stages of development 
[261].   This is important because although previous studies have used ‘dynamic mechanical 
assessment’ techniques to test surgical meshes [262], such tests require sophisticated 
equipment and expertise making it difficult to adopt for many research groups.  Nevertheless, 
the failure of Ultrapro mesh after 16,000 cycles has been reported together with permanent 
change in yarn structure [263]. In conclusion, using the simple fatigue testing under 
physiologic conditions electrospun polyurethane (PU) is shown to survive 80% strain equally 
well before and after the fatigue testing, while the commercial meshes failed the uniaxial 
tensile test after fatigue testing.  
A limitation of using such a fatigue testing protocol to detect material failure early during 
development is related to the current inability to estimate the cyclic loading conditions that 
the material will undergo at the site of implantation. This is mainly due to lack of 
understanding of the biomechanics of the female pelvic floor. Not only the anatomy is 
complex and the biomechanics are poorly understood, but also the consequences of other risk 
factors such as carrying full term pregnancies, vaginal deliveries and the loss of oestrogens at 
the menopause are not known.  
A comparison of fatigue behaviour of available candidate materials within the group 
demonstrated that electrospun PLA scaffolds underwent significant deformation after 7 days 
of dynamic distention in 7 days while electrospun PU Z1 and Z3 scaffolds remained elastic 
[113].  Hence the PU scaffolds has been studied as another good candidate to functionalized 
by incorporation of Estradiol and MSCs in the current section. The results demonstrated that 
Estradiol could effectively be blended into PU scaffolds and achieve a sustained release 
without having a negative effect on scaffold ultrastructure and mechanical properties. PU 
scaffolds survived the fatigue test better compared to commercial meshes and they stimulated 
new blood vessel formation with good tissue integration.   Therefore, Estradiol releasing PU 
scaffolds could be used effectively to stimulate new blood vessel formation and improve 
tissue integration for applications where non- degradable materials are desired.     
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Chapter 7.                                         
Summary and Future Work 
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7.1.Summary 
 
In summary this thesis explored the feasibility of functionalization of biomaterials by 
addition of drugs and cells with the ultimate aim of improving the biocompatability of the 
biomaterials by acheiving  increased angiogenesis and tissue integration. 
Firstly, an in vivo methodology to study the angiogenic potential of and the initial tissue 
response to constructed biomaterials was developed. The ex ovo CAM assay proved to be a 
feasible and effective  bioassay to assess the angiogenic potential of biomaterials with a 
unique advantage of allowing visualization of the developing blood vessels at all times during 
the experiment. The main limitations of this method was the inability to run the experiments 
beyond 14 days under in- house Home Office regulations and the lack of a developed 
immune system in the chick embryo in the early stages of embryonic development.  The 
latter mainly limited the assessment of the initial tissue response to the constructed 
materials.  This methodology was used as the main assay for assessing angiogenesis and 
early stage biocompatibility  throughout the thesis.  
Electrospinning was selected for the material production method and polylactic acid (PLA) 
was the main polymer used with its excellent biocompatiblity, drug releasing properties and 
degradability. The accumulated knowledge within the group was helpful in assessing  two 
candidate drugs to be incorporated into the constructed scaffolds to stimulate new blood 
vessel formation and tissue integration: Vitamin C and Estradiol. Both Vitamin C and 
Estradiol could effectively be incorporated into the electrospun PLA  scaffolds without 
causing significant disruptions to the ultrastructural and mechanical properties of the 
scaffolds. Vitamin C was released  from the scaffolds over several weeks whereas Estradiol 
was released  over months.  
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Both drugs increased extracellular matrix production of cells cultured on the scaffolds.  
Although both Vitamin C and Estradiol increased the angiogenic potential of the PLA 
scaffolds, Estradiol resulted in a more dramatic increase in new blood vessel formation.  
Stimulation of both ECM production and new blood vessel formation by drug releasing PLA 
scaffolds could prositively affect tissue integration of these materials. This was assessed by 
implantation on the CAM for seven days which demonstrated a good tissue integration for 
all electrospun PLA scaffolds with no significant differences between drug releasing and plain 
scaffolds. The contribution of Vitamin C or Estradiol released from electrospun PLA scaffolds 
now needs be assessed in longer term in vivo assays.     
The last stage of functionalization of the scaffolds that was assessed in the current studies 
whether the ability of the drug releasing scaffolds to stimulate angiogenesis and  better 
tissue integration would be improved with addition of mesenchymal stem cells (MSCs). 
Firstly, MSCs alone were demonstrated to have a mild pro- angiogenic effect on the CAM 
assay. MSCs in this case were initially implanted on the CAM using a hydrogel as a cell carrier 
system. Secondly, Estradiol releasing electrospun scaffolds pre-seeded with MSCs were 
shown to have an added effect on new blood vessel formation compared to plain Estradiol 
releasing electrospun scaffolds. However, the size of this additional effect was small. 
Additionally, pre- seeded scaffolds appeared to have a similar ability to integrate into tissues 
in short term implantation over seven days. Therefore, from a clinical translational point of 
view the use of pre- seeded biomaterials would need to be balanced with the complexities 
and expense of manufacturing an advanced therapy medicinal product. At the time of 
writing the additional angiogenic benefit of adding cells to the drug releasing scaffolds does 
not seem justified. 
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7.2.Future Work 
 
The first line of future work would involve confirmation of the pro- angiogenic and tissue 
integration properties of Estradiol releasing electrospun PLA scaffolds in small animal 
models. After the confirmatory study, the materials will need to be implanted in large 
animals for efficacy testing. Two large animal species have been used in the literature. The 
most widely used animal for vaginal implantation of a candidate mesh material is the sheep. 
The sheep stands out as it has a vagina that is very similar in size to the human female 
vagina. Other animals such as rabbit  have also been used a recipients of vaginal soft tissue 
implants before [264] however due to the smaller size of the vagina these could only accept 
implantation of a small piece of mesh material. This did  not demonstrate  vaginal mesh 
erosion in most studies [265] although some authors reported observation of mesh erosion 
with rabbit vaginal implants in the longer term [266]. It is important to use a model that can 
re- create mesh erosion as it is a significant mesh- related adverse effect. Vaginal 
implantation of mesh material into sheep vagina was demonstrated to lead to development 
of mesh erosion in 30% of sheep which received a vaginal mesh implant [101]. Additionally 
sheep are known to develop pelvic organ prolapse spontaneously after repeated 
pregnancies/ births like humans.  
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Another animal that has been used in vaginal implant testing is the rhesus macaque. These 
studies are mostly performed in the United States. The obvious advantage of the rhesus 
macaque is that they are standing upright similar to humans. Also rhesus macaque develop 
spontaneous pelvic organ prolapse, they have pelvic floor anatomy similar to women with 
hormone sensitive ligaments in paravaginal attachments. Additionally the fibroblast 
activities in the connective tissues of the pelvic floor of these animals was responsive to 
hormonal treatment in a way similar to that of humans [267]. However the implantation of 
three commercial meshes in rhesus macaque  resulted in erosion in only in 1 out of  32 
animals [256], regardless of the mesh weight and textile structure. However in this study the 
meshes were implantated abdominally after hysterectomy and this does not represent  
vaginal implantation. Another study reported vaginal implantation without using a vaginal 
mucosal incision [257] precluding the applicability of this data to represent vaginal mesh 
implantation surgeries. Hence, the available evidence supports the use of sheep for testing 
of candidate vaginal implant materials. After safety and efficacy testing in relevant animals 
the candidate material can go on to first pilot clinical trial. 
Another important point to consider during translation of these products into the clinic is 
about the changing regulatory approval processes for biomedical devices. It is increasingly 
being acknowledged that the available medical device regulations allowed the ‘faulty’ 
medical devices onto the market failing to ensure public and patient safety [257]. The 
scientific and surgical communities have also raised concerns on the ‘commercially privileged 
relationship’ between manufacturers and regulatory authorities [268].  A part of the 
problem is probably related to the inability of the old regulations to keep up with the pace of 
rapid technological and scientific developments in biomedical sciences and technologies in 
the last few decades. Although this new field of biomedical engineering offers new 
opportunities for treatment of disease and replacement of organs/ tissues in human body, 
the necessary novel legal definitions, new rules on governing their production and 
distribution and new processes for regulatory approval to safeguard public health appear to 
be missing.  
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Recently, two new EU regulations on medical devices entered into force [269] with the aim 
of establishing a robust, transparent, predictable and sustainable regulatory framework for 
medical devices which ensures public safety while supporting innovation. For this purpose 
the new EU regulations introduced new definitions such as ‘active device’, ‘implantable 
device’ and ‘single use device’ in addition to the medical device definition. Separate 
regulations for placing products on the market, traceability of supply chains and registration 
of devices and post- market surveillance are implicated.  Therefore, future work needs to 
consider these regulations. 
Another useful tool to guide safe and effective introduction of new surgical innovations is 
the IDEAL (Idea, Development, Exploration, Assessment and Long Term follow-up) 
guidelines, that define clear guidance on the types of studies and specific data requirements 
for each stage of approval and surveillance [270]. This involves stages of 0 to 4, where stage 
0 involves pre- clinical development with materials and components testing following real- 
world situations. Stage 1 is the first in human trial with a few studies followed by safety and 
efficacy studies (Stage 2) and then randomized controlled trials to study comparative 
effectiveness involving hundreds of patients (Stage 3). The final stage involves long term 
studies for quality assurance making use of device registries. No matter what scheme is 
followed, it is important to ensure a system whereby the issues with implantable medical 
devices can be identified.   
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